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Germline variants in high-penetrance breast cancer susceptibility genes BRCA1 and BRCA2 are 
often identified through routine diagnostic gene screening, typically performed for individuals 
from high-risk breast-ovarian families. Many BRCA1 and BRCA2 variants are known to 
increase breast cancer risk by disrupting mRNA splicing and compromising the tumour 
suppressor function of these genes, which work to repair single and double stranded breaks in 
DNA. A significant number of BRCA1/2 sequence variants are located in or near splice sites 
and splicing regulatory regions and may disrupt mRNA splicing; however, the relative level to 
which mRNA splicing is modulated by these common or rare DNA sequence variants has not 
been ascertained.  
Splicing assays undertaken to assess the clinical relevance of rare sequence variants in BRCA1 
and BRCA2 typically utilise a PCR-based approach and are able to detect the presence of 
aberrant isoforms and/or the absence of naturally occurring isoforms. The isoforms expressed 
are useful for determining the disruptive potential of each variant using the classification 
guidelines recommended by the ENIGMA (Evidence-based Network for the Interpretation of 
Germline Mutant Alleles) consortium.  However, to date PCR-based assays used to evaluate 
potential BRCA1 and BRCA2 spliceogenic variants have typically only provided qualitative 
expression profiles. Thus, detection of quantitative and allele-specific expression changes, 
which may be associated with variants conferring disease risk, has been limited. Advances in 
sequencing platforms over the last decade have produced technologies that generate 
quantitative and high throughput expression information, simultaneously overcoming many of 
the limitations previously reported for PCR-based approaches in splicing assays. 
The work presented here exploits the capabilities of a targeted RNA-seq platform to generate 
the first comprehensive expression profile of normally expressed BRCA1/BRCA2 mRNA 
isoforms from lymphoblastoid cell lines (LCLs). Although a high degree of mRNA expression 
variability was identified across samples, the calculated expression levels made it possible to 
highlight changes present in rare variant samples outside the expected natural range. 
Additionally, results from this work identified instances where PCR-based assay primer design 
prevented isoform detection in variant samples. 
Targeted RNA-seq was coupled with allele-specific expression (ASE) analysis to further 
explore the potential spliceogenic impact of genetic variation in BRCA1 and BRCA2, 
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highlighting ASE changes to natural mRNA isoforms for carriers of a rare variant. While the 
common variants included in this work were not found to have an obvious impact on splicing, 
observed allelic imbalances indicate that additional factors are likely to be influencing the 
mRNA expression variation seen. Exploration of this hypothesis found that common culturing 
practices, including liquid N2 storage and treatment with a nonsense mediated decay inhibitor, 
did not impact the mRNA isoforms expressed in a single LCL over time. However, the 
technology used for mRNA detection was found to play a significant role, with a direct 
relationship between the number of alternative events detected and the read depth in each 
sample. Further work into the extent to which cellular heterogeneity contributes to the observed 
mRNA variability was undertaken with a novel in situ hybridisation platform (RNAscope) to 
establish the level of variability in mRNA expression between individual cells. The results from 
this work highlighted how the inter-cell variation in BRCA1 and BRCA2 expression patterns is 
considerable, potentially explaining why variability is commonly observed when studying 
mRNA expression at a cell population level. Candidate gene analysis was completed for four 
patients who have a history of breast cancer but do not carry any disease-associated variants in 
BRCA1/2. This work did not identify any variants in other known susceptibility genes that are 
likely to have contributed towards their disease and further investigation into unexplored 
regions of the genome would be required to identify an underpinning genetic cause. 
Many women predicted to be high risk for breast cancer have yet to have their genetic basis 
successfully identified through genetic testing. The work undertaken here has established a 
technique to quantitatively assess BRCA1 and BRCA2 mRNA isoforms, while identifying 
technical and biological factors that influence the observed variability. This comprehensive 
analysis would benefit patient management as it provides a more informative base for variant 
classification from a better understanding of how disruptive any given genetic variant is likely 
to be. Clinicians and genetic counsellors will have the capacity to council patients more 
effectively as more variants of unknown clinical significance will be able to be given a 
classification that more informatively highlights their associated genetic risk. These more 
conclusive genetic test results will mean that patients are also less likely to be subjected to the 
stress and uncertainty that would otherwise be present with reported variants that remain 
unclassified. 
This work provides the basis for further studies to extend this work to other known breast cancer 
susceptibility genes, providing a more comprehensive assessment to identify variants that are 
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likely to be influencing disease risk in high risk women. Such data will be critical for the future 
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Cancer is the general term for hundreds of complex diseases that are genetic in origin. Cancers 
arise from a build-up of mutations within DNA that lead to uncontrolled cell growth, with the 
potential of spreading to other parts of the body through metastasis [Jorde et al. 2010, Tobias 
et al. 2011]. Cancer is a leading cause of mortality in New Zealand, accounting for 8905 deaths 
and 21,814 registrations in 2012 [Ministry of Health 2015]. The most commonly diagnosed 
cancer in the world for women is that of the breast [Ferlay et al. 2010]. 
1.2 Breast Cancer 
Breast cancer accounted for 28.9% of the female cancer registrations and 14.8% of cancer-
related cancer deaths in 2012 in New Zealand woman [Ministry of Health 2015]. In 1999, free 
breast screening was introduced for New Zealand women between the ages of 50 and 64 
(increased to include women 45-69 years of age in 2004), which may have contributed to the 
downward trend in breast cancer related deaths observed over this period by providing a more 
accessible means of earlier detection [Ministry of Health 2012]. Over her lifetime, a woman’s 
accumulative lifetime risk of developing breast cancer is one in eight [Politi et al. 2004].  
Breast cancer risk is influenced by environmental factors, including alcohol consumption, 
exercise, obesity, pharmaceutical hormones, age and country of residence [Zhang et al. 1999, 
McPherson et al. 2000, Van den Brandt et al. 2000, Bernstein et al. 2005, Danaei et al. 2005]. 
The risk associated with many of these factors can be reduced through healthier lifestyle 
choices [Berkey et al. 2012].  
1.2.1 Classification of breast cancer 
Breast cancer can be divided into specific sub-groups using several available classification 
schemes, each taking into account different features of the tumour. Such tools aid with 
decisions regarding the treatment options and likely prognostic outcomes, as certain tumour 
types have been shown to respond better to specific treatments over others.  
 
2 
Tumour histology has traditionally been used to classify breast cancer tumours as either 
invasive or in-situ carcinomas. In-situ carcinomas are pre-invasive, in that they are confined to 
the breasts ductolobular system, so have not yet invaded the surrounding tissue [Bane 2013]. 
These tumours are further categorised into either ductal carcinoma in-situ (DCIS), or lobular 
carcinoma in-situ (LCIS), with DCIS being the more prominently expressed of the two (~80% 
of in-situ carcinomas). LCIS is morphologically distinct, forming clumps of round cells, 
whereas DCIS is highly heterogeneous and grows in many different patterns, giving rise to 
several defined subtypes (Figure 1.1) [Bane 2013]. The wide assortment of features that define 
DCIS may be why tumour grade is often favoured over histological type to classify the invasive 
potential of the tumour [Bane 2013]. DCIS and LCIS can also be distinguished by E-cadherin 
protein expression, which is detected in DCIS but not in LCIS [Jacobs 2003].  
 
 
Figure 1.1. Breast cancer histological subtypes  
.
 





Invasive breast cancer tumours make up the second group of carcinomas, accounting for 
around 80% of newly diagnosed breast cancers, which splits into two main categories 
(invasive ductal carcinoma (IDC) (75%) and invasive lobular carcinoma (ILC) (15%)), in 
addition to several smaller groups of mixed type (~10%) [Li et al. 2003, Li et al. 2005]. 
Invasive carcinomas have spread from their primary site from within the terminal duct 
lobular unit [Guiu et al. 2014], and have a poorer prognosis than in situ carcinomas. The 
majority of IDC tumours have no defining features and so are sub-classified as “no special 
type” (NST), while characteristic morphological patterns are used to distinguish several 
rarer types (Figure 1.1) [Rakha et al. 2010]. ILC are morphologically distinctive from IDC 
in that the affected cells spread into the surrounding tissue by growing in single file, or in a 
sheet-like pattern, diminishing the likelihood of inducing an inflammatory response in the 
area [Martinez and Azzopardi 1979]. ILC have been found to often be larger than IDC, while 
also more frequently ER+ [Wasif et al. 2010]. Both tumour types also have differing 
molecular receptor status to help define them. The status of molecular markers ER, PR and 
HER2 is recommended for all invasive carcinomas.  
1.2.2 Grading of invasive carcinomas 
Invasive carcinomas are also categorised by histological grade, which is determined by the 
degree tumour morphology has differentiated from that of the normal epithelial cells [Rakha 
et al. 2010]. Originally developed in 1957, the Bloom-Richardson grading system is often 
used to assign tumours grades, where low grade (grade 1 - well differentiated tumours) look 
the closest to that of normal cells and tissue, while high grade (grade 3-4 - poorly 
differentiated) tumours have completely changed the architecture of the region and grow at 
a faster and more invasive rate [Bloom and Richardson 1957]. Tumour grade focuses on the 
degree of nuclear pleomorphism, glandular/tubule formation and mitotic rate present, 
assigning a score between one and three to each of these features [Bloom and Richardson 
1957]. The overall score indicates the histological grade, where 3-5 indicates a grade 1, well 
differentiated tumour, 6 or 7 a grade 2 moderately differentiated tumour, and 8 or 9 a grade 
3 poorly differentiated tumour [Zhang et al. 2012]. As expected, patients with grade 1 




1.2.3 Staging breast carcinomas 
Invasive breast cancer is staged according to the tumour-node-metastasis (TNM) system, 
which takes into account features of the primary tumour (T), involvement of local axillary 
nodes (N) and the presence more distant metastases (M), summarising the extent of disease 
[Edge and Compton 2010]. Each of these factors is thought to have an impact on patient 
prognosis and can be used for indicating the optimal treatment options. 
1.2.4 Breast cancer pathology 
Expression profiling of certain molecular markers has together defined six subtypes of 
biologically distinct disease including basal, luminal A, luminal B, normal breast like, 
HER2-enriched and, more recently, claudin low, each differing in overall and disease free 
survival [Sorlie et al. 2003, Prat et al. 2010]. The basal-like subtype is most accurately 
identified using a panel of five biomarker stains (oestrogen receptor (ER) negative, 
progesterone receptor (PR) negative, human epidermal growth factor receptor (HER2) 
negative, plus EGFR and cytokeratin 5/6 positive) [Cheang et al. 2008], whereas the HER2 
enriched subtype represents HER2+, PR- and ER- carcinomas [Eroles et al. 2012]. These 
distinguishing features have changed what treatments are offered and patient management, 
as ER positive and HER2 tumours would respond to treatments such as anti-estrogen 
hormonal (endocrine) therapies and trastuzumab respectively, whereas basal-like tumours 
would not as they lack the essential receptors[Martin-Castillo et al. 2015].  
1.2.5 Familial breast cancer 
Family history is known to be significantly associated with increased breast cancer risk. 
Women with first degree relatives who developed breast cancer before the age of 50 have a 
higher risk of disease than those whose affected relations were older at diagnosis, or are 
more distantly related [Pharoah et al. 1997, Colditz et al. 2012], while risk also increases 
with the number of affected first degree relations [Collaborative Group on Hormonal Factors 
in Breast Cancer 2001]. 
Of the breast cancer susceptibility genes that have been identified to date, BRCA1 and 
BRCA2 are the most highly penetrant. While pathogenic mutations in these genes are 
 
6 
relatively rare in the general population (combined occurrence of ~0.4%), they are detected 
in 3-5% of all breast cancer cases and in >20% of familial, multi-case families [Antoniou et 
al. 2008, Sevcik et al. 2012]. Absolute breast cancer risk associated with these high-
penetrance genes in females (up to 70 years of age) is significant, with estimates of ~65% 
and ~45% for BRCA1 and BRCA2 mutations, respectively [Antoniou et al. 2003]. Germline 
BRCA1 carriers are more likely to develop basal-like, or triple negative (ER-, PR- and   
HER2-) breast cancer, while BRCA2 tumours tend to fall within the luminal-complex 
subtype [Sorlie et al. 2003, Atchley et al. 2008, Jönsson et al. 2010]. Since their discovery, 
a number of moderate- to high-penetrance breast cancer susceptibility genes have been 
identified that also play a role in the BRCA1 and BRCA2 related pathways, including ATM 
(2.4-fold risk), CHEK2 (1.7-fold risk), PALB2 (2.3-fold risk), and TP53 (18-fold risk) 
[Rahman et al. 2006, Baynes et al. 2007, Byrnes et al. 2008, Apostolou and Fostira 2013]. 
Although our understanding of breast cancer susceptibility genes continues to advance, the 
genetic cause behind a large number of multi-case breast cancer families remains 
unidentified [Byrnes et al. 2008].  
Inherited genetic variability is currently unmodifiable; however, there are options available 
that reduce the likelihood of breast cancer. Risk-reducing surgical options include unilateral 
or bilateral mastectomy or salpingo-oophorectomy, which remove one or both of the breasts 
or ovaries, respectively [Rebbeck et al. 2004, Robertson et al. 2016]. It is therefore important 
to identify patients and their family members who carry high-risk mutations so such 
measures can be offered to those that would benefit the most from such risk-reducing 
procedures. 
1.2.6 BRCA1 and BRCA2 
BRCA1 (MIM #113705, NM_007294) was identified as the first breast cancer susceptibility 
gene using segregation analysis in 1990 and subsequently cloned in 1994 [Hall et al. 1990, 
Miki et al. 1994]. Located on chromosome 17q21, BRCA1 consists of 23 coding exons (24 
exons total), which together code for an 1863 amino acid protein. Exon 4 is not normally 
transcribed in the full length BRCA1 mRNA.  
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The BRCA1 multifunctional nuclear protein is vital to the maintenance of genomic stability 
through direct and indirect interactions with several damage-response proteins via its 
functional domains (  
Figure 1.2). BRCA1 has roles in several DNA repair pathways, including homologous 
recombination to repair double-stranded breaks in DNA, apoptosis and transcription [Roy 
et al. 2012]. 
  
Figure 1.2. BRCA1 and BRCA2 functional domains and associated protein binding partners. 
Functional domains are labelled above, and associated protein binding partners are labelled below, each mRNA 
BRCA1 and BRCA2 transcript [Roy et al. 2012]). Abbreviations: BRCT, BRCA1 C-terminal; NLS, nuclear 
localization sequence; SCD, serine cluster domain. 
 
BRCA2 (MIM #600185, NM_000059) was identified shortly after BRCA1 as another highly 
penetrant breast cancer susceptibility gene [Wooster et al. 1994, Wooster et al. 1995]. 
Located on chromosome 13q12-13, BRCA2 contains 27 coding exons, which encompass a 
3418 amino acid protein when transcribed at its full length. Like BRCA1, BRCA2 contains 
multiple domains that allow interaction with other proteins (  
Figure 1.2). However, the main known function of BRCA2 is to repair DNA by homologous 
recombination through its interaction with RAD51 [Thorslund and West 2007, Roy et al. 
2012]. 
BRCA1 and BRCA2 are essential elements of a protein complex formed to maintain 
genomic integrity by initiating homologous recombination to repair double-stranded breaks 
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in DNA. The homologous recombination pathway is limited to the S and G2 stages of the 
cell cycle, as the sister chromatid can only be used as a template for repair during this time 
(Rothkamm et al. 2003). While the exact number of proteins involved in this pathway is 
unknown, BRCA1 and BRCA2 have both been implicated to be crucial for this process to 
take place, and the expression of each of their respective proteins is known to increase during 
these stages of the cell cycle. 
Homologous recombination takes place after newly occurring double-stranded breaks are 
recognised by kinases ATM and ATR, triggering phosphorylation of several repair proteins, 
including BRCA1. BRCA1, aided by BRIP1, becomes a scaffold for the proteins required 
for DNA resection and HR to take place [Huertas 2010]. After DNA resection, BRCA1 
interacts with PALB2 to recruit BRCA2 (Sy et al., 2009), which is essential for ssDNA 
binding and a mediator of recombination [Jensen et al. 2010]. BRCA2 works with PALB2 
to recruit RAD51 to identify the homologous sequence in the sister chromatid to use as the 
template to accurately repair the broken DNA [Dray et al. 2010].  
1.2.7 Other breast cancer susceptibility genes 
1.2.7.1 TP53 
Tumour suppressor gene TP53 is the most frequently mutated gene in human cancers, with 
somatic variants identified in about a third (32.9%) of breast cancer tumours [Kandoth et al. 
2013].  While TP53 variants increase risk broadly across a large number of diseases, such 
changes have been associated more specifically with the more advanced subtypes of breast 
cancer, such as HER2 negative and triple negative [Olivier et al. 2010]. TP53 produces the 
p53 protein, which resides in the cell nucleus and regulates many important cellular 
processes, including cell metabolism, energy metabolism and angiogenesis [Teodoro et al. 
2006, Helton and Chen 2007]. It also has an essential role suppressing tumour development 
by regulating double strand break repair pathways and initiating apoptosis and cell cycle 
arrest when damaged DNA is deemed irreparable [Helton and Chen 2007]. Reduction of the 
nuclear p53 decreases the cells ability to self-destruct when such damage occurs, increasing 




PTEN is a haploinsufficient tumour suppressor gene, in that lowered expression due to 
disruptive variants can lead to insufficient levels to maintain normal cell function [Song et 
al. 2012]. One of the main roles of PTEN is as a negative regulator of the PI3K-AKT-mTOR 
pathway, which regulates cell growth and cell survival [Hollander et al. 2011]. Variants in 
PTEN that disrupt this pathway are commonly associated with diseases encompassed by 
PTEN hamartoma tumour syndrome (PHIS), including Cowden syndrome, with around 80% 
of such cases reporting PTEN genetic changes [Hobert and Eng 2009]. Incidence of PHIS 
increases the risk of multiple cancers, including that of the breast (25-50% lifetime risk), 
thyroid, kidney, endometrial, and colorectal cancers [Gustafson et al. 2007, Tan et al. 2012]. 
1.2.7.3 PALB2 
The PALB2 gene (Partner And co-Localiser of BRCA2), or FANCN, is crucial for DNA 
damage repair, with roles in homologous recombination via interactions with both BRCA1 
and BRCA2 [Xia et al. 2006, Zhang et al. 2009]. PALB2 interacts with BRCA1 via their 
respective coiled-coil domains [Sy et al. 2009]. PALB2 binds to ssDNA and its interaction 
with BRCA1 promotes subsequent recruitment of both RAD51 and BRCA2 to the site of the 
break [Bhattacharyya et al. 2000, Sy et al. 2009]. Complete loss of function variants in 
PALB2 leads to Fanconi’s anemia [Reid et al. 2007], while disruptive variants are also 
associated with increased risk of breast and pancreatic cancers [Erkko et al. 2007]. 
1.2.7.4 CHEK2 
CHEK2 codes for checkpoint kinase and tumour suppressor protein CHK2, which is 
activated in response to DNA damage to prevent the cell from entering mitosis while it 
undergoes DNA repair. ATM and ATR have both been identified to phosphorylate CHK2 
to induce DNA damage repair [Matsuoka et al. 2000, Melchionna et al. 2000]. CHK2 
interacts with a number of proteins, including with P53, BRCA1, FOXM1 and, indirectly, 
BRCA2, to activate the DNA repair pathway [Lee et al. 2000, Tan et al. 2007, Bahassi et al. 
2008]. Disruption of CHK2 can result with an accumulation of DNA damage, which may 
lead to the development of cancers, including that of the breast. One of the more well studied 
CHEK2 variants, c.1100delC in exon 10, disrupts the function of the gene and is thought to 
have an associated odds ratio of 4.8 (95% CI, 3.3-7.2) in familial breast cancer cases 




ATM is an important gene for maintaining normal cellular function as its encoding protein, 
ATM, initiates cell cycle checkpoint arrest after activation in response to dsDNA breaks 
[Kurz and Lees-Miller 2004, Jeggo and Lobrich 2006]. Following activation, ATM signals 
DNA repair machinery, including BRCA1, P53 and CHK2, to the site of the break to 
undertaken DNA resection and the subsequent repair processes [Ahmed and Rahman 2006, 
Prokopcova et al. 2007]. Disruptive variants in ATM have been shown to increase the risk 
of cancers, including breast cancer, gastric cancer and leukemia [Friedenson 2007, 
Prokopcova et al. 2007, Helgason et al. 2015]. Such changes in both ATM alleles suppress 
the ability of ATM to undertake its cell cycle arrest function, leading to Ataxia 
telangiectasia, which increases the risk of disease development [Ahmed and Rahman 2006, 
Lavin and Khanna 2009]. 
1.2.7.6 RAD51 
RAD51 is an essential protein in homologous recombination as it stimulates strand 
exchange, where a correct copy of the damaged DNA strand is obtained using the sister 
chromatid as a template to accurately repair double stranded breaks [Sung 1994]. The BRC 
repeats in BRCA2 allow it to interact and recruit RAD51, which uses DNA filaments to 
binds to the ssDNA at the site of the break [Carreira et al. 2009]. The BRCA2 BRC repeats 
then continue to stabilise RAD51 so this bond is maintained as the undamaged strand on the 
sister chromatid is used to synthesis a correct copy to repair the damaged region [Thacker 
2005]. The close relationship between RAD51 and BRCA2 makes it unsurprising that there 
has been shown to be a further increase of breast cancer risk in BRCA2 variant carriers when 
RAD51 also contains a disruptive variant [Thacker 2005]. 
1.2.8 Complexity of BRCA1 and BRCA2 
BRCA1 and BRCA2 are both highly complex genes with regard to the number of alternative 
splicing events they express. While previous work has established that an average of seven 
alternative splicing events are expressed by multi-exon genes [Pan et al. 2008], 63 BRCA1 
and 24 BRCA2 mRNA isoforms have been identified in comprehensive splicing analysis 
studies, including multiple predominantly expressed events as defined by their frequent 
detection in samples studied (  
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[Colombo et al. 2014] 
Δ 5  r.135_212del No FS 
Δ 9-10  r.548_670del No FS 
Δ 9-11  r.548_4096del No FS 
Δ 8p  r.442_444del No FS 
Δ 13p  r.4186_4188del No FS 
Δ 14p  r.4358_4360del No FS 
Δ 1Aq  r.-25_-20del UTR 
Δ 5q  r.191_212del PTC-NMD 
Δ 11q  r.788_4096del No FS 
BRCA2 
[Fackenthal et al. 2016] 
Δ3  c.68_316del249 No FS 
Δ6q,7  c.478-631del154 PTC-NMD 
Δ12  c.6842_6937del96 No FS 
Δ17,18  c.7806_8331del526 PTC-NMD 
Abbreviations: del, deletion; FS, frameshift; NMD, nonsense-mediated decay; PTC, premature termination 




Countless loci across numerous genes have been identified as significant contributors 
towards breast cancer risk [Michailidou et al. 2013]. Thousands of known genetic variants 
across BRCA1 and BRCA2 alone have been recorded in publically available online 




Table 1.2). The largest of these is BRCA Exchange (http://brcaexchange.org/), which 
includes classification status only for the subset of expertly reviewed variants submitted by 
the ENIGMA (Evidence-Based Network for the Interpretation of Germline Mutant Alleles) 
consortium (www.enigmaconsortium.org) (see Section 1.2.9). LOVD (Leiden Open 
(source) Variation Database, http://www.lovd.nl/3.0/home) allows users to populate the 
database and does not include the variants official classification, instead indicating if it has 
been reported to have an effect on protein function. The smallest database, BIC (Breast 
cancer Information Core, https://research.nhgri.nih.gov/projects/bic/) provides information 
regarding classification as indicated by the members who provided the entry. The number 
of BRCA1 and BRCA2 unclassified variants in these databases highlights the significant 
challenge that needs to be overcome to understand the degree each variant is contributing 




Table 1.2. Percentage of genetic variation currently recorded with no known classification in BRCA1 



















a Leiden Open (source) Variation Database, http://www.lovd.nl/3.0/home  
b http://brcaexchange.org/  
c Breast cancer Information Core, https://research.nhgri.nih.gov/projects/bic/ 
Databases accessed 28th April 2016. 
 
In addition to breast cancer, both BRCA1 and BRCA2 also have been associated with an 
increased risk of ovarian cancer [Mavaddat et al. 2013], while BRCA2 is also thought to 
increase risk of pancreatic and prostate cancers [Mersch et al. 2015], and colorectal cancer 
risk is increased with the presence of certain BRCA1 variants [Phelan et al. 2014]. 
1.2.9 Classifying variants 
Tools have been developed to evaluate the clinical significance of identified variants, often 
following a multifactorial approach [Richards et al. 2008, Lindor et al. 2012]. This method 
integrates clinical, molecular and tumour pathology data to target factors associated with 
known pathogenic BRCA1/BRCA2 mutations (Figure 1.3) to determine the role each variant 
has on disease development [Radice et al. 2011]. A posterior probability is calculated to 
assign each variant to one of five classes, following a scheme developed by the Unclassified 
Genetics Variants Working Group at the 2008 IARC (International Agency for Cancer 
Research) meeting (http://brca.iarc.fr/LOVD/home.php). Variants that fall into class 1 of 
this scheme are defined as low clinical significance (<0.01% probability of being 
pathogenic); class 2 variants are also low clinical significance (0.1%-4.9% probability); 
class 3 variants are of uncertain/unknown clinical significance (5%-94.9% probability); 
class 4 variants are likely pathogenic (95%-99% probability); while class 5 variants are 
defined as pathogenic (>99% probability). The multifactorial approach has been used to 
successfully classify at least 533 BRCA1 and 496 BRCA2 variants into classes outside of 
class 3 (uncertain) (http://brcaexchange.org/, accessed 28th April 2016). 
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Figure 1.3. Multifactorial model for classifying rare variants in BRCA1 and BRCA2 [Goldgar et al. 
2004]. 
 
The international ENIGMA consortium was established to pool resources from international 
collaborative groups to develop and improve the current methods used to classify variants 
in known breast cancer genes, including BRCA1 and BRCA2 [Spurdle et al. 2012]. 
ENIGMA’s work has comprehensively analysed BRCA1 and BRCA2 variants and mRNA 
isoforms in breast and blood samples, stressing the importance of determining the 
spliceogenic impact of variants when assessing them for classification [Colombo et al. 2014, 
Romero et al. 2015, Fackenthal et al. 2016]. This included an assessment of the IARC 
system, highlighting several recommendations and challenges associated with incorporating 
improvements into the current classification system to obtain a more comprehensive picture 
of exactly how each analysed variant is impacting disease risk [Walker et al. 2013]. 
1.3 Unclassified variants 
Genetic testing to screen BRCA1 and BRCA2 for deleterious mutations is routinely offered 
to individuals thought to have a high chance of carrying genetic variants that increase their 
risk of disease. In New Zealand, Genetic Health Services New Zealand (GHSNZ) offers 
such testing to those who have one or more of the predisposing criteria outlined by eviQ 
Unclassified rare variant 
Assign prior probability of pathogenicity for the variant 
(Based on splice site disruption, or conservation, position and nature of an amino change acid change) 
Determine likelihood ratios for causality for following factors included in the model 
Co-segregation 




mutation for each 
variant 
Personal and family 




each variant carrier 
Combine prior probability and individual likelihood ratios to determine the overall posterior probability of 
pathogenicity for the variant 
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Cancer Genetics (Breast and Ovarian Referral Guidelines (https://www.eviq.org. au/)) (Box 
1).  
Box 1. Example of criteria used to prioritise individuals for germline BRCA1/BRCA2 testing  
• Triple negative (oestrogen, progesterone and HER2 receptor negative) breast cancer and <40 yrs at 
diagnosis 
• Invasive non-mucinous ovarian, fallopian tube or primary peritoneal cancer at any age and a family history 
of breast or ovarian cancer 
• Personal and/or family history of both breast cancer and epithelial ovarian cancer 
• Ashkenazi Jewish ethnicity (for Jewish founder mutations) 
• Member of family with confirmed BRCA1 or BRCA2 mutation 
• Individual with a calculated BRCA1/2 mutation probability of 10-20% or more using a BRCA1/2 mutation 
probability risk calculator e.g. BRCAPRO or BOADICEA 
• Woman with bilateral breast cancer and a family history of breast and/or epithelial ovarian cancer  
• Male breast cancer 
• Breast cancer diagnosed before age 30 years 
• Bilateral breast cancer with first diagnosis under age 50 years 
 
While certain variants are defined as pathogenic due to their obvious disruption of the gene 
leading to protein truncation or other RNA splicing defects, genetic testing also identifies 
rare sequence variants that have an unknown impact on gene function and disease risk 
[Eccles et al. 2015]. These variants of unknown clinical significance, or unclassified variants 
(UVs), are identified in ~5–10% of BRCA1/BRCA2 genetic test results and often return 
missense changes that are difficult to define as either pathogenic or neutral [Lindor et al. 
2012]. The unknown risk associated with these UVs creates a significant challenge for 
counselling and clinical decision making when identified in patients with a strong family 
history of breast and/or ovarian cancer [Radice et al. 2011]. 
As massively parallel sequencing technologies become more affordable, a wider range of 
genetic tests will be offered by diagnostic laboratories, including both exonic and intronic 
regions of a large number of genes, all of which will be obtainable by a greater number of 
people. This will result in an increased number of UVs identified, and the accompanying 
uncertainty may lead to adverse psychosocial consequences for patients and their families 
[Eisenbraun et al. 2010]. While elevated stress levels have been observed in women known 
to carry pathogenic mutations, precautionary and preventative measures can be implemented 
as a result of this knowledge to significantly improve disease-free survival and individual 
outcome if disease does develop [Riley et al. 2012, Nelson et al. 2014]. On the other hand, 
negative genetic testing results can decrease patient anxiety and reduce health care costs as 
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treatment and preventative measures can be targeted at those thought to have an elevated 
risk of disease. However, individual risk remains at least that of the general population, if 
not higher due to other non-genetic and familial predisposing risk factors [Gooding et al. 
2006, Riley et al. 2012]. 
Known pathogenic variants are normally very rare in the general population and are 
generally predicted to lead to obvious or easily detectable molecular aberrations, as 
determined by splicing assays [Spurdle et al. 2008]. UVs may also impact the splicing 
process, and in doing so influence breast cancer risk; however, current splicing analysis tools 
utilise PCR-based approaches, which are restricted in their ability to both detect and quantify 
such changes. Because of this many changes may not be identified, preventing a complete 
understanding of the disruptive potential of each variant. Aberrant splicing can increase risk 
of disease by disrupting essential elements of a gene, resulting in a non-functional protein, 
or lowered levels of functional protein [Scotti and Swanson 2016]. Both BRCA1 and BRCA2 
are known to be haploinsufficient, in that disruption of one allele is enough to hinder normal 
cellular function and increase risk of breast cancer [King et al. 2007, Sedic et al. 2015]. Due 
to this, variants that are within essential splicing elements or domains of either gene are often 
very detrimental as they can lead to significant deletions, or prevent binding in important 
regions, both of which can prevent the protein from functioning normally. Establishing if an 
UV is causing any aberrant splicing changes would help to determine its molecular impact 
and allow genetic testing to be more informative for patients, their families and clinical 
management. 
1.4 RNA Splicing 
Splicing is the critical cellular process that allows functional messenger RNAs (mRNA) to 
be produced from precursor messenger RNA (pre-mRNA) transcripts (Figure 1.4) [Sironi et 
al. 2004, Pandya-Jones 2011]. These pre-mRNA transcripts are made up of coding regions 
(exons) with intervening sequences of non-coding regions (introns) [Cartegni et al. 2002], 
an alternating pattern that was recognised by researchers in the late 1970s [Berget et al. 
1977, Chow et al. 1977]. The average human gene has approximately 8.8 exons, which each 
have a typical length of approximately 170 base pairs (bp) [Sakharkar et al. 2004]. Introns, 
however, make up more than 90% of the pre-mRNA with an average length of 5419 bp 
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[Sakharkar et al. 2004, Stamm et al. 2005]. To generate a mature mRNA the introns must be 
excised, leaving the coding regions to be ligated, or spliced, together [Churbanov et al. 
2010]. Only when this essential process is complete can the mature mRNA be translated into 
amino acids, polypeptide chains, and finally proteins [Lipmann 1969]. 
 
Figure 1.4. Summary of mRNA splicing. 
Pre-mRNA transcribed from DNA; splicing removes the introns; exons are ligated to form the mature mRNA 
transcript; mRNA transcript undergoes translation to form a protein. 
 
Splicing must be carried out with the highest degree of accuracy possible, as a single 
nucleotide base either side of the correct splice site will alter the reading frame sequence for 
translation [Solnick 1985]. Therefore, several splicing regulatory elements (SREs) are 
present within the pre-mRNA to lower the risk of mutated proteins by providing the 
instructions as to the location of the correct splice site [Faustino and Cooper 2003]. 
However, these and other cis-acting elements (allele-specific elements from within the pre-
mRNA transcript) alone are not enough to achieve splicing, so additional trans-acting 
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factors (external to the pre-mRNA) are also vital to splicing regulation [Pajares et al. 2007, 
Gilad et al. 2008, Douglas and Wood 2011]. These two types of elements must work together 
to achieve splicing as the cis-acting elements are identified by, and provide the binding sites 
for, the trans-acting regulatory proteins [Goren et al. 2006, Chen et al. 2012]. SREs, for 
example, are required to signal for the assembly of the spliceosome; however, trans-acting 
elements are the regulating factors behind its construction [Pajares et al. 2007]. 
1.4.1 Trans-acting elements 
Trans-acting elements interact to form a large ribonucleoprotein particle, known as the 
spliceosome, which is the driving force behind pre-mRNA splicing [Wahl et al. 2009, Will 
and Luhrmann 2011]. For splicing to take place, the spliceosome must first identify the exact 
location of each splice site before removing the introns and ligating together the adjacent 
exons [Faustino and Cooper 2003]. Spliceosomes are made up of 5 small nuclear 
ribonucleoproteins (snRNPs) (commonly referred to as U1, U2, U5 and U4/U6) and around 
180 proteins [Wahl et al. 2009, Douglas and Wood 2011, Kalyna et al. 2012]. The 
spliceosome structure changes dramatically throughout the splicing process, mainly through 
interactions between different snRNPs, and between the pre-mRNA and snRNPs [Wahl et 
al. 2009]. Each individual snRNP is made up of proteins and one or two (as for U4 and U6) 
small nuclear RNA (snRNA), which are around 150 nucleotides long and hybridise to 
specific regions in the intron during splicing [Campbell and Reece 2008]. 
1.4.2 Splicing process 
The first assembly stage of the spliceosome involves snRNPs U1 and U2. U1 hybridises to 
the 5′-ss of the intron, while U2 recognises and binds to the intronic branch site (Figure 1.5) 
[Douglas and Wood 2011]. As RNA-RNA interactions are known to be fragile, U1 proteins 
and SR proteins are required to help stabilize the U1 binding process [Wahl et al. 2009]. The 
next stage involves U4, U5 and U6, which join together with the forming spliceosome. U4 
then separates, allowing U6 to replace U1 at the 5′ splice site, before U6 and U2 interact to 
bring the branch point and the 5′ splice site close together. The first transesterification 
reaction then occurs, cutting the 5′-end of the intron from the upstream exon and forming a 
loop by joining the now free 5′-end to the branch point [Douglas and Wood 2011]. The two 
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adjacent exons are then brought towards each other through several interactions controlled 
by U5. Finally, the second transesterification reaction takes place, which cuts through the 3′ 
end of the intron, freeing it entirely, before joining the two exons together (Figure 1.5) 
[Douglas and Wood 2011].  
 
Figure 1.5. Splicing machinery (snRNPs) identifying and removing an intron during splicing. 
1.4.3 Cis-acting elements 
Cis-acting elements occur as short oligonucleotide sequences in the pre-mRNA that help to 
identify the correct splice sites between introns and exons [Pajares et al. 2007, Pandya-Jones 
2011]. Of the well-known cis–elements, the 5′ donor splice site helps identify the exon-
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intron junction, while the intron-exon junction is defined by both the 3′ splice site and the 
polypyrimidine tract [Pandya-Jones 2011]. More than 99% of 5’ and 3’ splice sites are 
defined by their respective GU or AG nucleotide pair situated immediately adjacent to each 
exon (Figure 1.6) [Burset et al. 2000, Douglas and Wood 2011]. The branch point sequence 
in humans is YNYCRAY and is usually located around 18 to 40 nucleotides upstream from 
the 3′-end of the intron [Desmet et al. 2009, Douglas and Wood 2011, Will and Luhrmann 
2011, Delgado et al. 2012]. This sequence provides the site for the first of two 
transesterification reactions that take place during splicing (outlined in section 1.4.2) 
[Pandya-Jones 2011]. 
 
Figure 1.6. Position weight matrix of the most frequently observed nucleotides at the positions around 
the mRNA splice sites.  
Adapted from Denisov et al. (2014) licenced under Creative Commons Attribution 3.0. 
 
Splice site recognition becomes more difficult with the introduction of pseudo sequences, 
which can occur ten times more frequently than true splice sites [Faustino and Cooper 2003, 
Akker et al. 2004]. Exonic splice enhancers and silencers (ESEs and ESSs), and intronic 
splice enhancers and silencers (ISEs and ISSs), are four cis-elements that help to recognise 
the true intron/exon junctions, and are essential for accurate splicing to take place [Zhang et 
al. 2008, Churbanov et al. 2010, Kalyna et al. 2012]. Splice enhancer elements are often 
found in higher numbers around exons with weak splice signals as they compensate by 
providing alternative instructions relating to the position of the actual splice sites [Lo et al. 
2012]. The most well studied of these elements are the exonic splice enhancers (ESEs): short 
sequences recognised by serine/arginine rich proteins (SR proteins) [Sironi et al. 2004, 
Zhang et al. 2008]. When located in the exon they work to enhance splicing; however, when 
located in the intron they repress splicing and are referred to as intronic splicing silencers 
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(ISSs) [Fairbrother et al. 2002, Cartegni et al. 2003, Zhang et al. 2008]. By comparison, 
heterogeneous nuclear ribonucleoproteins, or hnRNP proteins, identify and bind to exonic 
splice silencers (ESSs), which are located in the exon and often act as splicing enhancers 
when found in the intron [Zhang et al. 2008, Chen et al. 2012]. Both ESEs and ESSs are 
found near the splice sites, which is also where the greatest amount of sequence is conserved 
in the exon [Zhang et al. 2008]. 
1.4.4 Alternative splicing 
It has been appreciated for decades that alternative mRNA splicing allows several isoforms 
to be produced from a single gene [Berget et al. 1977, Chow et al. 1977]. Occurring in >90% 
of protein coding genes in all human tissues, this diversity allows a large number of proteins 
of varying structure and function to be produced by a significantly smaller number of genes 
[Pan et al. 2008, Wang et al. 2008]. This diversity contradicts the previous theory that each 
gene codes for a single protein [Beadle and Tatumand 1941]. Nucleotide sequence 
variability can directly disrupt splicing to create additional mRNA transcripts, which if not 
corrected may lead to the production of a defective protein and/or altered levels of the coded 
protein. Understanding the impact these early changes may have on the protein is important 
as this information can then be used to determine if certain variants increase disease risk, or 
whether they are tolerated with no detrimental effects to cells [Easton et al. 2007]. 
Alternative splicing occurs most frequently in the presence of weak splice site signals 
[Moiani et al. 2012], which more readily allow the use of alternative splice sites and the 
inclusion of exon skipping events. Contrary to the simplified splicing process, where all 
introns are removed leaving the exons ligated together, alternative splicing can result in a 
number of different exon exclusion or intron inclusion events (Figure 1.7). While the 
majority of exons are constitutive, where they are always included in or excluded from the 
resulting mRNA, cassette exons are those that may or may not be included [Black 2003]. 
These events can also be mutually exclusive, where only one exon from a group of at least 
two adjacent exons is expressed at any one time. Preferential use of an alternative splice site 
can also occur, resulting in an increase or decrease in exon length (Figure 1.7) [Black 2003]. 
Although alternative splicing is an important process, up to a third of all events are thought 
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to result in a stop codon [McGlincy and Smith 2008]. This causes the mRNA to be degraded 
by the nonsense-mediated decay (NMD) pathway [McGlincy and Smith 2008]. 
 
Figure 1.7. Possible alternative splicing events. 
Rectangles represent exons, lines indicate intronic regions. Alternative splice junctions are highlighted by the 
diagonal bars. 
1.4.5 Identifying variant-associated splicing changes 
Molecular changes that occur in pre-mRNA cis-elements are more likely to alter gene 
splicing patterns than variants located anywhere else in the exon, an occurrence particularly 
noted in cancer genes [Pajares et al. 2007, Cooper et al. 2009]. This is because the 
information contained in these splicing regulatory elements is required by the spliceosome 
to achieve accurate splicing, but may not be recognised if it is disrupted by a variant. Major 
deletion/retention events and frame shifts can result from these changes, which may 
introduce premature termination codons and produce truncated proteins that lead to non-
functional isoforms that are destroyed by NMD [Jung et al. 2015].  
NMD is an essential cellular safety mechanism that regulates gene expression by limiting 
the translation of potentially damaging transcripts by targeting and degrading those that 
contain premature stop codons [Wittkopp et al. 2009]. If translated, the resulting gain or loss 
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of function in the aberrant proteins may have negative consequences in the cell by reducing 
the expression of proteins important for normal cellular functioning. The impact of 
potentially spliceogenic variants located outside known regulatory regions is usually less 
obvious, and a more in-depth analysis is often required to determine if any changes do occur 
as a result of these changes.  
NMD inhibitors, such as cycloheximide and puromycin, prevent NMD by binding to 
translationally active ribosomes, effectively inactivating them, and are used to detect 
transcripts that would otherwise be degraded. Identifying these transcripts may be crucial to 
help determine the spliceogenic effect of certain sequence variants. While many studies have 
highlighted the importance of employing NMD inhibitors to enhance the likelihood of 
isolating aberrant mRNA transcripts [Thomassen et al. 2012, Walker et al. 2013], several 
laboratories still do not include them in their splicing protocols and it is unclear if they are 
missing crucial information by not doing so [Whiley et al. 2014]. A consensus of whether 
or not NMD treatment should be undertaken routinely is required to standardise mRNA 
splicing assays. This will help ensure that the splicing patterns observed are more 
comparable across studies, and that the assays reflect the spliceogenic behaviour of the 
underlying genetic variant(s). 
Splicing assays to identify changes have historically employed a semi-quantitative PCR-
based approach; however, such assays are limited in their ability to fully evaluate mRNA 
isoform expression. The associated methodological issues have been highlighted by studies 
from the ENIGMA consortium (Box 2) [Walker et al. 2013, Whiley et al. 2014] and include: 
incomplete gene coverage with PCR primers designed to encompass only a subset of exons, 
lack of sequence information to confirm isoform type, and non-quantitative assessment of 
isoform expression patterns. Furthermore, a multi-laboratory study showed that different 
cell culture and storage protocols may contribute to variability in splicing assay results 




Box 2. Recommendations for assay design and reporting to facilitate interpretation of mRNA aberrations, 
as listed in Walker et al. (2013). 
 Consider NMD inhibition. 
- The detection of an aberrant isoform may be difficult in cells with functional NMD. 
 Sequence all products to confirm aberration. 
- Aberrant isoforms that differ in size by only a small number of bases from natural 
isoforms may go undetected with some methods used to resolve PCR products.  
 Design primers to encompass two or more exons. 
- Aberrant or natural isoforms involving skipping of two or more exons will be missed 
without primers designed accordingly. 
 Present data from at least 10 controls, where mRNA is from the same tissue type as the variant 
carrier, as reference for interpreting assays.  
- BRCA1 and BRCA2 express numerous isoforms that vary in expression levels between 
experiments, and that are also reported to vary between tissue types. It is important to 
distinguish an aberrant isoform from one that is naturally occurring.  
 Quantify variant allele contribution to full-length wild-type transcript. 
- Determining allelic expression profiles will enable quantitative changes in full-length 
expression to be measured and correlated with the rare variant allele.  
 Quantify aberrant transcript(s) relative to the full-length transcript. 
- Determining these expression ratios will help delineate the contribution of aberrant 
isoforms to the pool of transcripts produced by a variant carrier, and thus enable better 
comparisons of splicing profiles to be made between studies.  
 Consider the possible effect of missense substitutions in the absence of detected splicing 
aberrations for exonic variants.  
- Exonic variants may be associated with risk through an effect on protein function, and 
should be considered for assessment of risk using multifactorial analysis.  
 
1.4.6 Lymphoblastoid cell lines as a model system to study splicing 
Splicing assays are often undertaken on tissue samples that originate from affected patients. 
Lymphoblastoid cell lines (LCLs), lymphocytes and fibroblasts are cellular sources where 
DNA and RNA samples can be relatively easily obtained for the required assays. 
Lymphocytes are mature white blood cells that can occur in three forms: T cells, B cells and 
natural killer cells. Infecting B cells with Epstein-Barr virus (EBV) in vitro enables the cells 
to be immortalised, resulting in the establishment of lymphoblastoid cell lines (LCLs) 
[Neitzei 1986]. EBV is a gamma herpes virus that infects humans throughout the world and 
is present as a circular episome in infected cell nuclei [Arvey et al. 2013]. The interaction 
between the cells and virus was discovered in 1967 and is thought to be essential for cells to 
develop the ability to undergo unlimited growth [Henle et al. 1967, Reedman and Klein 
1973, Sie et al. 2009]. Fibroblasts are also able to be established as a long-lived cell line, 
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and are obtainable from almost any tissue in the body, including the skin [McAnulty 2007]. 
However, compared to LCLs, fibroblasts are very invasive as they require a skin graft or 
tissue sample to obtain the cells [Smith 2006]. 
Blood samples are often favoured for molecular analysis as the required cells are acquired 
through routine clinical sampling practices. In a research setting, immortalised cells can be 
used for many different molecular and genetic assays, which would otherwise require 
multiple blood draws from a single patient. LCLs therefore offer a valuable laboratory 
resource, providing a replenishable source of viable cells to obtain sufficient quantities of 
DNA/RNA and other molecules for multiple assays without the need for additional patient 
blood samples [Sie et al. 2009]. LCLs are cultured in media as a suspension, which enables 
a high density of cells to be supported with fewer materials, and often requires less time to 
culture compared to adherent cultures [Neitzei 1986]. 
One potential issue that arises with using LCLs in breast and ovarian cancer studies is that 
such samples are not derived directly from the diseased tissue. However, recent studies 
assessed BRCA1 mRNA expression in blood and breast tissue and found no tissue-specific 
transcripts in either sample type, suggesting that LCLs are a useful model that reflects the 
spliceogenic biology observed in the diseased tissues [Colombo et al. 2014, Romero et al. 
2015]. 
1.5 Molecular techniques for the analysis of RNA splicing  
1.5.1 PCR-based assays 
PCR-based assays have been the method of choice for many years for detecting splicing 
changes in variant samples. Walker et al. (2013) summarised 77 publications that utilised 
PCR to assess splicing changes in 411 unique variants, while dozens of variants have since 
been analysed with these techniques in more recent studies [Colombo et al. 2013, Ahlborn 
et al. 2015, Quiles et al. 2016]. 
Although PCR-based assays are the preferred option for determining splicing changes 
resulting from the presence of molecular variation, conflicting results raise questions 
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regarding its utility for this purpose. For example, several studies employed RT-PCR to 
analyse isoform changes associated with BRCA1 c.212+3 A>G [Claes et al. 2002, Meindl 
2002, Chen et al. 2006]. Interestingly, only one identified an increased expression of two 
frameshift events ∆5 and ∆5q (22nt) after a cryptic downstream splice site was activated 
[Claes et al. 2002]. The second study only detected the ∆5q (22nt) event [Meindl 2002], 
while the most recent study did not identify any splicing events, instead concluding the 
variant to be polymorphic [Chen et al. 2006]. The reason these changes were not identified 
by all groups may be due to probe placement and assay design, or because the PCR-based 
assays had differing sensitivity [Whiley et al. 2014]. 
Quantification of isoforms may be crucial to determine the true impact of a sequence variant, 
as the variant may not only influence which isoforms are expressed, but also the mRNA 
expression level of those isoforms. For example, a decrease of the full length isoform in 
samples containing BRCA2 c.7988 A>T (located in exon 18) has been observed concurrently 
with an increased expression of BRCA2 ∆18 and ∆17-18 using quantitative PCR [Walker et 
al. 2010]. Upregulation of alternative isoforms may limit concomitant production of 
sufficient wildtype isoforms that would otherwise be associated with healthy cells. More 
quantitative splicing assay approaches need to be established to allow a more complete 
evaluation of variant-induced splicing changes present in cells. 
Quantitative PCR (qPCR) is a method that has been frequently used to quantify and compare 
the expression of target molecules in a sample. It is difficult to quantify mRNA using 
traditional PCR methods, as the expression of the targets is determined by the relative size 
of the bands seen on an agarose gel. qPCR, on the other hand, measures the amplification of 
the targeted molecules after each cycle during the reaction process and is much more 
accurate. qPCR has been used successfully to determine the relative expression of mRNA 
isoforms in cells [Walker et al. 2010, de Garibay et al. 2014, de la Hoya et al. 2016] and is 
currently the method of choice for such analysis; however, other options are also available 
that can effectively quantify these changes.  
Digital droplet PCR (ddPCR) is an accurate technique that partitions the sample into tens of 
thousands of droplets prior to amplification and quantification. With the theory that one 
molecule is in each partition, ddPCR uses Poisson statistics to calculate expression of the 
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targeted molecule by determining the number of partitions that contain the target as detected 
using fluorescence. While ddPCR is a very sensitive and accurate technique, it is typically 
used for copy number changes [Hindson et al. 2011, Whale et al. 2012] and for detecting 
very small amounts of circulatory DNA [Sanmamed et al. 2015], although it could 
potentially be used to quantify mRNA splicing changes. 
While PCR-based platforms are considered the gold standard for determining the abundance 
of target molecules, they are a very targeted approach and are limited in their ability to 
provide sequence information without subsequent processing steps. Novel sequencing-based 
platforms, on the other hand, allow for vast amounts of genome-wide nucleotide-level 
information to be obtained very quickly [Mortazavi et al. 2008]. Higher sequencing depth 
allows for more sensitive detection, however, the ability of PCR-based methods to reliably 
detect lowly expressed molecules make them invaluable for validating RNA-seq findings 
[Trapnell et al. 2010]. 
1.5.2 Hybridisation-based assays 
NanoString is a hybridisation method at uses barcodes and single molecule imaging to 
quantify the expression of target molecules [Kulkarni 2011]. Target-specific barcodes allow 
for hundreds of reactions to be completed in parallel, with absolute counts of each barcode 
being returned without the requirement of any amplification [Goodwin et al. 2016]. The lack 
of processing required for this technique makes it ideal for use on degraded samples, such 
as FFPE [Tachibana 2015], in addition for its uses for CNV and variant detection validation 
[Sailani et al. 2013]. 
1.5.3 Sequencing technologies 
Novel methods for mRNA isoform expression analysis have been provided through the 
advances in Next-Generation (or massively parallel) RNA sequencing technology (RNA-
seq). RNA-seq allows mRNA isoforms to be detected at a degree of sensitivity that surpasses 
PCR-based capabilities, while also providing isoform expression levels in great detail. The 
current criteria provided by ENIGMA for BRCA1 and BRCA2 variant classification 
(https://enigmaconsortium.org/library/general-documents/) highlights that assays must be 
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able to identify aberrations that disrupt normal splicing. To achieve this, it is first essential 
to characterise normal splicing and determine the ‘normal’ expression range of all mRNA 
isoforms expressed from these genes. Such a goal is now achievable by exploiting the 
capabilities of RNA sequencing technologies. 
1.5.4 A history of sequencing 
DNA sequencing is the process used to determine the order of nucleotides along any given 
DNA strand [Sanger et al. 1977]. For three and a half decades genomic DNA and RNA 
sequencing techniques have been constantly evolving. The significant developments over 
this time can be separated into three main periods, commonly referred to as “generations”, 
with each generation symbolising a major step forward in the sequencing evolution.  
The earliest methods, including Sanger sequencing, used one sequencing reaction at a time, 
whereas current platforms can sequence millions of short DNA fragments in parallel 
[Moorthie et al. 2011]. The most recent technologies, often described as the third generation, 
remove the cycling steps of the previous platforms, and together with the clonal 
amplification of each strand, allow significantly improved speed and output capabilities 
[Moorthie et al. 2011]. Only the technologies that are easily attainable by most laboratories 
are included in this review. 
1.5.5 First generation sequencing 
DNA sequencing technology was first developed in the late 1970s [Sanger et al. 1977, Liu 
et al. 2012]. Although the results were not completely accurate, its comparative ease of use 
compared to other methods and its relative reliability resulted in its subsequent automation 
to establish the first generation of sequencing [Metzker 2010]. This sparked the beginning 
of a long list of methods and sequencing technologies that were refined from this original 
method, many using its basic principles, to shape what is used today [Hutchison 2007]. 
Chain-terminating sequencing, introduced by Fredrick Sanger and also known as Sanger 
sequencing, interrupts the DNA replication process to determine the nucleotide sequence of 
the target strand [Sanger and Coulson 1975, Sanger et al. 1977]. For this process the DNA 
 
30 
sequence was amplified, then heated to separate the two strands. Four mixtures were 
prepared, each containing the DNA of interest, DNA polymerase and a primer. The primer 
binds to its complementary DNA before the replication of the sequence begins. A 
combination of normal unbound nucleotides (deoxynucleoside triphosphates (dNTPs)) was 
then added, along with one of the four nucleotide analogues, known as dideoxynucleoside 
triphosphates (ddNTPs). ddNTPs lack the hydroxyl molecule, which is essential for a 
growing DNA strand as it binds to the sugar of the current dNTP on the strand before 
chemically binding to the phosphate group of the next dNTP. The presence of an altered 
ddNTP inhibited this chemical binding, effectively acting as a stop codon by preventing the 
strand from extending further. Once a ddNTP attached to a strand, that strand was released 
and the process started again. This process resulted in many DNA strands of various lengths, 
each with a terminal ddNTP at one end (Figure 1.8). 
 
Figure 1.8. The use of artificial nucleotides (ddNTPs) to determine the nucleotides sequence.  
A.) DNA strand to be sequenced. B.) Resulting oligonucleotides restricted by the ddNTP, which act as a stop 
codon by ending the strand. C.) The resulting nucleotide sequence created from combining the positions of the 
respective ddNTPs. 
 
Gel electrophoresis was used to separate the strands and order them according to size. A 
radioisotope was used to label the DNA fragments, allowing them to be detected on the gel 
as bands [Watson and Caudy 2007], thus revealing the position of each ddNTP and the 
nucleotide sequence [Hutchison 2007]. 
Sanger sequencing was originally a manual process, which was relatively laborious [Watson 
and Caudy 2007], and often resulted in sequence inaccuracies. Frequently, more than 10% 
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of bases were incorrectly labelled or were not able to be identified at all [Watson and Caudy 
2007]. An important improvement of Sanger’s method was the introduction of fluorescent 
labelling of the ddNTPs [Smith et al. 1985]. This allowed each sequence to be defined using 
only one reaction instead of four, which, together with the automation of this method in the 
mid-1980s [Smith et al. 1985], allowed more data to be obtained in a shorter, more efficient 
time frame.  
1.5.6 The first generation: Automated Capillary Array Electrophoresis 
In 1986, the first automated DNA capillary sequencer was released by Applied Biosystems 
(the AB 370A platform) [Venter et al. 2001]. This method removed the human error 
previously reported in sequencing, both during the slab gel electrophoresis phase and 
nucleotide identification step, by automating the process and employing the use of 
capillaries [Marziali and Akeson 2001]. After strand synthesis using the normal and altered 
Sanger sequencing nucleotides (dNTPs and ddNTPs), the sequencing reaction was 
transferred automatically into narrow capillary tubes. Instead of using a slab gel, the 
signature fluorescent label of the stop nucleotide (ddNTP) was detected with a laser to 
identify the nucleotide sequence as the strands passed through the capillaries. With one 
sample per capillary, together with the use of an increased voltage and more rapid heating, 
capillaries were capable of providing faster running times and a higher resolution compared 
to earlier methods [Marziali and Akeson 2001]. In addition, the advanced ability of the 
machine to load the samples and reuse the capillary tubes many times allowed large numbers 
of samples to be processed automatically [Watson and Caudy 2007]. 
1.5.7 Next-Generation Sequencing 
The first human genome was largely completed with the use of the dideoxy sequencing 
method, which necessitated a significant amount of time and resources [Venter et al. 2001]. 
This highlighted an urgent need for faster and more efficient techniques, spurring the 
development of the next generation of sequencers, which are largely used today [Metzker 
2010, Mardis 2013]. Several significant changes were introduced to the basic method of 
Sanger sequencing that differentiate the later technologies from those used previously. The 
high throughput next-generation sequencing (NGS) platforms did away with bacterial 
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cloning, instead adopting cell-free library preparation. NGS also operates in a massively 
parallel manner where millions of sequencing reactions, and the subsequent base detection, 
are undertaken on all reads simultaneously [van Dijk et al. 2014]. These improvements 
meant that the work to complete the first human genome, that took more than a decade, can 
now be undertaken in less than a week.  
The current commercially available NGS platforms encompass a range of capabilities that 
allow them to sequence whole genomes, exomes (coding regions of the genome), 
transcriptomes, or targeted regions thereof. While many of these platforms provide very high 
throughput, one of the main limitations that is still to be overcome is their short read length 








Table 1.3. Summary of next-generation sequencing platforms and their specifications and capabilities. 
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1.5.7.1 454 - Pyrosequencing 
The first commercially available NGS platform was released in 2005 by 454 Life Sciences 
(acquired by Roche Diagnostics in 2007) [Margulies et al. 2005]. It utilizes emulsion PCR, 
which allows thousands of reactions to take place simultaneously within microdroplets, each 
containing generic primers linked to beads.  
One kilobase fragmented transcripts anneal to the bead primers (one read per bead) before PCR 
amplification creates multiple copies to completely cover the beads’ surface. One of the four 
possible nucleotides is added, binding to the template strand only if it complements the next 
base in the sequence. If there is a repeat of that base (two or more adenines in a row, for 
example), then the corresponding number of nucleotides is added. Each time a nucleotide is 
added, pyrophosphate is released, which is used in a series of chemical reactions to generate a 
detectable light signal that is recorded for that bead. The intensity of the signal indicates the 
number of bases added. The unbound nucleotides are degraded and the cycle is repeated several 
times for all four bases [Margulies et al. 2005]. 
Since its initial release, the end point read length of 454 technology has greatly improved from 
150 bp to 1,000 bp, while the run time of less than a day also makes it one of the fastest options 
currently on the market (Table 1.3). However, developments are still required to improve this 
platform’s ability to accurately identify the number of bases in homopolymer regions (regions 
of identical consecutive nucleotides) [Luo et al. 2012].  
1.5.7.2 SOLiD - sequencing by ligation 
The first SOLiD (Sequencing by Oligo Ligations Detection) platform was released in 2007 by 
Applied Biosystems utilising a sequencing by ligation approach [Mardis 2008]. While using 
emulsion PCR to amplify the reads on beads in a similar manner to that of the 454 technologies, 
SOLiD utilises a smaller bead, allowing higher throughput [Mardis 2008]. After amplification 
the beads are transferred and attached to a glass slide within the sequencing platform.  
As opposed to the techniques mentioned earlier, where bases are individually added and 
identified in sequential steps, this platform exploits a different approach involving the ligation 
of oligonucleotide probes for nucleotide detection [Mardis 2008]. The ligation process starts 
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with the annealing of a complementary sequencing primer to the adaptors on the library reads. 
A defined set of fluorescently labelled 8 bp oligonucleotide probes is then washed over the 
glass slide. These probes have a very specific content. The first two bases of each of the 16 
probes are probe specific, each including one of the 16 possible combinations for two 
consecutive nucleotides. The five bases following these are degenerate, in that they do not code 
for a nucleotide, so their sequence is not read and has no impact on the probes’ ability to bind 
to a DNA fragment. A fluorescently detectable label is bound to the last nucleotide. During 
ligation, the probe that contains the two probe-specific bases complementary to the first two 
bases next to the primer of the library read hybridises to that read, and is ligated to the primer 
sequence via a DNA ligase. The unbound probes are washed away and the identity of the 
successful probe is determined using the signal from the fluorescent label. The last three bases 
of the probe, including the detectable label, are then cleaved via enzymatic trimming, and the 
ligation is repeated when the oligonucleotide probes are washed over the slide again [Mardis 
2008, Valouev et al. 2008].  
Approximately seven cycles of ligation are completed before the resulting DNA strand is 
denatured to allow the whole process to start again and be undertaken five times in total. Each 
of the four subsequent reactions starts with a complementary sequencing primer that is offset 
by one base compared to the previous cycle. This allows each of the nucleotides on the DNA 
strand to be read twice and more accurate sequencing to be undertaken [Myllykangas et al. 
2012]. The main downfall of this method is that it restricts the length of sequenced reads to 
around 35 bases [Mardis 2008], providing the shortest sequence reads on the market. The two 
SOLiD platforms currently on offer (the 5500 and the 5500xl system) are both limited by short 
reads and long run times, but are capable of high data generation, which surpasses all except 
the Illumina suite (Table 1.3).  
1.5.7.3 Ion Torrent - semiconductor sequencing 
As with 454 and SOLiD platforms, Ion Torrent (Life Technologies) employs emulsion PCR to 
amplify the strands bound to the individual beads. Like 454, these beads are each placed in a 
single well on a slide before it is flooded with one of the four nucleotides. Ion Torrent platforms 
differ from the other techniques at this point, as they use a semiconductor-based detection 
system to measure the pH in each well [Rothberg et al. 2011]. An H+ ion is released each time 
a nucleotide binds, decreasing the pH of the reaction solution. The degree of reduction also 
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informs how many bases are added in each cycle. If no nucleotide is added, then no change 
will be detected [Liu et al. 2012]. The unbound nucleotides are then washed away and the 
process repeated. 
Of the available Ion Torrent platforms, the PGM (Personal Genome Machine) follows 
Illumina’s MiSeq as a benchtop sequencer. While the Proton I generates a higher number of 
reads compared to the PGM, both platforms have a short read length compared to the other 
sequencers on the market, and have high error rates when reading homopolymer regions (Table 
1.3).  
1.5.7.4 Pac bio – single molecule real time 
Pacific Biosciences (PacBio, Menlo Park, CA, USA) have developed a sequencing platform 
that eliminates the requirement for the PCR amplification preparation step [Liu et al. 2012]. 
This single molecule real time (SMRT) sequencing approach determines the nucleotide 
sequence in real time, as each base is added to the complementary strand.  
The technology works using DNA polymerase molecules, which are bound to the DNA 
template strands, each anchored to the bottom of its own nanophotonic visualisation chamber, 
known as ZMW (zero-mode waveguide) chambers. Fluorescent labels are attached to the 
terminal phosphate of special nucleotides, known as phospholinked nucleotides [Korlach et al. 
2010]. Sequencing is undertaken as these nucleotides diffuse in and out of the ZMW chamber. 
DNA polymerase cleaves the fluorescent label from the correct complementary nucleotide 
when incorporating it into the strand. It takes several milliseconds for the DNA polymerase to 
incorporate each nucleotide, during which time its fluorescence is detected. As the unbound 
nucleotides are diffusing in and out of the ZMW chamber in microseconds, it is possible for 
the cleaved fluorescent labels to be detected over the background of unbound nucleotides. This 
process is completed in thousands of ZMW chambers in parallel [Eid et al. 2009]. 
The PacBio RS platform provides the longest read length of any platform mentioned here, and 
its advanced technology also allows very short run times. However, work is required to 
improve its low output and high error rate to make it a stronger competitor in the sequencing 
market [Quail et al. 2012]. The Sequel was announced in late 2015 as the latest addition to the 
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PacBio platforms. It is claimed to increase throughput over the PacBio RS by including seven 
times as many ZMWs to each sequencing chip (totalling one million). However, little 
information regarding improvements to the accuracy of the previous system has been released 
and it is not included in the comparison table (Table 1.3). 
1.5.7.5 Illumina - Sequencing by synthesis 
Solexa (bought by Illumina in 2007) was second to 454 in developing the first commercially 
available next-generation sequencer, releasing the Genome Analyser in 2006. This technology 
uses the Sanger chain termination method, but incorporates reversible dye terminators and a 
process referred to as bridge amplification.  
An automated process fragments the DNA before ligating short oligonucleotide adapters to 
both ends (Figure 1.9) [Desai and Jere 2012]. Primers P7 and P5 are added to allow multiple 
strands to be synthesised from both ends of this template [Liu et al. 2012]. This ‘library’ of 
strands is then washed over a flow-cell, which is a solid support for the numerous 
oligonucleotide adapters grafted to its surface [Liu et al. 2011]. One of the adaptors on each 
library strand randomly binds to one of these oligonucleotides [Mardis 2008] before the surface 
adaptors elongate to complement the DNA of the attached strand, which is then released. Next, 
the DNA strand undergoes bridge amplification, a process where the original strand bends to 
attach its free end to a vacant surface adaptor close by, before being amplified to make a copy 
via an extension reaction [Bentley et al. 2008, Holt and Jones 2008]. These two complementary 
strands separate and repeat this process multiple times to form tight groups of amplified strands, 
referred to as clusters, which are all unique and number in the hundreds of millions (Figure 
1.9) [Desai and Jere 2012]. The end of each of the remaining strands is capped before a 




Figure 1.9. Schematic of Illumina’s library preparation and sequencing.  
Adaptors are ligated to both ends of the fragmented DNA before it binds, single stranded, to the surface of a flow 
cell. Multiple cycles of bridge amplification occur to create clusters of identical fragments. Up to around 300 
cycles of sequencing occur where fluorescently labelled nucleotides are washed over the flowcell with one able 
to bind to each strand per cycle. The flowcell is fluorescently imaged to identify the base added to each cluster 
before the next cycle starts with another wave of nucleotides. Figure adapted from “Technology Spotlight: 
Illumina® Sequencing” pamphlet (http://www.illumina.com/documents/products/techspotlights/techspotlight_ 
sequencing.pdf), courtesy of Illumina, Inc. 
 
 
Sequencing occurs in all amplicon clusters templates simultaneously through numerous cycles 
involving four reversible dye terminator nucleotides [Mardis 2008]. For each cycle, a single 
complementary reversible dye terminator nucleotide binds to each of the strands forming the 
clusters [Glenn 2011]. These nucleotides have their 3’OH bonds chemically disabled, 
permitting only a single nucleotide to be included during each cycle [Mardis 2008]. The flow-
cell is fluorescently imaged to identify each base after it is added (Figure 1.9) [Liu et al. 2011]. 
This sequencing process, also known as ‘sequencing by synthesis’, is known to be very 
accurate, even for repetitive sequences, producing reads of up to 300 bp in length [Mardis 2008, 
van Dijk et al. 2014]. 
Illumina currently have a large suite of sequencing platforms available, each with specifications 
tailored to target a range of project sizes. While their main limitation is their short read length, 
the massive output possible with the HiSeq suite (450 Gb/day) make them very affordable with 
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regard to reagent cost and per base sequenced for large projects. The MiSeq, and subsequently 
the NextSeq and MiniSeq, together make up a large proportion of the currently defined 
‘benchtop’ sequencers. While they are lower capacity instruments (<120 Gb/day), they provide 
high throughput sequencing for smaller projects in single day experiments, as opposed to the 
10 days required when using the HiSeq [Caporaso et al. 2012, Quail et al. 2012].  
1.5.8 RNA-seq 
RNA-sequencing (RNA-seq) is a method used to qualitatively and quantitatively study all the 
genes and mRNA isoforms expressed in a sample using the massively parallel capabilities of 
NGS. While total RNA is used, a poly(A) tail-enriched library is often generated from 
synthesised cDNA to remove the ribosomal RNA that otherwise makes up around 90% of the 
total RNA in each cell, to target the coding RNA in the study sample [Wang et al. 2009]. 
Adaptors are added to one or both ends of these reads prior to an optional PCR amplification 
step before sequencing on almost any NGS platform [Wang et al. 2009]. 
RNA-seq provides mRNA expression results comparable to alternative detection techniques 
(qPCR and microarrays), but unlike these hybridisation techniques is not limited by 
primer/probe design [SEQC/MAQC-III Consortium 2014]. Instead, the high sensitivity of 
RNA-seq is able to detect novel transcribed regions, even those expressed at low levels, and 
more easily distinguish specific mRNA isoforms [Marioni et al. 2008]. Additionally, RNA-seq 
generates qualitative or quantitative information at nucleotide sequence resolution, rather than 
being restricted to amplicon/fragment resolution provided by microarrays and qPCR [Wang et 
al. 2009]. 
1.5.8.1 Targeted RNA-seq 
While RNA-seq has proved to be a useful tool in identifying mRNA isoforms for determining 
isoform-specific expression changes [Pan et al. 2008] and establishing allele-specific 
expression changes [Pirinen et al. 2015], it is still a costly approach, especially when the focus 
is on a small number of genes. Due to this, several methods have been developed that allow 
the advantages of RNA-seq to be applied to specific regions of the transcriptome. Of the 
targeted RNA-seq platforms currently available, each offers a custom design option to specify 
multiple genetic targets and simultaneously study their expression across all study samples. 
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1.5.8.1.1 QuantSeq-Flex Targeted RNA-Seq platform 
Lexogen’s QuantSeq-Flex Targeted RNA-Seq platform (Lexogen Inc., Vienna, Austria) is 
marketed as a targeted technique to measure gene expression. It uses target-specific primers 
custom designed by the user that are recommended to be 20-50 nucleotides (nt) long to select 
for the genes of interest from total RNA. Magnetic beads are used to purify the library prior to 
amplification and sequencing [Lexogen 2015]. While QuantSeq technology is advertised to be 
very accurate by only producing one read per transcript, to date no work has been undertaken 
using this platform. 
1.5.8.1.2 SureSelect Custom RNA 
Agilent’s SureSelect Custom RNA (Agilent Technologies, Santa Clara, USA) uses 
Biotinylated RNA oligo ‘baits’ 120 nt long to select the targeted molecules, which are purified 
with magnetic beads. While the length of these baits allows high specificity, they may also 
limit detection of some target regions due to insufficient space for bait placement in small 
exons without overlapping splice junctions, which would prevent the detection of alternative 
splicing events. This limitation may be why previous work utilising this platform targeted gene-
specific rather than isoform-specific expression [Kohli et al. 2015]. 
1.5.8.1.3 Ion AmpliSeqTM RNA Panels 
Life Technologies offers Ion AmpliSeqTM RNA Panels (Life Technologies, Carlsbad, USA) for 
quantitative targeted gene expression analysis. The amplicons for this platform have been 
predesigned for more than 20,000 genes; however, these have been designed to target 
expression at the gene level so mRNA isoform information is not obtainable with this kit. Up 
to 300 genes can be included in an assay of up to 96 samples. 
1.5.8.1.4 TruSeq Targeted RNA Expression 
Illumina’s TruSeq Targeted RNA Expression kit (described further in Section 2.9) allows 
customers to customise assay design by selecting from a database of more than 400,000 pre-
designed probe pairs to target certain genes, mRNA, or coding SNPs (cSNP). Up to 1,000 
probes and 384 samples can be included on a single run, although sequencing depth is sacrificed 
when higher numbers are selected. The assay works by hybridising 20-25 nt probes to the input 
cDNA before DNA polymerase extends down the molecule to ligate to the adjacent probe. 
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Probes are situated on either side of each specified target (splice junction or cDNA) to obtain 
targeted expression information across each gene. The 50 bp reads are PCR amplified to create 
libraries that are sequenced with a single run on the MiSeq. Projects are designed in Illumina’s 
DesignStudio, which is accessible from the company website (www.illumina.com). A key 
advantage of using this method over other targeted RNA-seq platforms is the established 
database of probes pre-designed for optimal detection across numerous genes. Discovery of 
alternative splicing events is also possible as these probes are located in almost every exon 
across many genes.  
1.6 Whole exome sequencing to identify disease causing variants 
Whole exome sequencing (WES) was developed to overcome the cost limitations restricting 
many laboratories from utilising whole genome sequencing (WGS) by providing a more 
affordable, targeted alternative. WES focuses on the ~3% of the genome that encompasses the 
exonic regions thought to harbour ~85% of genomic disease-associated variation [Dunham et 
al. 2012, Rabbani et al. 2014]. As WES focuses is on a fraction of the genome, the volume of 
data acquired is also more manageable and requires much less computational power for 
analysis than WGS. 
There are several strategies that can be used to enrich the targeted regions for WES, including 
hybrid capture, in-solution capture, molecular inversion and PCR [Teer and Mullikin 2010]. 
The most commonly used approach is in-solution capture, which uses a pool of custom 
designed oligonucleotide probes to target and hybridise with the fragmented exonic transcripts. 
Magnetic streptavidin beads label each of these probes to allow pull-down, preventing them 
from being washed away with the unbound non-target transcripts. This labelling is then 
removed prior to PCR amplification and sequencing (Figure 1.10) [Warr et al. 2015]. This in-
solution enrichment approach is used by each of the main enrichment platforms currently on 
offer: Agilent Technologies’ (Santa Clara, USA) SureSelect Human All Exon v6, Roche 
NimbleGen’s (Westconsin, USA) SeqCap v3+UTR, and Illumina’s TruSeqTM Exome 
Enrichment and Nextera Expanded Exome kits. While numerous studies comparing these 
platforms have overall found them to be reasonably similar, the differences that are noted 
should be considered when designing a WES project [Samorodnitsky et al. 2015, Shigemizu et 
al. 2015]. The Nimblegen platform, for example, is able to more sensitively detect variants at 
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a low sequencing depth, but covers fewer of the targeted regions compared to the other 
platforms [Clark et al. 2011], whereas Illumina returns the highest coverage across coding and 
untranslated regions [Chilamakuri et al. 2014]. Updated versions of these platforms should 
always be considered as they provide a better coverage of the coding regions as our 
understanding of the human genome improves [Sulonen et al. 2011, Meienberg et al. 2015]. 
 
Figure 1.10. Schematic of in-solution target capture for exome enrichment.  
Oligonucleotide probes hybridise with the fragmented exonic genomic DNA. Streptavidin coated magnetic beads 
bind to the probes for pull-down and washing, before removal prior to amplification and sequencing. This figure 






Initial research into rare Mendelian diseases using WES included a very limited number of 
individuals, yet was still effective in identifying the genes behind several illnesses including 
MYH3 in Freeman-Sheldon syndrome [Ng et al. 2009] and DHODH in Miller syndrome [Ng 
et al. 2010]. This is because families often harbour novel underlying genetic variants that 
predispose an increased risk of familial disease. The application of WES in familial studies has 
been invaluable for identifying such disease susceptibility loci as variant discovery is not 
restricted to sites of known susceptibility loci. Instead it is possible to detect both the known 
and novel variation present across the exonic regions of all coding genes.  
WES analysis of at least two family members is often followed by cheaper and more targeted 
assays to screen the remaining members for the shared variants that were identified with WES 
and thought the most likely to have an association with disease risk. Such research has 
successfully identified rare, and often novel, changes in breast cancer families [Thompson et 
al. 2012]. Other follow-up approaches include screening cohorts of woman for the candidate 
variants in large case-control studies to determine if there is a disease association [Gracia-
Aznarez et al. 2013], or to include the variants in large genome-wide association studies 
[Michailidou et al. 2013]. As the cost of sequencing continues to decline, WGS may overtake 
WES as the preferred variant discovery tool. However, WES currently remains the more 
affordable option for comprehensively screening for rare and novel variation that may explain 
an increased risk of disease in many multicase breast cancer families. 
1.7 Allele-specific expression 
mRNA expression levels can differ between the two gene haplotypes (or alleles) due to a 
number of factors, including environmental, epigenetic, promoter sequences, copy number 
changes and genetic variants disrupting splicing regulatory elements [Cheng et al. 2005, 
Pastinen et al. 2006, Hatchwell and Greally 2007, Montgomery and Dermitzakis 2009, 
McDaniell et al. 2010]. A pathogenic variant in one allele could be expected to cause an allelic 
imbalance, especially if the variant allele produces mutated transcripts that are being destroyed 
by NMD, resulting in an increased relative abundance of isoforms from the wild type variant 
[Tan et al. 2008]. Allele-specific expression (ASE) is a measure of the gene-specific expression 
differences between the nucleotides of heterozygous variants. ASE indicates if there is likely 
to be an underlying genetic factor present causing a significant imbalance in expression 
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between the two gene copies [Tan et al. 2008]. Detecting these imbalances would indicate the 
impact the causative variant may have on splicing, and whether homozygosity of that variant 
may lead to complete loss of function of the gene. 
1.7.1 Allele-specific expression of BRCA1 and BRCA2 
ASE imbalances have been identified previously in both BRCA1 and BRCA2 and are 
hypothesised to be due to the underlying splicing changes resulting from disruptive variants 
present in each sample studied [Chen et al. 2006, Chen et al. 2008]. Rare variants across both 
genes have been shown to lead to significant splicing aberrations, such as truncated transcripts 
inducing NMD, and the resulting ASE variation is likely to be influenced by the splicing 
changes observed. Such allele imbalances have been found to be larger in familial and non-
familial breast cancer affected individuals compared to unaffected controls [Chen et al. 2008]. 
This is possibly because of the higher risk of carrying a disruptive variant in BRCA1 or BRCA2 
for breast cancer patients. ASE imbalances may therefore be a good indicator of underlying 
variants leading to splice defects prior to splicing analyses [Caux-Moncoutier et al. 2009]. 
1.8 In-situ Hybridisation technologies 
Sequencing technologies are continually advancing our ability to study genetic information at 
the individual cell level. However, the costs associated with such studies remains significant, 
and any information that could be gained from looking at spatial differences is difficult to 
obtain [Crosetto et al. 2015]. In situ hybridisation (ISH) is a technique that uses labelled probes 
for the localisation of specific genetic targets in fixed tissue samples. These relatively low cost 
assays are a useful way to identify spatial expression differences of DNA or RNA loci in the 
single cells of the sample studied, usually targeting gene level expression data [Lambros et al. 
2006]. The techniques available typically employ either fluorescence (FISH) or chromogenic 
(CISH) detection methods [Saez et al. 2006, Garcia-Caballero et al. 2010]. FISH allows 
multiple targets to be measured simultaneously and is the more sensitive option for detecting 
expression changes of the target molecule, but unlike CISH, the resulting signals have a limited 
detection period [Lambros et al. 2006]. Platforms that utilise these techniques are quickly 
advancing, with the relatively recent release of RNAscope (Advanced Cell Diagnostics (ACD), 
Inc., Hayward, CA, USA). This platform overcomes the limitations of previous ISH-associated 
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gene detection sensitivity and specificity issues by employing a dual Z-probe design to 
selectively target and quantify specific mRNA in single cells (described further in Chapter 7) 
[Wang et al. 2012]. These assays are an invaluable complement to sequencing for determining 
how the expression of certain mRNA targets varies at the intra-cellular level. However, to date 
IHC tools have not been used to explore the intracellular expression of specific BRCA1 or 
BRCA2 mRNA isoforms. 
1.9 Summary and thesis aims 
Accurate genetic assessment of individual disease risk is crucial to increase the chance of 
earlier detection and intervention, leading to improved outcome and survival. However, a 
growing number of BRCA1 and BRCA2 variants remain unclassified after assessment with 
current classification tools, and the genetic change(s) responsible for most women predicted to 
be at high-risk of breast and ovarian cancer remain unknown. Splicing analysis is a crucial part 
of the recommended guidelines proposed by ENIGMA for variant classification. However, 
normal BRCA1/2 splicing is not well understood at the quantitative level. The work presented 
in this thesis aimed to explore limitations in the current splicing assays, in addition to the 
variation in mRNA isoform expression and mechanisms or factors behind it. The early work 
of the thesis contributed to and builds on the multicentre study [Whiley et al. 2014] that showed 
limitations with current assays, and that the extent and reasoning for observed isoform 
expression variability is unknown. Subsequent work was completed using novel technologies 
to understand where the observed variability originates.  
The aims of this thesis were:  
1)  To provide the first qualitative and quantitative assessment of BRCA1 and BRCA2 mRNA 
isoforms in LCLs 
2)  To identify genetic and technical factors which influence the expression levels of BRCA1 
and BRCA2 mRNA isoforms in LCLs 




: Materials and Methods 
2.1 Samples 
The twenty-seven lymphoblastoid cell lines (LCLs) from the Kathleen Cuningham Foundation 
Consortium for Research into Familial Breast Cancer (kConFab) included in this work were 
derived from 17 BRCA1 or BRCA2 rare variant carriers (nine unique rare variants), and ten 
healthy controls ( 
Figure 2.1, Table 2.1). 
Table 2.1. LCL samples included in this work. 
The corresponding BRCA1 and BRCA2 rare variants contained within each sample are listed. All samples were 
obtained from kConFab. 
Sample ID Variant (BIC) Variant (HGVS) rs ID 
Rare variant carriers     
1 BRCA2 IVS 4-12 -8 del5 c.426-12_8 delGTTTT rs27617844 
2 BRCA1 IVS 23+5 G>C c.5467+5 G>C rs397509287 
3 BRCA2 IVS 25+3 A>T (9501+3 A>T) c.9501+3 A>T rs61757642 
4 BRCA1 IVS 10-2 A>G c.671-2 A>G rs80358108 
5 
BRCA1 IVS 9-2 A>C 
BRCA1 760 A>G (D214G) 
c.[594-2 A>C;  641A>G] 
rs80358033; 
rs55680408 
6 BRCA1 IVS 4-1 G>T c.135-1 G>T rs80358158 
7 BRCA2 8216 A>T (E2663V) c.7988 A>T rs80359031 
8 BRCA2 IVS 20+1 G>A c.8632+1 G>A rs397507997 
9 BRCA1 2640 C>T c.2521 C>T rs1800709 
10 BRCA1 2640 C>T c.2521 C>T rs1800709 
11 BRCA1 2640 C>T c.2521 C>T rs1800709 
12 BRCA1 2640 C>T c.2521 C>T rs1800709 
13 BRCA1 2640 C>T c.2521 C>T rs1800709 
14 BRCA1 2640 C>T c.2521 C>T rs1800709 
15 BRCA1 2640 C>T c.2521 C>T rs1800709 
16 BRCA1 2640 C>T c.2521 C>T rs1800709 
17 BRCA1 2640 C>T c.2521 C>T rs1800709 
Controls   
18-27      
Abbreviations: BIC, Breast Cancer Information Core; HGVS, Human Genome Variation Society; ID, Identifier; 





Figure 2.1. Location of BRCA1 and BRCA2 variants in study samples. 
Rare variants are labelled above the genes and common variants (minor allele frequency >5%) are listed below. 
The numbering reflects the cDNA nucleotide, with +1 corresponding to the A of the translation initiation codon 
AUG in the reference sequence of both BRCA1 (GenBank accession # NM_007294.3) and BRCA2 (GenBank 
accession # NM_000059.3). 
 
Variants included in this study are referred to by the recommended Human Genome Variation 
Society (HGVS) (http://www.hgvs.org) nomenclature, including use of A in the ATG 
translation initiation codon to start the nucleotide numbering [den Dunnen and Antonarakis 
2000]. 
2.2 Cell culture 
Lymphoblastic cell lines (LCLs) were cultured in RPMI 1640 media, with fetal calf serum 
(10%) and Penicillin Streptomycin (1%) (Gibco), while incubated at 37ºC in a 5% CO2 
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atmosphere. RNA was isolated from cycloheximide (Sigma, St Louis, MO, USA) treated (four 
hours 100µL/mL) and untreated LCLs using the RNeasy Mini Kit (Qiagen, Valencia, CA, 
USA), according the manufacturer’s instructions. A NanoDrop 8000 UV-Vis 
Spectrophotometer (ND-8000) (Thermo Fisher Scientific, Waltham, MA, USA) was used to 
quantify the RNA, and gel electrophoresis was used to check the RNA quality. 
2.2.1 Salting-out method for DNA isolation 
Cells, obtained from cell culture or the buffy coat of whole blood, were resuspended in 15 mL 
Falcon tubes in a solution containing 1 mL nuclei lysis buffer, 17 µL proteinase K (20 mg/mL) 
and 17 µL 20% SDS. Lysis solution was prepared by combining 10 mL 2 M Tris, pH 8, 0.8 
mL 0.5 M EDTA, pH 8, and 6.6 mL 3 M NaCl. Solution was made up to 200 mL with ultrapure 
water prior to being autoclaved to sterilise. Capped tubes were inverted gently 50 times to mix. 
The solution was transferred into 1.5 mL Eppendorf tubes, prior to incubation at 56°C for 60 
minutes, or until cells were completely lysed. 300 µL saturated NaCl was then added to each 
sample, and the tubes were vigorously shaken for 2 minutes before a 4°C centrifugation for 15 
minutes at 12,000 rpm. The supernatant was extracted, leaving the pellet of precipitated protein 
behind, and transferred into a new 15 mL Falcon tube containing 4.5 mL ethanol, pre-chilled 
in ice. Capped tubes were then gently inverted until the DNA precipitated. A pipette was used 
to transfer 500 µL of the solution, which included all the detectable DNA, into a 1.5 mL 
Eppendorf tube and centrifuged at 13,000 g for five minutes. Supernatant was removed prior 
to resuspension of the pellet in 1 mL 70% ethanol and centrifuged again at 13,000 g for one 
minute. Ethanol was removed, and the DNA pellets were air dried in open tubes for two hours. 
DNA was dissolved in 250 µL TE buffer (10 mM Tris Cl, pH 8.0, 1 mM EDTA) (Qiagen). 
Protocol adapted from [Miller et al. 1988]. 
2.3 cDNA Synthesis 
cDNA synthesis was undertaken using Superscript III First Strand Synthesis System 
(Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. Briefly, each 
20 μL reaction included 10 μL of 2x RT Reaction Mix (oligo[dt]20, random hexamers, MgCl2 
and dNTPs), 2 μL of RT Enzyme Mix (including, Superscript® III RT and RNaseOUTTM) and 
8 μL of extracted mRNA. Reactions were incubated for 10 minutes at 25°C, 30 minutes at 50°C 
 
49 
and 85°C for 5 minutes. 1 μL of E.coli RNase H was then added to each reaction, followed by 
20 minutes incubation at 37°C. Each reverse transcription run included a ‘no template’ control. 
The samples were frozen at -20°C until used for PCR. 
2.4 Polymerase chain reaction 
PCR reaction volumes (25 μL) contained 10 × PCR Buffer (Applied Biosystems, Scoresby, 
Victoria, Australia) (2.5 μL), 10 μM forward primer (1.25 μL), 10 μM reverse primer (1.25 
μL), 10 mM dNTP (Thermo Fisher Scientific) (0.5 μL of each), 25 mM magnesium (1.5 μL), 
5 U/μL AmpliTaq (Applied Biosystems) (0.13 μL), 1 μL cDNA, and 16.87 μL water. PCR 
were carried out using a BioRad iCycler with the following reaction conditions: an initial 
denaturation at 95C for 7 minutes followed by 35 cycles of 94 ºC for 30 seconds 
(denaturation), 55°C for 30 seconds (annealing), 72 ºC for 1 minute (extension) with a final 
extension of 7 minutes at 72C. Primers used were B1_Ex7_F 
(CCAACTCTCTAACCTTGGAACTGTG), B1_Ex9_R 
(CTTCCAGCCCATCTGTTATGTTG) and B1_Ex13-14_R 
(GATGACCTTTCCACTCCTGGTTC). The PCR products were run on an electrophoresis gel 
for analysis and stored at -20C. Primers were ordered from Integrated DNA Technologies 
(IDT) (Coralvilla, USA). 
2.5 Gel Electrophoresis 
PCR products were run on an electrophoresis gel, which was made up of 70 mL of 1 × TBE 
and 1.05 g of agarose (Lonza Group, Switzerland). 10 × TBE contained 108g Tris, 55g 
orthoboric acid and 3.7g EDTA, made up to one litre with millipore purified water. 1% agarose 
gels were prepared by heating the agarose and TBE for 1.5 minutes in a microwave until the 
agarose had completely dissolved. 2.5 µL SYBR® Safe DNA gel stain (Invitrogen) was then 
added and mixed gently. The gel was cooled slightly before it was poured into a 9 cm × 11 cm 
gel tray, which contained two lines of 14 wells. 1xTBE buffer was used to completely submerge 
the gel. Each sample was mixed with 1/5th volume of 10 × Blue Juice Gel Loading Buffer 
(Thermo Fisher Scientific) before being loaded. 2 µL 100 bp DNA Ladder was mixed with 
loading buffer for the first space in the gel. Gels were run at 70 watts for 60 minutes. 
 
50 
2.6 Automated electrophoresis 
Visualisation using the automated Microchip Electrophoresis System for DNA/RNA Analysis 
MCR® 202 (MultiNA) system (Shimadzu Corporation, Kyoto, Japan) was undertaken as 
follows. A separation buffer, marker solution and ladder solution were required, but varied 
depending on the mode of analysis undertaken (DNA-500, DNA-1000 and DNA-2500). Here, 
DNA-1000 separation buffer was used to allow for the detection of molecules up to 2000 bp in 
length. The DNA-1000 separation buffer was freshly prepared with 1 × SYBR® Gold Nucleic 
Acid Gel Stain (Life Technologies, Carlsbad, CA, USA) at a 100:1 ratio. The required amount 
of each reagent for each run depended on the number of samples processed and was calculated 
by the platform software. Each solution was placed in its designated location within the 
MultiNA instrument prior to automated processing of the samples. The resulting 
electropherograms were visually inspected to check that the ladder markers had separated as 
expected with the upper and lower markers present, indicating that the analysis was suitably 
complete. 
2.7 Cloning 
Agar plates were prepared prior to cloning. First 20g LB broth base (Invitrogen) was added to 
1 litre of H2O, mixed then autoclaved, to make the LB broth. 15 g agar per litre of LB broth 
was mixed, autoclaved, then 50µg/mL of ampicillin antibody was added and the solution 
poured into agar plates (~4 mm thick). Plates were immediately covered, left to set, and stored 
at 4°C. 
Cloning of plasmids was undertaken using the TOPO® Cloning reaction kit (Qiagen) following 
the manufacturer’s instructions. Briefly, a reaction mix containing PCR product (2 µL), salt 
solution (1 µL), water (2 µL) and Topo® vector (1 µL) was mixed and incubated at room 
temperature for 5 minutes to yield colonies for analysis. This was stored on ice before 2 mL 
was added to one vial of One Shot® Chemically Competent E. coli, and incubated on ice for 
up to 30 minutes. Cells were then heat-shocked for 30 seconds (42°C) then stored back on ice. 
250 µL of room temperature S.O.C. medium (Invitrogen) was added before a 37°C incubation 
while shaken for 1 hour. 15 µL from each transformation was spread onto a pre-warmed 
selective agar plate and incubated overnight at 37°C.  
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2.7.1 Colony selection 
Up to 20 isolated colonies were selected and half of each was individually transferred into 50 
µL of sterile water. Each sample was then boiled for 10 minutes before centrifugation at 16,000 
× g for 5 minutes. Supernatant (2.5 µL) was analysed using PCR (Section 2.4), and amplified 
products were visualised on an agarose gel (Section 2.5) to select colonies for further 
investigation. 
2.7.2 Plasmid extraction 
The remaining half of the chosen colonies were transferred from the agar plate into 50 mL 
Falcon tubes with 3 mL of LB broth. These tubes were stored on a moving incubator (200 rpm) 
at 37°C for 12 hours before extracting the plasmid using a QIAGEN Plasmid Mini kit, 
following the manufacturer’s protocol. 
Briefly, bacterial cultures were harvested by centrifugation (6000 × g for 15 minutes at 4°C). 
The bacterial pellet was re-suspended in 0.3 mL Buffer P1 before adding 0.3 mL Buffer P2 and 
mixing by inverting tubes 4–6 times. Tubes were then incubated at room temperature (15–
25°C) for 5 min. Pre-chilled Buffer P3 (0.3 mL) was added and mixed by inverting tubes 4–6 
times before incubating on ice for 5 min. Tubes were centrifuged (15,000 × g) for 10 minutes 
at 4°C before the supernatant was transferred into an equilibrated QIAGEN-tip flow column 
and left to transfer through by gravity flow. Buffer QC (2 mL) was used twice to wash the flow 
column. Buffer QF (0.8 mL) was then used to elute the DNA into a 1.5 mL Eppendorf tube. 
DNA was precipitated by adding 0.56 mL (0.7 volumes) isopropanol then pelleted by 
centrifugation (15,000 × g for 30 min) at 4°C. Supernatant was removed and the DNA pellet 
washed with 1 mL 70% ethanol prior to centrifugation (15,000 × g for 10 min). Supernatant 
was decanted, and DNA pellets were left at room temperature to air dry before resuspension in 
50 µL TE buffer (pH 8.0). 
2.7.3 DNA Digestion 
DNA was digested using the Tango enzyme (Thermo Fisher Scientific). Each sample’s reaction 
mix contained 10 × Buffer (2 µL), substrate DNA (1 µL), restriction enzyme (Tango) (10 × 1 
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µL) and water (to 20 µL). Reactions were incubated at 37°C for 1.5 hours. Digestion was 
checked on an agarose gel and sequences confirmed with Sanger sequencing. 
2.8 Sanger Sequencing 
Sanger sequencing was completed by Macrogen (Seoul, Korea). Samples (10 µm, 100 ng/µL) 
were sent for analysis in deionized water. Sequencing reagents and primers were provided by 
Macrogen. Raw sequencing files were analysed using GeneiousTM software (Biomatters, Ltd., 
Auckland, New Zealand). 
2.9 RNA-seq analysis 
Targeted RNA-seq was undertaken by NZGL (New Zealand Genomics Limited) on all 
cycloheximide treated and untreated LCLs using the Truseq Targeted RNA Expression kit 
(Targeted RNA-seq) (Illumina Inc., San Diego, CA) (see Section 1.5.8.1.4) on the MiSeq. The 
targeted sequencing assay was custom designed in Illumina’s design studio using 34 BRCA1 
and 28 BRCA2 oligonucleotides chosen from a database of predesigned probes (Figures 2.2 
and 2.3; Appendix A, Tables S1 and S2). Capture of the targeted cDNA sequences was 
performed according to the manufacturer’s specifications (Figure 2.4). Raw single-end reads 
were returned for processing. 
BRCA1 and BRCA2 mRNA splicing isoforms were also analysed using whole transcriptome 
data from one control LCL (Sample #24, Table 2.1). The sample was sequenced twice, 
cycloheximide treated and untreated, on the HiSeq2000 (2×100 paired-end) using the Truseq® 






















Figure 2.4. Truseq Targeted RNA Expression assay summary. 
After cDNA synthesis each oligonucleotide pair hybridises to their complementary sequence upstream and 
downstream of the region of interest on the target cDNA fragment. An extension-ligation reaction extends from 
the upstream probe to the downstream probe to form the template strand, which is PCR amplified using primers 
that add an index at each end. AMPure XP beads (Agencourt Bioscience, Beverly, MA, USA) are then used to 
purify the PCR products and the libraries are pooled to create a sequence ready library (Illumina Data Sheet, 
Truseq® Targeted RNA Expression) for the MiSeq platform (Illumina Inc.). 
 
2.9.1 Read mapping and processing 
Targeted RNA-seq and whole transcriptome read mapping was undertaken as follows. The 
Homo_sapiens.GRCh37.72 reference genome was downloaded from Ensembl 
(ftp://ftp.ensembl.org/pub/release-72/fasta/homo_sapiens/dna/Homo_sapiens.GRCh37.72.dna 
.primary_assembly.fa.gz) and the chromosomes arranged into lexicographic order prior to 
mapping. Sequence reads were mapped using the two pass approach of the STAR (Spliced 
Transcripts Alignment to a Reference) aligner using the default settings unless specified 
otherwise [Dobin et al. 2013]. The second pass incorporated an updated genome that 
augmented the additional splice junctions detected in the first mapping pass to improve 
mapping accuracy and increase the number of successfully mapped reads. Maximum intron 
length was set to 100,000 nucleotides to accommodate for splice junctions that span the length 
of each gene. Detected splice junctions for each sample were extracted from STAR’s SJ.out 
file for further analysis. Coding for all mapping steps is shown in Appendix B; sample- and 
junction-specific read counts are listed in Appendix C (Table S3-Supplementary Table 9). 
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2.9.2 Targeted RNA-seq data analysis: Normalisation 
Raw read counts of all alternative splicing events were normalised to measure the relative 
number of individual spliced exon/exon junctions in each sample. This was achieved by 
calculating the read depth of the full length transcript. To normalise read depth, the total read 
count between two adjacent exons (exons 2 and 3 in BRCA1 and BRCA2, respectively) was 
used as the reference junction (henceforth referred to as “reference junction”) to calculate the 
relative expression of the full length and alternative mRNA transcripts for both BRCA1 and 
BRCA2. To achieve this, the sum of all non-overlapping exon 2-3 alternative splicing events 
was deducted from the reference junction for each gene independently. This leaves a proportion 
of reads that solely represent the full length transcript (Figure 2.5, Bi). To determine the relative 
proportion of each splice junction, the total number of reads for each sample was first 
calculated. This consisted of the sum of the reads encompassing the alternative splicing events 
together and the previously calculated full length transcript (using reference junction exons 2-
3, see above) (Figure 2.5, Bii). The relative proportion of the individual isoforms in each 
sample is determined by dividing its respective read count by the total number of reads for that 
sample (Figure 2.5, Biii). These expression values were incorporated into a comparative 
expression analysis, using the mean and standard error (95%) of each isoform across the 
controls. This approach does not account for the possibility that some of the detected alternative 






i. Calculate full length transcripts 
 = RJ-∑(non-overlapping AJ) 
 = 1000-100(∆4)-200(∆5) 
FL = 700 
ii. Calculate the total number of transcripts expressed (TE) 
 = FL + ∑(AJ) 
 = 700 + (100+50+100+200) 
TE = 1150 
iii. Calculate expression levels of splicing events (AJ/TE) 
(See expression column) 
Figure 2.5. Exemplar of how splice junction expression was calculated from Targeted RNA-seq data.  
A. Alternative splicing events that overlay the shaded region (i.e. ∆2 and ∆3-4) indicate those that would be 
excluded from the full length calculations (B.i.). Exons directly involved with an exon skipping event are indicated 
with solid lines. B.i-iii Calculations for determining expression of each detected junction. AJ – Alternate junction; 
RJ – Reference junction. 
 
Alternative events were excluded from these calculations if they had questionable probe 
efficiency (as observed for BRCA1 FL 10-11 and ∆9-10; see Appendix C, Supplementary Table 
S4) or were common NAG events [Hiller et al. 2004]. These are shown to commonly co-occur 
with the other events detected [Colombo et al. 2014], and so are not deducted as separate 
alternative splicing events when calculating the full length transcript. The resulting proportions 
were compared using complementary log-log confidence intervals [Brown et al. 2001]. 
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: Variability and reproducibility of BRCA1 and BRCA2 
mRNA isoforms detected in splicing assays 
3.1 Introduction 
Variant assessment, using splicing analysis, is performed in a growing number of research and 
clinical laboratories worldwide, using an unstandardised assortment of patient tissue types and 
protocols, which has led to several cases where splicing assays have resulted in conflicting 
classifications (such as BRCA1 variants c.212+3A>G, c.670+8C>T, and c.736T>G and BRCA2 
variant c.517-19C>T, as listed in Whiley et al. (2014)). Establishing whether this reported 
variability is a consequence of protocol diversity has not been previously assessed. It is also 
not understood how this variability influences the uniformity of results between published 
studies.  
The following research was undertaken as part of a project initiated by the ENIGMA Splicing 
Working Group to determine the extent of variation in mRNA splicing profiles between 
multiple research and diagnostic laboratories. All 23 participating laboratories used their 
preferred protocols to assay the same lymphoblastoid cell lines (LCLs) to identify the spectrum 
of splicing changes occurring within a cohort of individuals carrying known BRCA1 and 
BRCA2 variants [Whiley et al. 2014]. Phase one of this study required laboratories to identify 
the isoforms present in each sample using their in-house protocols. Phase two was carried out 
for one LCL using a standardised PCR assay design [Whiley et al. 2014].  
I undertook analysis of LCLs as an extension of phase two, including BRCA1 c.671-2 A>G, 
which was identified in phase one to contain a large number of mRNA isoforms with varying 
expression levels, none of which were detected consistently across laboratories. Differences 
between each participating laboratory, in both their protocols and results, allowed a 
comprehensive analysis to help establish guidelines on optimal methods for mRNA detection 
to maximise consistency and sensitivity across laboratories. However, the role of 
methodological factors (cell culture, storage and assay design) that potentially contribute to 
variability in isoform expression patterns was unclear. Each of these factors has the potential 
to play a role in what mRNA transcripts are detected at a given time point [Warren et al. 2006]. 
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Therefore, a more in-depth assessment of BRCA1 splicing was conducted to determine whether 
inter-laboratory factors contribute to intra-laboratory variation in mRNA isoform detection.  
3.2 Methods 
3.2.1 Subjects and lymphoblastoid cell-lines 
LCLs from the Kathleen Cuningham Consortium for Research into Familial Breast Cancer 
(kConFab) were cultured at QIMR Berghofer Institute of Medical Research and sent to each 
participating study site for analysis (Samples #1-8, 18-27, Table 2.1). Phase one of this study 
was undertaken by 16 diagnostic and research laboratories, using their own PCR-based 
protocols to detect BRCA1 or BRCA2 mRNA isoforms for each sample (Appendix D, Table 
S10). The second phase of this work required 10 laboratories to repeat the analysis for all 
variants, and 12 laboratories (including the Mackenzie Cancer Research Group) to repeat the 
analysis for LCLs from one variant (BRCA1 c.671-2 A>G (Sample #4, Table 2.1)) carrier using 
specified primers and PCR cycling conditions. This analysis focused on BRCA1 c.671-2 A>G 
and ten controls (Samples #4, 18-27, Table 2.1) to establish which BRCA1 mRNA isoforms 
are present in LCLs derived from the rare variant carrier and non-variant controls.  
3.2.2 cDNA synthesis and PCR analysis 
LCLs were cultured for one week and analysed using methods described in Chapter 2. Briefly, 
RNA was extracted from LCLs cultured with and without cycloheximide (100µg/mL, four 
hours), followed by cDNA synthesis (Superscript III First Strand Synthesis System, Thermo 
Fisher Scientific), according to the manufacturer’s instructions (Section 2.3). PCR was 
undertaken as specified in Section 2.4, with the location of the BRCA1 primers specified by the 
ENIGMA Working Group (Table 3.1) illustrated in Figure 3.1. The PCR products were 
visualised using electrophoresis on a 1.5% agarose gel and using the MultiNA Microchip 
electrophoresis system (Section 2.6). Isoforms that contain all known exons between the 





Table 3.1. Primers and PCR cycling conditions specified by ENIGMA for analysis of BRCA1 c.671-2 A>G 
[Whiley et al. 2014]. 
 
Forward Primer Reverse Primer 
Amplicon 
   size 
Anneal 
Temp ᵒC 
1 CCAACTCTCTAACCTTGGAACTGTG CTTCCAGCCCATCTGTTATGTTG 510 56 
2 CCAACTCTCTAACCTTGGAACTGTG GATGACCTTTCCACTCCTGGTTC 719 56 
 
 
Figure 3.1. Positioning of PCR primers in the BRCA1 gene shown from exon 8 to exon 15.  
F denotes the forward primer for both assays, and R1 and R2 mark the position of two reverse primers. 
 
3.2.3 Time point assessment of mRNA isoform expression 
With the aim of eliminating as many external factors as possible that could otherwise influence 
mRNA isoform detection, a single standardised splicing protocol was used to analyse one 
sample at multiple time points during normal culturing practices. This study focused on one 
LCL, not known to contain any BRCA1 variants (Sample #7, Table 2.1). 
The LCL was cultured to confluence at six time points, and RNA isolated at 1-2 week intervals, 
using the GeneJET Purification kit, according to the manufacturer’s instructions 
(Thermo Fisher Scientific). At each time point half of the cultured cells were treated with 
cycloheximide for 4 hours. The remaining cells continued in culture for a week between 
treatments to allow for adequate growth to replenish the population. The second and fourth 
time points included a freeze-thaw process where the cells were stored in liquid nitrogen 
overnight and thawed the following day to continue culturing (Figure 3.2). 
 
 
Figure 3.2. Six replicates of an LCL (Sample #7) taken at time points one week apart. 
Time points are indicated by tube labelling. Sun symbols are reference to cell thawing, snowflakes are reference 




PCR products were visualised on the MultiNA Microchip electrophoresis system. Selected 
fragments from PCR-amplified samples were cloned with the TOPO® TA Cloning® Kit for 
Sequencing, using One Shot® TOP10 Chemically Competent E. coli (Invitrogen) (Section 
2.7), prior to Sanger sequencing to confirm the isoforms present.  
3.3 Results 
3.3.1 Inter-laboratory analysis of BRCA1 isoforms 
BRCA1 splicing analysis of RNA from a BRCA1 c.671-2 A>G carrier and 10 non-carrier 
controls (Samples #4, 18-27, Table 2.1) was performed by 12 laboratories using primers 
encompassing exons 9-13. Using my protocol (study site #20) as one of the 12 laboratories, a 
total of eight BRCA1 mRNA isoforms were identified in both the carrier and at least one control 
(Figure 3.3, Table 3.2) using the primer design and PCR conditions established by ENIGMA. 
Five isoforms (full length (FL), ∆9, ∆9-10, ∆(9,10,11q), ∆11q) were identified in all samples; 
∆9-11 was identified in the case and eight of the controls, whereas ∆10-11 and ∆(9,11) were 
identified in the case and only two controls (Figure 3.3C). While laboratories that were not 
utilising capillary gel electrophoresis for PCR product detection identified between three and 
seven isoforms, the protocol used here identified eight isoforms (  
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Table 3.3), each of which was identified by at least one other site (Table 3.2). These results 
show that qualitative analysis alone was insufficient to show a clear difference between isoform 
expression patterns in the carrier LCL and non-carrier controls. 
Despite the standardisation of significant parts of the protocols used by the participating 
laboratories, five different PCR product detection methods were utilised (see Whiley et al. 
(2014)), each providing a different level of detection sensitivity and so adding another level of 
variability in the results. For this step the protocol used here differed from the majority by using 
the MultiNA, whereas the other components and procedures used up to this point were also 
utilised by several other laboratories. The suggested protocol changes allowed all the 
laboratories to detect at least half of the highly abundant transcripts, of which were not 
consistently identified in phase one, plus at least one additional alternative splicing event in 
most cases [Whiley et al. 2014].  
 




  1 2 3 4 5 6 7 8 9 10 
Primers 
1 
FL 510 + + + + + + + + + + + 
Δ9 464 + + + + + + + + + + + 
Δ9-10 387 + + + + + + + + + + + 
Primers 
2 
Δ11q 719 + + + + + + + + + + + 
Δ9,10,11q 596 + + + + + + + + + + + 
Δ9,11 553 +     +   +           
Δ10,11 522 +             + +     
Δ9-11 476 + +     + + + + + + + 
Figure 3.3. MultiNA RNA- 1000 ladder analysis of LCLs for ENIGMA study. 
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(A) Primers in BRCA1 exon 8 [F] and 14-15 [R2]; (B) Primers in BRCA1 exons 8 [F] and 11 [R1]. Control numbers 
correspond to the samples listed in Table 2.1; (C) Summary of mRNA transcripts identified across the case 
(BRCA1 c.671-2 A>C) and study controls. 
 
Table 3.2. BRCA1 c.671-2 A>G transcripts identified using PCR-based assays. 
Transcripts identified by the subset of laboratories included in both phase one and phase two compared to the 
transcripts identified in this study (Laboratory 20) are shown. See full list in Whiley et al. (2014). Sites 2 and 8 
employed capillary electrophoresis for the detection of PCR products. 
 Phase 1  Phase 2 
 Site  Site 
Transcript 1 2b 3 4 8b 16  1 2
b 3 4 8b 16  20
ac 
FL + + + - + +  + + + + + +  + 
Δ9 - + - - - -  - + + - + -  + 
Δ9-10 + + - - + +  + + + + + +  + 
Δ9-11 + + - - + +  + + + + + +  + 
Δ9,10,11q  + + - - + -  + + - - + -  + 
Δ10  - - - - - -  - + - - + -  - 
Δ11 + + + + + +  + + + + - +  - 
Δ11q - + - + + -  - + - + + -  + 
Δ9-12 - - - - - +  - - - - - +  - 
Δ9,11 - + - - - -  - + - - - -  + 
Δ10-11 + + + - + +  + + + + + +  + 
Δ10,11q - - - - - -  - - - - + -  - 
Δ11-12 - - - - - -  - + - - - -  - 
Δ~3.2kb exon 11 + - + - + -  + - - - - -  - 
Δ9,11q - - - - - -  - + - - + -  - 
ins i21 - - - - - -  - - - - + +  - 
Δ11q+ins i13 - - - - - -  - + - - + -  - 
a The results from my protocol. 
PCR product analysis technique: b Capillary electrophoresis; c MultiNA; the remaining laboratories listed here 
used sequencing. All laboratories listed here except site #2 used NMD inhibitors. 
 
 
3.3.2 Time point assessment of RNA isoform expression using RT-PCR 
The second stage of this project was undertaken to investigate the contribution of LCL storage 
in liquid N2 and culture to variability in RNA isoform detection. RT-PCR assays identified 11 
isoforms in the LCL sample #7 (Table 2.1) in at least one of the six time points (Figure 3.2). 
Eight of these isoforms were annotated after detection by MultiNA. Δ9-10, Δ11q, Δ(9,10,11q) 
and the full length isoform levels appeared to be higher than the other isoforms in both the 
cycloheximide treated and untreated samples for all time points assayed. However, this is based 
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on semi-quantitative PCR-based data. A notable exception was the weak detection of 
Δ(9,10,11q) isoform at time point 1a (treated) (  
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Table 3.3). Two additional isoforms were also detected at moderate levels across every time 
point, but not in both the treated and untreated samples. The Δ9 frameshift isoform was not 
detected in the treated 1b and 2a time points, while the in-frame Δ9-11 isoform expressed solely 
in the untreated samples across all time points (  
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Table 3.3). The remaining two isoforms were both frame-shifts events. Δ10 was detected in the 
treated and/or untreated sample across five time points, while Δ(10,11q) was detected only in 
the treated sample at three time points, in addition to both treated and untreated samples in 3b, 
consistent with what would be expected for out of frame NMD isoforms (  
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Table 3.3).  
Cloning validated several isoforms (  
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Table 3.3), including the FL, Δ9-10 and Δ11q, while also detecting an additional isoform (Δ9-
12) in the 3a untreated sample and highlighting the predominant Δ13p (NAG) present in 
conjunction with Δ11q and Δ11q, ▼12 (66nts). Small sequence additions and deletions, such 
as Δ13p NAG events, are not distinguishable from other events when detecting solely with the 
MultiNA. The MultiNA image of these results is in Appendix E (Figure S1). 
Variability was observed when studying mRNA isoforms of a LCL in a single laboratory; 
however, no consistent effects were identified between the detected mRNA isoforms and liquid 




Table 3.3. BRCA1 mRNA splicing isoforms for Sample #7 detected using RT-PCR at six time points.  
+ denotes the isoforms detected at that time point. Shading indicates the relative signal intensity form the PCR 
products analysed by the MultiNA. 
  Time point 1a 1b 2a 2b 3a 3b 
 Primers 1 Treated/Untreated T U T U T U T U T U T U 
FL 510 + + + + + + + + + + + +# 
Δ9 465 + +   +   + + + + + + + 
Δ10 433 +     + +   +   + +     
Δ9-10 398 + +# + + + + + + + + + +# 
  384   +                     
  353           + + + + + + + 
Primers 2                           
Δ11q, ins i12 Δ13p 782 +   +# +           +   + 
Δ11q (del 3309) 719 + + +#* + + + + + + + + + 
  690     + +               + 
Δ9,10,11q 596 + + + + + + + + + + + + 
Δ10,11q 524     +   +   +       + + 
Δ9-11 479   +   +   +   +   +   + 
Abbreviations: T, Treated with cycloheximide; U, Untreated.  
#Isoforms validated using Sanger sequencing.  
*Sequencing of cloned PCR products detected Δ11q, Δ13p (3nt) for this band, which was not distinguishable from 
Δ11q using MultiNA. 
 
3.4 Discussion 
The importance of including mRNA splicing assays as a means to enhance current variant 
classification tools has been highlighted previously [Walker et al. 2013]. Cases have come to 
light where inconsistent splicing aberrations have been reported [Whiley et al. 2014], 
questioning the current tool’s effectiveness for determining a variant’s true impact on mRNA 
splicing. The main aim and greatest challenge of these analyses is to separate variant-induced 
splicing changes from normal splicing events associated with BRCA1 and BRCA2. Establishing 
a protocol that utilises the most sensitive and consistent detection methods is an essential step 
toward gaining comparable and accurate results for making more informed decisions regarding 
variant classification [Hongoh et al. 2003]. Furthermore, eliminating methodological factors 
that alter detected mRNA isoform expression patterns will help better determine what changes 
result from genetic variants. 
The ENIGMA-based study showed that careful planning of primer positioning and PCR 
cycling conditions is essential for any splicing assay. Incomplete results from suboptimal assay 
design can limit what mRNA isoforms are detected, and therefore the identification of a 
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spliceogenic variant [Whiley et al. 2014]. Standardising these conditions in phase two of the 
study highlighted a significant improvement across all laboratories in the detection of BRCA1 
c.671-2 A>G mRNA isoforms, while a comparable number of isoforms was also detected in 
our assay using these specified conditions. Primers positioned in exon 9 and/or 10 in phase one 
prevented two thirds of the groups from detecting several major transcripts for this variant, 
which had exons 9, 10 and/or 11 deleted [Whiley et al. 2014]. This highlights the importance 
of primer design, especially as primers located in deleted exons will prevent the detection of 
certain transcripts (Figure 3.4). Several sets of primers should be used in each gene studied, 
ideally located in constitutively expressed exons [Gardina et al. 2006], as this may improve 
transcript detection rates when prior knowledge of transcripts is limited, or not available.  
 
 
Figure 3.4. Exemplar of mRNA isoform detection with primers situated at different locations within the 
mRNA transcript.  
A, B and C represent the locations of three separate forward primers, each with the same reverse primer located 
in exon 11. Ticks and crosses represent the ability of each primer pair to detect each of the three splicing isoforms. 
 
 
Additional transcripts for BRCA1c.671-2 A>G, including the FL, were not identified by some 
laboratories in phase one as the number of PCR cycling conditions was not sufficient to extend 
down and amplify transcripts longer than 3kb. Other transcripts were not detected consistently, 
which could be assumed to be because they are of very low abundance. While RT-PCR is very 
sensitive, more quantitative techniques are required to assess these isoforms and accurately 
determine the levels at which they are expressed. 
While the combination of cloning and sequencing PCR products helps to isolate expressed 
transcripts, and is shown to be more accurate than sequencing alone, the most sensitive method 
highlighted in this study was capillary gel electrophoresis [Whiley et al. 2014]. Our splicing 
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protocol incorporated the MultiNA, which was the next most sensitive detection method. Using 
this technique, a higher number of isoforms was identified compared to all the laboratories that 
did not utilise capillary gel electrophoresis in phase two (Sites 1, 3, 4 and 16). The laboratories 
that used capillary gel electrophoresis in phase two (sites 2 and 8) displayed a high level of 
consistency between their detected isoforms, while the use of NMD inhibitors by Site 8, but 
not Site 2, did not seem to have any effect on the number of isoforms each site identified. The 
only other site that did not use NMD inhibitors in phase two (Site 18) opted for band excision 
and sequencing for product detection and only reported the prominently expressed mRNA 
isoforms. RT-PCR-based assays with MultiNA detection were able to identify the majority of 
isoforms with and without NMD inhibitors, with many of the less prominent isoforms detected 
in the treated sample at multiple time points. It could be expected that isoforms containing 
premature termination codons would be present in a sample for a short period before the 
initiation of translation; however, very sensitive methods would be required to detect them, 
making the decision for the use of NMD inhibitors dependent on the technology available for 
detection. My protocol did not include either sequencing or capillary electrophoresis which 
might allow for more sensitive detection of less abundant isoforms; however, these PCR-based 
tools will only provide non-quantitative expression information. 
As shown in this study, a standardised mRNA splicing protocol improved the consistency and 
reproducibility of the isoforms detected in samples across different laboratories; however, 
variability remains. While much of the persisting inconsistency is shown to be attributed to 
protocol differences, standardising these protocols does not eliminate all variation, and the aims 
of the research utilising these protocols do not take into consideration the additional factors 
that could be responsible for the remaining differences identified between groups. A level of 
variation is likely to be biological, potentially caused by normal cell cycling fluctuations, 
genetic, or epigenetic differences [Wills et al. 2013]. There are also many technical elements 
that could be influencing the observed expression pattern. Differing cell culture practices, and 
mRNA expression variability between sample aliquots, may be having an impact, in addition 
to the capabilities between the range of instruments, kits, and treatment protocols currently 
available. The impact of many of these factors has not individually been tested previously. The 
detection rate of the major BRCA1 mRNA isoforms was consistent across the time points 
(regardless of NMD treatment or number of liquid N2 freeze-thaws or period of culturing) for 
Sample 7 (Table 2.1) using our standardised protocol; however, a level of variability remained 
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in the minor isoforms. This detection pattern is likely explained by the expression level of each 
isoform, as indicated by the strength of MultiNA bands. The isoforms displaying weaker bands 
are likely expressed at a low level, making them more difficult to detect, which suggests that 
their detection rate will be more variable than higher expressed isoforms. My findings are 
consistent with a subsequent ENIGMA study [Colombo et al. 2014], showing consistent 
detecting of “predominant” (Δ9-10, Δ11q and Δ9-11) isoforms across all time points, whereas 
the other “minor” isoforms were detected sporadically. 
Isoform detection is restricted by the capabilities of the available technologies as the mRNA 
expression levels in some samples may exist below the detection level of the assay. This would 
explain the disparity of what minor isoforms were reported by each of the laboratories in the 
first part of this work, in addition to the reduced variability when the same detection technology 
was used for the LCL culture (Sample #7) time points. It is important to accentuate that the 
splicing events detected here are not necessarily present at the same level in each of the cells 
sampled, nor does the overall expression level of each isoform remain at a fixed level over time 
[Raj et al. 2006]. The variation observed in these assays is representative of the mRNA isoform 
expression fluctuations that we would expect to see naturally for BRCA1 and BRCA2 in LCLs 
studies. Quantitative methods are therefore necessary to accurately determine normal 
expression levels in the tissue(s) being assayed. 
The results from this study provide a better understanding of how well diagnostic and research 
laboratories are profiling variant-induced splicing changes, which can be used as evidence 
toward variant classification [Whiley et al. 2014]. As highlighted here, there is huge disparity 
in mRNA isoform detection methods based on RT-PCR technology. The work reported here 
for phase two of the study coined by the ENIGMA splicing working group helped highlight 
how utilising a well-researched primer design and associated PCR conditions improved the 
consistency in mRNA detection in a BRCA1 rare variant carrier. The work in phase one was 
limited by these factors, as the primers were often designed by the participating laboratories to 
be too close to the variant of interest to detect the expressed mRNA changes. These detection 
differences could potentially lead to conflicting classifications concluded from the observed 
splicing aberrations. Interestingly, culturing practices are unlikely to play a role as no 
relationship was observed between the mRNA isoforms detected and the time points of 
culturing or the number of liquid N2 freeze-thaws undertaken. However, the use of NMD 
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inhibitors was found to improve mRNA isoform detection. Finally, analysis should not be 
restricted to a qualitative assessment of the expressed transcripts. Instead, the utilisation of new 
quantitative technologies is required to better assess the effect of BRCA1 and BRCA2 
spliceogenic variants on isoform expression levels. 
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: Comprehensive review of naturally occurring BRCA1 
and BRCA2 mRNA isoforms with quantitative measurement 
4.1 Introduction 
Distinguishing between normally expressed and aberrant BRCA1 and BRCA2 mRNA isoforms 
has been facilitated over the past few years with in-depth qualitative data published for each 
gene [Colombo et al. 2014, Fackenthal et al. 2016]. Such information is critical for applying 
mRNA splicing information to the 5-tier classification system developed by the ENIGMA 
consortium (Evidence-based Network for the Interpretation of Germline Mutant Alleles) for 
interpreting possible spliceogenic variants [Walker et al. 2013]. Splicing assays have 
historically employed a semi-quantitative PCR-based approach; however, such assays are 
limited in their ability to fully evaluate mRNA isoform expression patterns. These 
methodological issues have been previously highlighted and include 1) incomplete gene 
coverage with PCR primers designed to encompass a subset of exons, 2) lack of sequence 
information to confirm isoform type, and 3) non-quantitative assessment of isoform expression 
patterns [Walker et al. 2013, Whiley et al. 2014].  While a multi-laboratory study (Chapter 3) 
showed that different cell culture and storage protocols were not shown to contribute to 
variability in splicing assay results [Whiley et al. 2014], quantitative assessment was not 
undertaken for this analysis. One such protocol under consideration is the use of nonsense-
mediated decay (NMD) inhibitors, which facilitates the detection of mRNA transcripts that 
would otherwise be degraded within the cells. While many studies have highlighted the 
importance of employing NMD inhibitors to enhance the likelihood of isolating aberrant 
mRNA transcripts [Thomassen et al. 2012, Walker et al. 2013], several laboratories do not 
include them in their splicing protocols [Whiley et al. 2014]. A consensus of whether NMD 
treatment should be undertaken routinely is required to standardise mRNA splicing assays and 
make the splicing patterns observed more comparable across studies. It remains unclear 
whether standardising culture and assay protocols will reduce the inter-laboratory isoform 
expression variability observed by Whiley et al. (2014). 
Increased utilisation of RNA-seq technology bypasses many of the difficulties associated with 
consistency and comparability between PCR-based assays, but not without introducing new 
challenges. Decreasing cost associated with this technology, together with an ever advancing 
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understanding of bioinformatics capabilities, will increase the progression away from PCR-
based assessment of gene expression. The capability of RNA-seq platforms to detect mRNA 
isoforms qualitatively and quantitatively [Wang et al. 2009, Trapnell et al. 2010] enables 
comprehensive transcript profiling to be carried out across the whole gene. Such information 
is critical for evaluating the relationship between genetic variants and expression of both 
mRNA isoform type and quantity. By establishing a range of gene-specific ‘normal’ mRNA 
expression profiles, variants causing BRCA1 and BRCA2 isoform expression change may be 
more easily identified. 
In this study, a targeted RNA-seq approach was utilised to provide the first comprehensive 
review of the naturally occurring BRCA1 and BRCA2 mRNA isoforms that includes 
quantitative assessment. These results show that the relative levels of alternate transcripts 
compared to the full-length transcripts differ between BRCA1 and BRCA2. 
4.2 Methods 
4.2.1 Samples 
mRNA splicing isoforms were analysed in twenty-seven lymphoblastoid cell lines (LCLs), 
detailed in Section 2.1 (Samples #1-27, Table 2.1). Cell lines were cultured as stated in Section 
2.2. RNA was extracted using Qiagen RNeasy Mini kit (Qiagen) and reverse transcribed into 
cDNA using Superscript III First Strand Synthesis System (Invitrogen), according to the 
manufacturer’s instructions (Section 2.3). Samples were sequenced using the Illuminas Truseq 
Targeted RNA Expression protocol and the sequence reads were normalised as described in 
Section 2.9. Qualitative detection of each alternative event is recognised if there are at more 
than 10 sample-specific reads are detected that span the junction of interest. 
4.2.2 Quantitative PCR (qPCR) validation of splicing events 
The expression levels observed for the exon 10-11 BRCA1 junction, and associated alternative 
events ∆10 and ∆9-10, were validated with qPCR using the Roche LightCycler® 480 qPCR 
platform (Roche Applied Science, Indianapolis, IN, USA).  
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For each assay, three bulk master mixes (MM) were prepared, each containing a different target 
probe. The volume of each MM was dependent on the number of samples assayed, and an 
additional amount equivalent to an extra sample was included to account for loss when 
pipetting. Briefly, each MM contained 5 µL of KAPA Probe Master Mix (2x), 1 µL DEPC-
treated water, 0.5 µL reference probe (20 µM) (HEX reporter dye, filters 465-510) and 0.5 µL 
of the target BRCA1 probe (20 µM) (FAM reporter dye) primer. Primers were designed to 
encompass each targeted deletion, with the corresponding probe spanning the junction (Table 
4.1). MMs were each mixed with a vortex, before 7 µL was aliquotted into the sample wells of 
a 96 well plate. 3 µL of cDNA (diluted 1:25 in DEPC-treated water) was added in triplicate to 
each MM solution to reach a final reaction volume of 10 µL. The plate was covered with an 
optical sealer and briefly centrifuged in an Eppendorf 5810-R centrifuge to remove bubbles 
and certify that the samples are sitting at the bottom of the wells. The plate was then loaded 
into the LightCycler®. The PCR cycling conditions included an activation step at 95°C for 10 
minutes, followed by 40 cycles of denaturation at 95°C for 20 sec and annealing and elongation 
at 60°C for 1 min. The plate was then cooled and held at 37°C. Samples included BRCA1 c.594-
2 A>C and three controls (Samples #2, #3 and #7, Table 2.1). All probes were synthesised by 
Integrated DNA Technologies, suspended in DEPC-treated water to a concentration of 100 µM 
and stored at -20°C.  
Relative expression was calculated with the LightCycler® Software using the Cp model. ∆Cp 
is the calculated difference between the Ct value (the average threshold cycle of the sample 
triplicates) for the target junction (BRCA1 ∆10, ∆9-10 and FL 10-11) and that of the reference 
junction (BRCA1 FL 2-3). Ct is inversely proportional to the level of cDNA present in each 
sample, determined from the point during the cycling when the amount of fluorescence 







Table 4.1. qPCR probes used to validate mRNA expression levels observed in Targeted RNA-seq data. 






FWD PrimeTime Std DNA Primer I GCTCTTCGCGTTGAAGAAGTA 21 
Hex Rev PrimeTime Std DNA Primer I CACACTTTGTGGAGACAGGTT 21 
PRB PrimeTime Assay Std Probe 5'  /5HEX/AGAGTGTCC/ZEN/CATCTGTCTGGAGTTGA/3IABkFQ/ 26 
        
Delta 
9-10 
FRD PrimeTime Std DNA Primer I TGTGGGAGATCAAGAATTGTTAC 19 
FAM REV PrimeTime Std DNA Primer I CTGGGTTGATGATGTTCAGTATTT 22 
PRB PrimeTime Assay Std Probe 5' 6-FAM/ZEN/3' IBFQ /56-FAM/CCCTCAAGG/ZEN/AACCAGGGATGAAATCA/3IABkFQ/ 27 




FRD PrimeTime Std DNA Primer I TGTGGGAGATCAAGAATTGTTAC 23 
FAM REV PrimeTime Std DNA Primer I CTGGGTTGATGATGTTCAGTATTT 24 
PRB PrimeTime Assay Std Probe 5' 6-FAM/ZEN/3' IBFQ /56-FAM/CCCTCAAGG/ZEN/AACCAGGGATGAAATCA/3IABkFQ/ 26 
        
Delta 
10 
FWD PrimeTime Std DNA Primer I CAACTTATTGCAGCTGCTTGT 21 
FAM REV PrimeTime Std DNA Primer I GCTTCTCAGTGGTGTTCAAATC 22 
PRB PrimeTime Assay Std Probe 5' 6-FAM/ZEN/3' IBFQ /56-FAM/CTGAGACGG/ZEN/ATGTAACAAATACTGAACATC/3IABkFQ/ 30 





4.3.1 Identification of BRCA1 and BRCA2 transcripts from targeted RNA-seq data 
36 BRCA1 and 18 BRCA2 isoforms were detected using RNA-seq in LCLs from healthy 
controls using the probes specifically targeting exons in BRCA1 and BRCA2 (Tables 4.2 and 
4.3). Nomenclature symbols used here are illustrated in Figure 4.1. All samples were cultured 
with and without a NMD inhibitor. Of the isoforms detected, 13 BRCA1 and 14 BRCA2 
transcripts have not been reported in previous publications. Previous studies using qualitative 
data describe “predominant” events as those expressed in a high proportion of the samples 
studied, while the remaining isoforms are defined as “minor” events [Colombo et al. 2014]. As 
expected from predominant events found in Colombo et al. (2014), the most dominant BRCA1 
splicing events detected by targeted RNA-seq were Δ9-10, Δ11q and Δ8p. All four isoforms 
were found in at least eight of the 10 treated controls, NAGNAG events Δ13p and Δ14p were 
both detected in seven controls, and alternative donor shift events ▼1aA and Δ1Aq were 
detected across 10/10 and 9/10 controls, respectively (Table 4.2). In contrast to the other events 
shown here, ▼1aA has not previously been reported as a predominant event. The most 
predominant BRCA2 mRNA splicing events, Δ12 and ▼20, were detected in eight and ten 
controls, respectively. In contrast to the Δ12 event [Fackenthal et al. 2016], BRCA2 ▼20 has 
not previously been observed. Importantly, all predominant events were also detected using the 







Table 4.2. BRCA1 mRNA isoforms detected in controls using targeted RNA-seq. 
Splice Junction 
  




Detected in whole 
transcriptome control 
RNAa Function + NMD - NMD + NMD - NMD 
Cassette               
Δ2 r.-19_80del Non-Coding 2 1 Yes Yes No 
Δ5 r.135_212del No FS 3 3 Yes Yes No 
Δ9 r.548_593del PTC-NMD 4 2 Yes Yes No 
Δ10 r.594_670del PTC-NMD 3 0 Yes Yes No 
Δ11 r.671_4096del No FS 1 2 Yes Yes No 
▼13 r.4357_4358ins4358-2719 No FS 1 1 Yes Yes No 
Δ14 r.4358_c.4484del PTC-NMD 3 1 Yes Yes Yes 
Δ15 r.4485_4675del PTC-NMD 3 0 Yes Yes No 
Δ17 r.4987_5074del PTC-NMD 2 1 Yes Yes No 
Δ21 r.5278_5332del PTC-NMD 1 2 Yes Yes No 
Δ22 r.5333_5406del FS-alt STOP 2 3 Yes Yes Yes 
Multi-cassette        
Δ8-10 r.442_670del PTC-NMD 1 0 Yes Yes No 
Δ9-10 r.548_670del No FS 10 10 Yes Yes Yes 
Splice Acceptor shift        
Δ8p r.442_444del No FS 10 9 Yes Yes Yes 
Δ13p r.4186_4188del No FS 7 4 Yes Yes Yes 
Δ14p r.4358_4360del No FS 7 5 Yes Yes Yes 
Splice Donor shift       
Δ1Aq r.-25_-20del UTR 10 10 Yes Yes Yes 
▼1aA r.-20_-19ins-20+1_-20+89 UTR 9 6 Yes Yes Yes 
Δ5q r.191_212del PTC-NMD 3 1 Yes Yes Yes 
Δ6q r.293_301del No FS 1 0 No Yes No 
Δ11q r.788_4096del No FS 8 8 Yes Yes Yes 
a According to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl 
reference transcript ENST00000357654. 
b Colombo et al. (2014). 
c  Detected from q end and actual length of insertion is unconfirmed. 








Table 4.2. (continued) BRCA1 mRNA isoforms detected in controls using targeted RNA-seq. 
Splice Junction RNAa Function 




Detected in whole 
transcriptome control 
+ NMD - NMD + NMD - NMD 
Splice Acceptor shift +cassette       
▼1aA (89nt) Δ2 r.-20_-19ins-20+1_-20+89 + -19_80del No FS 1 0 No Yes No 
Δ2, Δ3p (7nt)  r.-19_87del Non-Coding 1 0 No No No 
▼10p r.670_671ins670+1-670-21 No FS 1 1 No Yes No 
Splice Donor shift +cassette  
     
Δ1Aq, 2 r.-25_80del Non-Coding 2 2 Yes Yes No 
Δ1Aq-10 r.-25_670del No FS 1 0 Yes No No 
Splice Donor + splice acceptor + cassette        
Δ13q, Δ14-23, Δ24p  r.4355_6858del No FS 1 0 No No No 
Δ13q, Δ14-23, Δ24p r.4334_6867del FS - alt STOP 3 3 No No No 
Exonisation   
     
▼1 r.-20_-19ins-20-620_-20->669 No FS 5 6 Yes Yes No 
▼2c r.80-81del81-3336_81 Unknown 2 1 No Yes No 
▼8c r.547_548 ins 548-202 Unknown 3 0 No Yes No 
▼12c r.4185_4186 ins4186+709 Unknown 2 1 No No No 
▼13c r.4357_4358ins4358-389 Unknown 1 0 No No No 
▼19c r.5193_5194ins5194-1087 Unknown 1 1 No Yes No 
▼21Ac r.5332_5333 ins 5333-866 Unknown 3 1 No Yes Yes 
▼21Bc r.5332_5333 ins 5333-586 Unknown 2 0 No No No 
a According to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl 
reference transcript ENST00000380152. 
b Colombo et al. (2014). 
c  Detected from q end and actual length of insertion is unconfirmed. 








Table 4.3. BRCA2 mRNA isoforms detected in controls using targeted RNA-seq. 
 
 
   




Detected in whole 
transcriptome control 
Splice Junction RNAa Function + NMD - NMD + NMD - NMD 
Cassette               
Δ11 c.1910_6841del No FS 1 1 No Yes Yes 
Δ12 c.6842_6937del No FS 8 2 Yes Yes Yes 
Δ20 c.8488_8632del PTC-NMD 0 1 Yes Yes Yes 
Δ22 c.8755_8953del PTC-NMD 1 0 Yes No Yes 
        
Multi-cassette          
Δ3-4 c.68_c.425del359 PTC-NMD 1 0 Yes No Yes 
Δ9-10 c.682_1909del PTC-NMD 1 1 No Yes Yes 
Δ15-16 c.7436_7805del PTC-NMD 1 0 No No Yes 
        
Splice Acceptor shift        
Δ12p c.6842_6844del No FS 3 1 No Yes Yes 
        
Splice Donor shift          
Δ8q c.681_682ins681+1_681+4 PTC-NMD 1 0 No No Yes 
Δ17q,18p c.7825_8308 del PTC-NMD 0 1 No Yes Yes 
Δ19q,20,21p c.8477_8645 del No FS 1 0 No No Yes 
        
a According to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl 
reference transcript ENST00000380152. 
b Fackenthal et al. (2016). 
c  Detected from q end and actual length of insertion is unconfirmed. 








Table 4.3. (continued) BRCA2 mRNA isoforms detected in controls using targeted RNA-seq.  
Splice Junction RNAa Function 
Number of controls 
expressing (n=10) Identified 
previouslyb 
Detected in whole 
transcriptome control 
+ NMD - NMD + NMD - NMD 
Exonisation        
▼15c c.7617_7618ins7618-212 Unknown 1 0 No No Yes 
▼20A c.8632_8633ins8633-1262_8633-1294 Unknown 10 5 No Yes Yes 
▼20B c.8632_8633ins8633-1327_8633-1264ins64 Unknown 1 0 No No Yes 
ins i24c c.9256_9257ins9257-11559 Unknown 2 1 No Yes Yes 
ins i24c c.9256_9257ins9257-10657 Unknown 7 3 No Yes Yes 
ins i25c c.9648_9649ins9649-781 Unknown 5 3 No Yes Yes         
Intronisation         
Mid exon 11  c.1004_1109 del PTC-NMD 0 1 No Yes Yes 
a According to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl 
reference transcript ENST00000357654. 
b Fackenthal et al. (2016). 
c  Detected from q end and actual length of insertion is unconfirmed. 





Figure 4.1. Illustration of nomenclature used to indicate splicing changes.  
Δ: deletion of part or whole of an exon. “p” or “q” specifies the location of the change as being at the beginning 
or end of the named exon, respectively.▼: insertion of part or whole of an intron. 
 
Eleven BRCA1 and seven BRCA2 alternative transcripts are solely detected in the NMD 
inhibitor treated samples, of which almost all were detected exclusively in a single sample 
(7/11 BRCA1 and 7/7 BRCA2) (Tables 4.2 and 4.3). Of these BRCA1 events, five are in-frame 
or non-coding events each detected in a single control sample, three are intronic retention 
events (▼13, ▼8 and ▼21b), and three are all previously identified frame-shift events 
(BRCA1 ∆10, ∆15 and ∆8-10). ∆10 and ∆15 are detected in three control samples, and ∆8-10 
is detected in a single control (Table 4.2). Seven of the eleven events have not been previously 
identified in previous studies of LCLs. All seven BRCA2 NMD inhibitor treated-specific events 
were detected in a single sample, four of which led to a frameshift (Table 4.3). Three additional 
BRCA2 isoforms were detected solely in single untreated samples (∆20, ∆17q-18p, 
intronisation of mid exon 11). 
The targeted RNA-seq approach utilised here detected 31/63 of the BRCA1 isoforms validated 
in Colombo et al. (2014) (Table 4.4), and 5/22 BRCA2 isoforms seen in Fackenthal et al. (2016) 
(Table 4.5). Of those not detected in BRCA1, the majority (25/32) were due to restricted probe 
placement (confined to those pre-designed for each gene by Illumina), while the remainder 
(7/32) were not expressed at detectable levels in the cultured cell lines (Table 4.4). The majority 
of BRCA2 mRNA isoforms (13/17) were not detected due to probe placement limitations, and 
the remaining four were not expressed, or were expressed at undetectable levels (Table 4.5). 
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Between the observations presented here, and those reported in previous publications 
[Colombo et al. 2014, Fackenthal et al. 2016], all BRCA1 mRNA exons are known to be deleted 
in at least one naturally occurring alternative mRNA transcript. By comparison, seven BRCA2 












detection Reasons for 
non-detection 
Controls Cases 
Cassette biotype     
∆2 r.-19_80del Non-Coding Yes Yes   
∆3 r.81_134del PTC-NMD1 No No No probe set 
▼4 
r.134_135ins135-
4047_135-3932 PTC-NMD No No No probe set 
∆5 r.135_212del No FS Yes Yes   
∆9 r.548_593del PTC-NMD Yes Yes   
∆10 r.594_670del PTC-NMD Yes Yes   
∆11 r.671_4096del No FS Yes Yes   
∆13 r.4186_4357del PTC-NMD No No Probe overlap 
▼13A 
r.4357_4358ins4358-
2785_4358-2719 No FS No No Probe overlap 
∆14 r.4358_c.4484del PTC-NMD Yes Yes (BRCA2)   
∆15 r.4485_4675del PTC-NMD Yes Yes   
∆17 r.4987_5074del PTC-NMD Yes Yes   
∆18 r.5075_5152del No FS No Yes (BRCA2)   
∆20 r.5194_5277del No FS No No Probe overlap 
∆21 r.5278_5332del PTC-NMD Yes Yes   
∆22 r.5333_5406del FS-alt STOP Yes Yes (BRCA2)   
∆23 r.5407_5467del FS-alt STOP No Yes   
Multi-cassette biotype     
∆2,3 r.-19_134del Non-Coding No No No probe set 
∆2-5 r.-19_217del Non-Coding No No No probe set 
∆2-10 r.-19_670del Non-Coding No Yes (BRCA2)   
∆8-9 r.442_593del PTC-NMD No No 
No or low 
expression 
∆8-10 r.442_670del PTC-NMD Yes No   
∆9-10 r.548_670del No FS Yes Yes   
∆9-11 r.548_4096del No FS No Yes   
∆9-12 r.548_4185del PTC-NMD No Yes   
∆10-11 r.594_4096del PTC-NMD No Yes   
∆10-12 r.594_4185del PTC-NMD No No Probe overlap 
∆11-12 r.671_4185del PTC-NMD No No 
No or low 
expression 
∆14-15 r.4358_4675del No FS No Yes   
∆14-17 r.4358_5074del No FS No Yes   
∆14-18 r.4358_5152del No FS No No Probe overlap 
∆14-19 r.4358_5196del PTC-NMD No No Probe overlap 
∆15-17 r.4485_5074del PTC-NMD No No 
No or low 
expression 












detection Reasons for 
non-detection Controls Cases 
Multi-cassette biotype     
∆21-22 r.5278_5406del No FS No No Probe overlap 
∆21-23 r.5278_5467del FS-alt STOP No No 
No or low 
expression 
∆22-23 r.5333_5467del FS-alt STOP No No Probe overlap 
Splice acceptor shifts     
∆2p r.-19_-7del UTR No No 
Cuts into 
probe 
∆8p r.442_444del No FS Yes Yes   
∆13p r.4186_4188del No FS Yes Yes   
∆14p r.4358_4360del No FS Yes Yes   
Splice donor shifts     
∆1Aq r.-25_-20del UTR Yes Yes   
▼1aA r.-20_-19ins-20+1_-20+89 UTR Yes Yes   
∆5q r.191_212del PTC-NMD Yes Yes   
∆11q r.788_4096del No FS Yes Yes   
Intronization     
11∆3110 r.788_3897del PTC-NMD No No No probe set 
11∆3240 r.788_4027del No FS No No No probe set 
Terminal modification     
(1B)   UTR Yes Yes   
(IRIS)   
IntronSTOP
+polyA No No No probe set 
Splice donor shift + (Multi)-cassette     
∆1Aq-2 r.-25_80del Non-Coding Yes No   
∆1Aq-3 r.-25_134del Non-Coding No No No probe set 
∆1Aq-5 r.-25_217del Non-Coding No No 
No or low 
expression 
∆1Aq-10 r.-25_670del Non-Coding Yes Yes (BRCA2)   
(Multi)-cassette + Splice acceptor shift     
∆10-13p r.594_4188del PTC-NMD No No 
No or low 
expression 
∆11-13p r.671_4188del PTC-NMD No No 
No or low 
expression 








Table 4.4 (continued) BRCA1 isoforms detected in Colombo et al. (2014). 
Abbreviations: del, deletion; FS, frame shift; ins, insertion; NMD, nonsense-mediated decay; PTC, premature 







detection  Reasons for 
non-detection Controls Cases 
Terminal Modification + (Multi)-cassette    
(1B),∆2 r.-19_80del Non-Coding Yes Yes  
(1B),∆2-3 r.-19_134del Non-Coding No No No probe set 
(1B),∆2-5 r.-19_217del Non-Coding No No No probe set 




ns135-4047_135-3932 Non-Coding No No No probe set 
Splice donor shift + Splice acceptor shift    
∆1Aq,Δ2p r.-25_-7del UTR No No 
Cuts into 
probe 




ns135-4047_135-3932 Non-Coding No No No probe set 
          




20+89 + r.-19_5074del 
No FS2 
No No Minor isoform 
∆3-5 r.81_217del PTC-NMD No No Minor isoform 
∆5q,6 r.191_301del PTC-NMD No No No probe set 
∆6-7 r.213_441del PTC-NMD No No Probe overlap 
∆13-19 r.4186_5193del No FS No No Minor isoform 
∆17-19 r.4987_5193del No FS No No No probe set 
∆18-20 r.5075_5277del PTC-NMD No No Probe overlap 
∆19 r.5153_5193del PTC-NMD No No Minor isoform 
 
88 







detection Reason for 
Non-Detection 
Controls Cases 
Cassette biotype     
∆2 c.-38_67del Non-coding No No No probes 
∆3 c.68_316del no FS No No No probes 
∆4 c.317_425del PTC-NMD No No Minor isoform 
∆5 c.426_475del PTC-NMD No No No probes 
∆6 c.476_516del PTC-NMD No No No probes 
∆12 c.6842_6937del no FS Yes Yes   
∆17 c.7806_7976del no FS No No Minor isoform 
∆18 c.7977_8331del PTC-NMD No No No probes 
∆19 c.8332_8487del PTC-NMD No No No probes 
∆20 c.8488_8632del PTC-NMD Yes Yes   
∆22 c.8755_8953del PTC-NMD Yes No   
Multi-cassette biotype     




∆3-7 c.68_631del no FS No No No probes 
∆4-7 c.317_631del no FS No No No probes 
∆5-6 c.426_516del PTC-NMD No No Minor isoform 
∆5-7 c.426_631del PTC-NMD No No No probes 
∆12-13 c.6842_7007del PTC-NMD No No Minor isoform 
∆17-18 c.7806_8331del PTC-NMD No No No probes 
Splice acceptor shift     
∆23p c.8954_9004del PTC-NMD No No No probes 
Cassette + Splice donor shift     
∆6q,7 c.478_631del PTC-NMD No No No probes 
Cassette + Splice acceptor shift     
∆22,23p c.8755_9004del PTC-NMD No No No probes 




PTC-NMD Yes No   




4.3.2 Quantitative assessment of BRCA1 and BRCA2 transcripts from targeted RNA-
seq data 
To derive quantitative information from the targeted RNA-seq data, the relative expression 
range was calculated for alternative BRCA1 and BRCA2 splicing events detected across 
multiple control samples. The expression range of a total of 25 transcripts for BRCA1 and 14 
for BRCA2 was calculated based on the criteria that at least two control samples expressed the 
transcript with more than 10 reads, each sample was represented by more than 10,000 reads 
per gene, and each sample expressed at least two minor transcripts for the studied gene. A 
correlation between the number of alternative events detected and the total read count per 
sample was observed for both BRCA1 (R2 =0.68) and BRCA2 (R2=0.69) (Figure 4.2). 
 
Figure 4.2. Number of alternative isoform events detected in relation to total read count for BRCA1 (A) 
and BRCA2 (B) observed in study controls. 
 
Comparing the relative levels of expressed isoforms for BRCA1 and BRCA2 shows that the full 
length transcript is most highly expressed and shows the greatest expression variability 
(Figures 4.3A and 4.4A). The ranges for all alternative events were shown to be more tightly 
regulated in BRCA1 (24 events) than BRCA2 (11 events). No BRCA1 exon skipping event was 
expressed above 20% of the total transcripts, compared to BRCA2 where the upper expression 
limit of three isoforms (∆9-10, ∆12 and ▼20) exceeded this level. 
Expression ranges were calculated for around half as many alternative transcripts for untreated 
compared to treated samples for both BRCA1 (13/25) and BRCA2 (7/12) (Figures 4.3 and 4.4). 
Two BRCA1 transcripts, ∆9 and ∆11, showed an expression range that exceeded 20% in the 
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untreated samples, while the upper limit for ∆5 and ∆13p was reduced by 55% and 65%, 
respectively (Figure 4.3). Of those calculated in both groups for BRCA2 isoforms, the 
expression ranges remained either above or below 20% of the total gene expression, with the 
only exception of ∆9-10, which has a narrower expression range in the untreated sample 
(average, 2.07%; range 1.8%-2.3%) compared with the treated sample (average, 2.1%; range 






Figure 4.3. The natural BRCA1 mRNA expression ranges calculated from control LCLs. 
A: isoform expression ranges in NMD inhibitor treated samples; B: isoform expression ranges in non-treated 
samples. mRNA splice isoforms have been included if they were detected by more than 10 reads in at least two 






Figure 4.4. The natural BRCA2 mRNA expression ranges calculated from control LCLs. 
A: isoform expression ranges in NMD inhibitor treated samples; B: isoform expression ranges in non-treated 
samples. mRNA splice isoforms have been included if they were detected by more than 10 reads in at least two 
controls. Mean and upper and lower limits (standard error (95%)) shown for each isoform. 
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4.3.3 qPCR validation of over-expressed junctions 
qPCR was used to calculate the relative expression of BRCA1 ∆10, ∆9-10 and the full length 
10-11 junction in comparison to the reference junction (BRCA1 FL 2-3) in a variant carrier 
(BRCA1 c.594-2 A>C, Sample #5, Table 2.1) compared to controls. ∆10 and ∆9-10 were both 
expressed more highly in BRCA1 c.594-2 A>C compared to the controls (Table 4.6), while the 
full length 10-11 junction was expressed at a lower level than seen in the controls. RNA-seq 
consistently detected a higher expression of each junction analysed compared to qPCR (Table 















 Target/Ref  Target/Ref 
 qPCR  RNA-seqa  
BRCA1 c.594-2 A>C 5 ∆ 10 FL2-3 28.70 27.370  0.398  0.578 
Control 19 ∆ 10 FL2-3 35 28.884  0.014  0.077 
Control 24 ∆ 10 FL2-3 35 27.615  0.006  0.029 
Control 20 ∆ 10 FL2-3 35 29.439 
 
0.021  0.000 
        Carrier/average of controls  28.688 
 16.262 
BRCA1 c.594-2 A>C 5 ∆ 9-10 FL2-3 27.82 27.248  0.671 
 
1.241 
Control 19 ∆ 9-10 FL2-3 28.61 27.893  0.607 
 
0.852 
Control 24 ∆ 9-10 FL2-3 27.92 27.037  0.542 
 
2.380 
Control 20 ∆ 9-10 FL2-3 29.33 28.595 
 
0.601  1.055 
        Carrier/average of controls  1.150 
 0.869 
BRCA1 c.594-2 A>C 5 FL10-11 FL2-3 28.20 27.435  0.587 
 
2.222 
Control 19 FL10-11 FL2-3 27.97 27.840  0.915 
 
7.660 
Control 24 FL10-11 FL2-3 27.37 26.724  0.640 
 
4.335 
Control 20 FL10-11 FL2-3 28.32 28.158 
 
0.895  3.615 
    Carrier/average of controls 
 0.718  0.427 




4.3.4 Comparison of targeted RNA-seq to PCR-based assays 
The ability of the targeted RNA-seq approach to evaluate splicing in rare variant carriers 
(Samples #1-8, Table 2.1) was assessed by comparing the events presented here with those 
previously reported from ENIGMA’s protocol comparison study Chapter 3 [Whiley et al. 
2014]. While 54 splicing isoforms were each detected in at least one control (Tables 4.2 and 
4.3), 17 events were found exclusively in rare variant carrier samples (Table 4.7). The mRNA 
isoforms identified in LCL#4 (BRCA1 c.671-2 A>G) by this study, but not by Whiley et al. 
(2014), included BRCA1 11q (3317), ∆ mid exon 10, and ins 10p (21 nt). The remaining events 
detected in this study encompassed regions that were not included in the PCR assay designs 
reported in Whiley et al. (2014). Of the nine BRCA1 c.671-2 A>G isoforms detected by Whiley 
et al. (2014) but not in this work, two (∆3.2kb exon 11 and ∆11q + ins i13) were due to the 
lack of targeted RNA-seq probes at one or both ends of the deletion. Four events consisted of 
separate deletions (∆(9-10,11q), ∆(9,11), ∆(9,11q) and ∆(10,11q)), which are not possible to 
detect together due to the targeted nature of this RNA-seq design. The remaining three BRCA1 
events had sufficient placement of the probes for detection. One of these isoforms (∆11-12) 
was not detected in any other samples in this work, while ∆9-12 was detected in Sample #2 
(BRCA1 c.5467+5 G>C) and ∆11q (3309 nt) was detected in 8/10 controls (Tables 4.2 and 4.7). 
These results show that the targeted RNA-seq approach utilised here was successful in 
identifying isoform changes missed by PCR-based technologies. However, further 
development is required to overcome the remaining limitations that are currently preventing 
the detection of several prominent events in the samples studied.
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Table 4.7. Aberrant splicing events detected compared to those detected by Whiley et al. (2014). 
Events detected in LCLs carrying a rare BRCA1 or BRCA2 variant are compared to those detected in Whiley et 
al. (2014) in the same LCL. Isoforms detected here and by Whiley et al. (2014) are listed in the overlapping boxes. 
Variant and sample 
number#* 
Splicing change observed using 
Targeted RNA-seq 
Alternative splicing events detected 
previously by Whiley et al. (2014) 
BRCA1               
BRCA1 c.671-2 A>G 
(IVS 10-2 A>G) 
Sample #4 
1B Δ2 Δ mid exon 10a 
  
    Δ9-10,11q   
▼1aA Δ2 Δ11q 
(3317nt)a 
Δ9  Δ9,11   
Δ5 Δ13p (3nt) Δ9-10  Δ9-12   
Δ5q Δ14p (3nt) Δ10  Δ9,11q   
Δ6pa Δ15 Δ11  Δ10,11q   
Δ8p (3nt) Δ17 Δ9-11a  Δ11q 
(3309nt) 
  
ins10p (21nt)  Δ10-11a  Δ3.2kb exon 11 
     ▼21  Δ11q+ins i13 
            Δ11-12   
BRCA1 c.5467+5 G>C 
(IVS 23+5 G>C) 
Sample #2 
1B Δ2 Δ9-12a     Δ21,23   
Δ5 Δ11     Δ22-23   
Δ5q Δ11q 
(3309nt) 
    Δ22   
▼8 Δ14-15a Δ23a     
Δ9 Δ15 Δ21     
Δ9-10 Δ17        
Δ8p (3nt) Δ18-19a        
Δ13p (3nt) ▼21        
Δ14p (3nt)         
BRCA1 c.135-1 G>Tb 
(IVS 4-1 G>T) 
Sample #8 
Δ10         Δ5q Δins i3 
Δ9-10  
No overlap 
 Δ3 Δins i3 +Δ5 
Δ8p (3nt)   Δ3,5  
          Δ5-6   
BRCA1 c.594-2 A>Cb 
(IVS 9-2 A>C) 
Sample #5 
Δ11         Δ9 Δ10,11q 
Δ22  Δ10 
 Δ9-11 Δ11q 
Δ13p (3nt)  Δ9-10 
 Δ9,10,11q Δ11q+insi13 
Δ8p (3nt)         Δ9,11q ins i21 
BRCA2               
BRCA2 c.426-
12_8delGTTT 
(IVS 4-12 -8 del5) 
Sample #1 
Δ12  
    Δ3,5 Δ5-7 
▼20 (21nt)  No overlap  
Δ3-5 Δ6-7 
▼24   Δ4-7 Δ6q,7 
▼25      Δ5 ins 18bp 
BRCA2 c.9501+3 A>T 
(IVS 23+5 A>T) 
Sample #3 
Δ15q-16pa         ▼i23   
▼20 (21nt)  Δ25a 
  
    
              
BRCA2 c.7988 A>T 
Sample #7 
▼20 (21nt)      Δ17-18   
▼24  No overlap  Δ18   
Δ27pa             
BRCA2 c.8632+1 G>A 
(IVS 20+1 G>A) 
Sample #6 
Δ12         Δ19   
▼25a  Δ20     
   Δ19-20
a     
   ▼20 (21nt)     
              
*Sample numbers in Table 2.1. 
aIsoform was detected solely in the variant carrier sample specified.  
 bLow read count returned resulting in few alternative mRNA isoforms detected. 




4.3.5 Rare variant quantitative assessment 
Current splicing assays are restricted by their inability to quantitatively assess spliceogenic 
changes, instead often reporting only the qualitative changes. Assessment of the BRCA1 c.[594-
2A>C;641A>G] variant carrier was associated with an 8.8-fold increase in the expression of 
Δ10, along with smaller increases for Δ15 (2.8-fold) and ▼21 (5.0-fold). Interestingly, BRCA1 
c.594-2A>C has recently been re-classified as of low clinical significance despite the increased 
expression of ∆10, a frameshift event, in variant samples [de la Hoya et al. 2016]. The reason 
for this phenomenon is that another variant found in cis (c.641 A>G), causes the ∆10 event, 
while c.594-2 A>C increases the expression of ∆9-10. The concomitant increase in ∆9-10 is 
predicted to provide a protective effect by allowing expression of in-frame transcripts with 
their tumour suppressor function intact [de la Hoya et al. 2016]. A 1.3-fold increase of Δ11 and 
▼21 was also seen for BRCA1 c.671-2 A>G (Figure 4.5). Prominent isoform expression 
changes were also observed that were associated with BRCA2 c.426-12_8delGTTTT, where 
one splicing event (▼20) was expressed at levels 2.3-fold higher than those seen in controls, 
and another (▼25) was expressed at levels 2.4-fold and 4.5-fold higher than controls in c.426-
12_8delGTTTT and c.8632+1G>A, respectively (Figure 4.6). No expression patterns differed 







Figure 4.5. Relative expression of BRCA1 mRNA isoforms in rare variant samples compared to controls. 
The natural BRCA1 mRNA expression ranges were calculated from 12 control LCLs. mRNA splice isoforms have 




Figure 4.6. Relative expression of BRCA2 mRNA isoforms in rare variant samples compared to controls. 
The natural BRCA2 mRNA expression ranges were calculated from 11 control LCLs. mRNA splice isoforms have 
been included if they were detected by more than 10 reads in at least two controls. 
  
BRCA1 c.594-2 A>C  
BRCA1 c.5467+5G>C  
BRCA1 c.671-2 A>G  
BRCA2 c.426-12 delGTTTT 
BRCA2 c.9501+3 A>T  




To date, PCR-based splicing assays have typically been used to assess mRNA splicing 
transcripts qualitatively. While it has been suggested that genetic variation can induce abnormal 
isoform expression changes [Thery et al. 2011], these abnormalities are not easily determined 
using the traditional PCR-based techniques. Here a targeted RNA-seq approach has been used 
to generate a comprehensive expression profile of the normally expressed BRCA1 and BRCA2 
mRNA isoforms. Novel mRNA isoforms are detected using this platform, while “natural” 
expression levels are also defined to highlight variant-induced changes that are outside the 
expected expression range.  
4.4.1 Qualitative analysis identifies novel mRNA isoforms 
Multiple BRCA1 and BRCA2 mRNA isoforms were detected here that are additional to the 
comprehensive summaries respectively reported on each gene [Colombo et al. 2014, 
Fackenthal et al. 2016]. The majority of BRCA2 isoforms detected by targeted RNA-seq have 
not been reported previously in the literature. Of the three novel BRCA2 exon skipping events, 
BRCA2 Δ11 was identified in one control LCL. The largest of the 27 coding exons in BRCA2 
(4,932 bp), exon 11, encompasses the eight conserved BRC motif repeats, which allows it to 
interact with RAD51 for recombinational DNA repair [Wong et al. 1997, Carreira and 
Kowalczykowski 2011]. Exclusive deletion of BRCA2 exon 11, while not a frameshift event, 
has been shown to cause embryonic lethality in mice, whereas individuals expressing some full 
length transcript are able to function normally [Jonkers et al. 2001], suggesting that expression 
of this isoform is tolerated. The second novel event, BRCA2 Δ9-10, overlaps a proposed cancer 
cluster region, within which mutations are thought to increase the risk of breast cancer 
[Rebbeck et al. 2015]. This suggests that expression of BRCA2 Δ9-10 may have a protective 
effect in certain variant carriers. As this exon skipping event results in an out-of-frame 
transcript it may be destroyed by NMD, although this was not indicated here with detection in 
a treated and an untreated control sample (Table 4.3). The third novel BRCA2 splicing event, 
Δ15-16, is also out of frame and overlaps the helical domain. Many tumour-derived mutations 
have been shown to be situated in this region, indicating Δ15-16 to have an important tumour 
suppressing function [Yang et al. 2002]. Detection in a single cycloheximide treated sample 
suggests that the truncated transcript is destroyed by NMD prior to translation, preventing the 
synthesis of protein isoforms lacking this crucial region.  
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Several of the novel events identified were those located in intronic regions (retention events 
highlighted by ▼, Tables 4.2 and 4.3). The targeted RNA-seq probe design allows detection 
only from the 3’ end of such regions. This prevents the characterisation of the full insertion as 
the sequenced reads are restricted to a length that does not accommodate more than a few bases 
between probes, and so prevents the detection of the full insertion and the adjacent probe when 
these additional sequences are included in the transcript. While BRCA1 mRNA isoforms have 
been comprehensively studied, the only intronic insertions identified previously were exons 4 
and 13A [Colombo et al. 2014]. The high number of novel retention events detected in this 
study may be due to the large number of probes used for isoform detection across each gene, 
not restricted to a small number of probes/primers as in many PCR-based assays. Additionally, 
the number of alternative mRNA splicing events detected was found to have a strong 
correlation to the number of gene-specific reads mapped in each sample. Five of the seven ▼ 
events were detected in two or more controls, which highlights how there is still likely to be 
mRNA variation that is yet be detected, even in control samples and in well-characterised genes 
like BRCA1 and BRCA2. Validation of the novel mRNA events identified in this work is 
recommended, should any of these findings be further characterised in the future. 
4.4.2 Quantitative expression identifies variant-associated changes 
Aberrant isoforms resulting from disruptive variants are well documented, but changes in 
isoform expression levels have not previously been reported. While the relative mRNA 
expression levels in variant carriers fell to within that seen in controls, BRCA1 c.[594-2 A>C; 
641A>G ] Δ10 and c.671-2 A>G Δ11 were both quantitatively found to fall outside that range 
(Figures 4.5 and 4.6). Delta 11 is a common isoform, whereas Δ10 is not normally observed in 
controls [Romero et al. 2015], but is present in conjunction with Δ11q in several variant 
samples [Lixia et al. 2007, Colombo et al. 2014]. Contrary to these previous findings, Δ10 was 
detected here in three controls, but only in NMD inhibitor treated samples, suggesting that this 
frameshift event is destroyed by NMD prior to translation. As both variants discussed here are 
situated in, and so directly disrupt, the splice sites of their respective exons, splicing changes 
are not unexpected. While increased expression of c.[594-2 A>C; 641A>G ] Δ10 event has 
been shown before [de la Hoya et al. 2016], a higher than expected level of Δ15 and ▼21 was 
also observed in this study. As each of these events is also detected in controls, qualitative 
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analysis alone would be insufficient to detect any aberrant change. However, such changes in 
expression levels were not associated with pathogenicity. 
Interestingly, the expression ranges established here for normally expressed mRNA isoforms 
were greater in BRCA2 compared with BRCA1. While there are more isoforms in BRCA1 than 
BRCA2, the overall expression levels of the alternative transcripts is still higher in the latter. 
Interestingly, all BRCA1 exons have been recorded in a ∆ event, whereas several BRCA2 exons 
have not. One hypothesis for the disparity between these genes is that it may be due to differing 
conservation levels in each, allowing a higher number of alternative mRNA isoforms to be 
tolerated in BRCA1 compared to BRCA2. Tighter regulation of those BRCA1 isoforms may 
also prevent high variation of detectable mRNA expression. Molecular portraits have been 
established for breast cancer subtypes, identifying variants in certain genes that relate to the 
tumour phenotype, with several groups of variants found in some genes that relate to different 
subtypes. Germline BRCA1 breast cancers are often basal-like (triple negative), while BRCA2 
tumour subtypes tend to be more heterogeneous but are more likely to be luminal [Sorlie et al. 
2003, Jönsson et al. 2010]. Future research is required to determine if a link is present between 
molecular subtypes of breast tumours and BRCA1/2 mRNA isoform expression patterns. 
It has been suggested that an expression increase from minor to predominant levels for some 
BRCA1 and BRCA2 transcripts is sufficient to classify pathogenic isoforms [Gambino et al. 
2015]; however, consensus of what defines a “predominant” event needs to be established first 
for consistency in reporting results between studies. While previously defined from a 
qualitative aspect [Colombo et al. 2014], semi-quantitative measures have more recently 
suggested that predominant events are those that are expressed at >10% of the full length signal 
[Romero et al. 2015]. With advancing massively parallel sequencing technologies, it is now 
possible to derive a comprehensive quantitative measure of each isoform being expressed. In 
addition to identifying absolute changes in isoform expression level, these data can also prevent 
a false interpretation of relative expression, such as when a decline in full length isoform level 
is confused with increased expression of an alternative splicing event. By identifying all 
transcripts expressed, a better foundation can be used to develop an understanding of which 
events should be correctly classed as predominant, and which should remain minor. 
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4.4.3 Comparison of PCR-based assays and targeted RNA-seq   
A comparison of the isoforms identified here with those identified previously in the same LCLs 
using PCR-based methods highlighted between two and 18 events per variant-carrier LCL that 
were not detected in the earlier study [Whiley et al. 2014]. Unsurprisingly, the majority of these 
events were located outside of the exons immediately adjacent to the variant of interest. The 
reasoning behind this is that PCR-based analyses often target the exonic regions immediately 
surrounding the variant to detect spliceogenic changes. However, it has been shown here and 
elsewhere that splicing changes can potentially occur throughout the gene, and larger deletions 
spanning multiple exons may not be detected due to limitations in PCR assay design. The 
ability to evaluate the whole gene would enable the detection of all aberrantly expressed events 
and determine how disruptive a variant is. 
Only three events were not detected in the sample containing BRCA1 c.671-2 A>G using 
targeted RNA-seq compared to those in Whiley et al. (2014) (∆11-12, ∆9-12 and ∆11q (3309 
nt)) when sufficient probe placement was present. Of these events, ∆11-12 and ∆9-12 have 
been shown to be detected at very low levels previously (2/12 and 1/12 participating 
laboratories, respectively) [Whiley et al. 2014]. With the comprehensive studies now 
completed for all known naturally occurring BRCA1 and BRCA2 mRNA isoforms, improved 
probe placement would be achievable to allow detection of many of the isoforms not detected 
in this work. Quantitative information may then be obtainable for all isoforms to identify the 
aberrations that are predominantly expressed and likely to be very disruptive in the cell. 
4.4.4 Use of NMD inhibitors for evaluating spliceogenic variants  
Nonsense-mediated decay inhibitors are used to facilitate the detection of transcripts that would 
otherwise be degraded to some degree, if not totally, by the natural control mechanisms within 
the cells. Identifying these transcripts may be crucial to help determine the disease risk of 
certain sequence variants. Here, samples treated with NMD inhibitors consistently provided a 
higher number of mRNA isoforms compared to the untreated samples, while several isoforms 
were detected solely in treated samples. Inhibitors like cycloheximide prevent NMD, while 
simultaneously eliminating mRNA translation, leading to a build-up of all expressed mRNA 
transcripts. While the use of NMD inhibitors for enhancing the likelihood of isolating aberrant 
mRNA transcripts is appreciated [Thomassen et al. 2012, Walker et al. 2013], several 
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laboratories still do not include them in their splicing protocols, and the results obtained here 
suggest that they may be missing information by not doing so.  
4.4.5 Targeted RNA-seq limitations 
This work utilised a large number of probes to maximise the likelihood of detecting all mRNA 
isoforms expressed throughout BRCA1 and BRCA2. While this approach is much more 
comprehensive than traditional splicing assays, not all transcripts were detectable as the length 
of some exons was insufficient for probe placement at both ends, or one was unable to bind 
due to probe overlap. Interestingly, probes spanning exons 10 and 11 in both BRCA1 and 
BRCA2 were consistently upregulated compared to the other regions of each gene. This 
occurrence also extended to the connecting BRCA1 isoforms (i.e. ∆10, ∆9-10). qPCR showed 
similar isoform expression changes found by RNA-seq when comparing a BRCA1 c.594-2 
variant carrier with controls. However, when comparing junction expression levels across 
BRCA1, qPCR did not replicate the increased expression of the BRCA1 10-11 full length 
junction, or that of the ∆10 and ∆9-10 isoforms, instead indicating similar levels to the 
normalising BRCA1 exon 2-3 junction. The most likely theoretical reason for this finding is 
that an increased ratio of the probes specific to that junction was added to the probe master mix 
used for the RNA-seq. While there was no remaining probe mix to use to confirm this, it is 
likely that this was a one off occurrence due to the custom nature of the assay design. 
Here the first comprehensive review of the naturally occurring BRCA1 and BRCA2 mRNA 
isoforms with quantitative assessment using targeted RNA-seq technology is presented. The 
calculated threshold defines mRNA expression changes that are within the natural expression 
range and those that are aberrations likely caused by the variants present. This information has 
been used to highlight several variant-induced changes not detectable by semi-quantitative 
methods. Incorporating these mRNA isoform thresholds into the current ENIGMA guidelines 
[Walker et al. 2013] would potentially improve their utility for risk assessment of spliceogenic 
variants. The novel mRNA isoforms detected here highlights how the full complexity of normal 




This research highlights the usefulness of targeted RNA-seq for mRNA isoform detection and 
quantification. Future research including additional control samples would improve our 
understanding of normal variation associated with BRCA1 and BRCA2 mRNA isoform 
expression patterns. Such information would provide an invaluable resource in a research and 
diagnostic setting for determining if the observed splicing variation is aberrant. The more that 
is known about the mRNA variability in each gene, the better informed we are to make 
decisions regarding whether observed changes are natural variation, or if they are likely to be 




: Genetic factors that influence mRNA expression 
5.1 Introduction 
Genetic variants in breast cancer susceptibility genes account for around 35% of familial breast 
cancer risk, ~40% of which stems from common variants [Michailidou et al. 2013]. These 
variants can increase risk by disrupting splicing regulatory elements and altering mRNA 
splicing. The work in Chapter 4 identified a significant level of mRNA variability between the 
samples studied using RNA-seq, both in what isoforms are present and in the expression levels 
of each. Rare variants were found to express aberrant splicing isoforms and alter the expression 
of natural isoforms to that outside the range observed in controls. However, the impact of 
common variants was not studied. These variants may account for some of the remaining 
variability observed, and potentially have an effect on disease risk. 
Allele-specific expression (ASE) imbalances are thought to be a good indicator of underlying 
splicing changes that result from the degradation of mRNA transcripts containing premature 
termination codons [Chen et al. 2006, Chen et al. 2008]. This has been shown previously after 
the allelic imbalance of a common variant in BRCA2 led to the identification of a truncating 
variant that induced NMD (BRCA2 c.2041 ins A) [Tan et al. 2008]. NMD inhibitors are often 
included in splicing assays to prevent such degradation to increase the detection of mRNA 
isoforms through a mechanism that simultaneously prevents NMD and translation from taking 
place [Maquat 2004]. The work in Chapter 4 identified a higher number of isoforms when 
treating with NMD inhibitors, but did not explore whether such treatments influence allele-
specific expression in the samples studied. Understanding if this treatment is having an impact, 
other than allowing detection of incomplete transcripts that would otherwise be degraded, 
would help determine whether its use in mRNA assays is justified or if it is having a detrimental 
effect on the observed isoform expression levels. 
While the RNA-seq platform employed in Chapter 4 successfully detected and quantified more 
mRNA isoforms than previous studies utilising PCR-based approaches, the restricted nature of 
the probes prevented variant discovery in the samples studied. In this work, RNA-seq was 
combined with genotyping and allele-specific expression analysis to explore the possibility that 
common and rare variants have an impact on the BRCA1 and BRCA2 isoform expression 
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variability observed in Chapters 3 and 4. In addition, an allele-specific approach is also used to 
assess the effect of NMD inhibitors on the expression of BRCA1 and BRCA2 mRNA isoforms.  
5.2 Methods 
5.2.1 Samples 
Sequencing, genotyping and ASE was analysed in nineteen lymphoblastoid cell lines (LCLs), 
detailed in Section 2.1 (Samples #9-27). All culturing, extraction, RNA-seq sequencing and 
normalisation steps were undertaken as described in Chapter 4.  
5.2.2 Bioinformatic analysis of sequence variants 
Common variants situated within BRCA1 and BRCA2 were analysed bioinformatically for their 
predicted effect on splicing by Human Splicing Finder [Desmet et al. 2009], Max Ent Scan 
[Yeo and Burge 2004], ESE Finder [Cartegni et al. 2003] and ESE Rescue [Fairbrother et al. 
2002]. Ten variants, predicted by at least one bioinformatics tool to disrupt splicing, were 
selected for genotyping and allele-specific expression (ASE) analysis (Table 5.1). 
5.2.3 Genotyping and Allele Specific Expression 
Genotyping and ASE analysis was undertaken by the Sequenom Facility at Auckland 
University using Sequenom iPLEX™ assays (Sequenom, Hamburg, Germany) [Oeth et al. 
2007]. Assay design was completed for all ten variants after passing quality control measures. 
Genomic DNA for genotyping assays and RNA for allele specific expression assays were 
isolated from all LCLs (cycloheximide treated and untreated) using protocols described in 








Table 5.1. Splicing analysis of common variants with bioinformatic predictor tools.  
Ten variants predicted by at least one tool to alter splicing. 
  MAFa Gene Location 
HSFb MESc ESE Finder ESE Rescue 
    Wild 
Type 
Mutant Variation Wild 
Type 








rs4986850 c.2077G>A 0.0568 BRCA1 exon 10 NSC NSC 1 - 1 - 
rs1799967 c.4956G>A 0.0176 BRCA1 exon 15 
43.8 72.74 66.09 
NPA 3 4 NPA 
70.55 59.97 -14.99 
rs8176318 c.*421G>T 0.4465 BRCA1 exon 23 78.05 49.1 -37.09 0.12 6.72 5500% 2 1 1 - 
rs12516 c.*1287C>T 0.4449 BRCA1 exon 23 NSC NSC 2 1 NPA 
BRCA2                             
rs766173 c.865A>C 0.0518 BRCA2 exon 10 NSC 2 -3.82 -291%   2  1 
rs144848 c.1114A>C 0.2779 BRCA2 exon 10 NSC NSC   2 1   
rs1799944 c.2971A>G 0.0534 BRCA2 exon 11 NPA NPA NPA 2 1 
rs1801426 c.10234A>G 0.0227 BRCA2 exon 27 45.8 74.74 63.21 NPA 1 3 NPA 
rs15869 c.*105A>C 0.1607 BRCA2 exon 27 NSC NPA NPA 4   
rs7334543 c.*369A>G 0.222 BRCA2 exon 27 NSC NSC 1 1 NPA 
aMAF obtained from EXAC database and 1000 genomes. 
bVariation in HSF scores of >5% for loss of splice sites and >60% for gain of site are regarded as significant [Whiley et al. 2011]. 
cVariation in MES scores of >15% for loss of splice sites and >200% for gain of site are regarded as significant [Whiley et al. 2011]. 
Abbreviations: ESE, Exonic Splicing Enhancer; HSF, Human Splicing Finder; MES, MaxEntScan; NPA, no prediction available; NSC, no significant change. 
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5.2.4 Statistical analysis 
Differential expression analyses were undertaken using a T-test to compare the expression of 
each splice junction in samples containing the alternative allele of each variant (rare and 
common) compared to the expression of those containing the wild type. P-values were adjusted 
for multiple comparison using Bonferroni correction. Z-scores and odds ratios (OR) were 
calculated for the heterozygous variants in each sample to identify those that show significant 
expression differences to what is expected. 
Additional work was undertaken to determine if NMD inhibitors are influencing the observed 
ASE patterns. The allelic balance of each common heterozygous variant was compared 
between NMD inhibitor treated and untreated variants in matched samples using a one sample 
T-test. Briefly, the difference in ASE between the treatment groups was tested to determine if 
it differed from the expected 0.0. A single sample T-test was also used to determine if the allelic 
expression of each of the common heterozygous variants deviated from the expected 0.5 in 
NMD treated and untreated samples, respectively. 
5.3 Results 
5.3.1 Common variants in BRCA1 and BRCA2 and their effect on isoform expression 
variability 
To assess whether common variants influence isoform expression variability, differential 
expression analyses were undertaken for each splice junction in samples containing variants 
which have heterozygous genotypes. While all common variants analysed are predicted by at 
least one bioinformatics analysis tool to alter splicing (Table 5.1), expression analysis found 
no significant difference between alleles for all variants analysed (Figure 5.1). These results 











Figure 5.1. Expression analysis of isoforms using RNA-seq data from control samples. 
The position of the common variant analysed is indicated by the vertical blue line. Nominal p=0.05 significance indicated by the horizontal red dotted line; multiple comparison 




rs144848 BRCA2 rs8176318 BRCA1 









Figure 5.1 (continued) Expression analysis of isoforms using RNA-seq data from control samples. 
The position of the common variant analysed is indicated by the vertical blue line. Nominal p=0.05 significance indicated by the horizontal red dotted line; multiple comparison 
adjusted significance is indicated by the solid red line (Bonferroni corrected p-values). Junctions are shown as black horizontal lines. 
  
rs7334543 BRCA2 rs4986850 BRCA1 
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5.3.2 BRCA1 and BRCA2 common variants and their effect on allele specific 
expression 
When determining whether NMD inhibitors have a significant impact on the ASE patterns 
observed in the samples analysed here, only one variant (BRCA1 c.*1287 C>T, rs12516) 
reached the Benjamini and Hochberg multiple testing correction for significance (<0.0429) 
[Benjamini and Hochberg 1995], but not Bonferroni significance (<0.0071) (p-value = 0.0123, 
Figure 5.3). A high correlation (R2=9973) was observed for ASE between treated and untreated 




Figure 5.2. Comparison of allele-specific expression for variants in NMD inhibitor treated and untreated 
samples. 
 
Tests to determine if the ASE patterns of common variants deviated from the expected 1:1 in 
NMD inhibitor treated and untreated samples identified four of the six variants (BRCA1 
rs12516, rs4986850, BRCA2 rs144848 and rs8176318) significant at the Bonferroni level, 
while BRCA2 rs15869 was significant at the less conservative Benjamini and Hochberg 
corrected level (Figure 5.3). The common variants included in this analysis that are known to 
be in linkage disequilibrium (LD), rs12516 and rs8176318, had comparable ASE across the 
heterozygous samples (Figure 5.3). There did not seem to be a correlation between minor allele 









Figure 5.3. Box plots of the observed allele-specific expression for common variants in the samples studied. 
P-values derived from 1-sample T-tests comparing the proportion of the major allele to the expected 0.5 for treated and untreated samples, respectively, and comparing the 
differences in proportion between treated and untreated to the expected 0 if treatment does not have an effect. *denotes significant P-values according to the Benjamini and 
Hochberg correction for multiple testing (<0.0429) [Benjamini and Hochberg 1995]; **Denotes P-values that are significant according to the Bonferroni correction (<0.0071). 








Figure 5.3 (continued) Box plots of the observed allele-specific expression for common variants in the samples studied.  
P-values derived from 1-sample T-tests comparing the proportion of the major allele to the expected 0.5 for treated and untreated samples, respectively, and comparing the 
differences in proportion between treated and untreated to the expected 0 if treatment does not have an effect. *denotes significant P-values according to the Benjamini and 
Hochberg correction for multiple testing (<0.0429) [Benjamini and Hochberg 1995]; **Denotes P-values that are significant according to the Bonferroni correction (<0.0071). 
Number of heterozygous samples for each variant analysed is noted in the bottom left of each graph. 
 
113 
5.3.3 Effect of the rare variant BRCA1 c.2521 C>T on isoform expression variability 
The assessment of rare variants and isoform expression in Chapter 4 was limited due to only 
one LCL being available for each variant. Thus, no measure of isoform expression variability 
could be determined for these sequence variants. To begin to address this issue, the kConFab 
resource was searched for LCLs based on the following criteria: 1) at least five LCLs carrying 
the same rare variant, 2) previous studies have come to conflicting conclusions regarding the 
clinical classification, 3) bioinformatics analysis predicts splice disruption of rare variant, 4) 
PCR-based studies have not detected any evidence for a splicing change, and 5) iCOGS data 
(http://ccge.medschl.cam.ac.uk/research/consortia/icogs/) indicate a possible association with 
breast cancer risk. One rare variant (BRCA1 c.2521 C>T; Minor allele frequency = 0.0025) 
was identified using those criteria. Bioinformatics analysis predicts functional disruption 
[Rajasekaran et al. 2007], and Align-GVGD (http://agvgd.hci.utah.edu/agvgd_input.php) 
predicts a slight increase in breast cancer risk (C15) [Borg et al. 2010]. Moreover, iCOGS 
found a nominal association with decreased breast cancer risk (p-value = 0.03, OR = 0.80) 
(personal communication from Dr Logan Walker). 
Nine LCLs carrying the rare variant BRCA1 c.2521 C>T (Samples 9-17) were analysed using 
targeted RNA-seq. Bioinformatic predictions for this variant suggest that it disrupts an ESE 
site (Table 5.2), although previous PCR-based studies have not detected any evidence for a 
splicing change [Anczukow et al. 2008]. Quantifying the isoform expression patterns found 
c.2521 C>T to be associated with a significant upregulation of BRCA1 ∆9-10, and 
downregulation of exon-exon junction 10-11 (Figure 5.4). This result suggests that 
bioinformatic predictions may be more accurate than previously thought, as the expression 
changes were not quantified with previous PCR-based assays. RNA-seq provides a more 
quantitative and sensitive platform that allows the detection of even small expression 
differences of commonly expressed isoforms, as shown here. 
Table 5.2. ESE Finder splicing predictions for BRCA1 c.2521 C>T. 
Sequence Position cDNA Position Reference Motif (value 
0-100) 
Variation 
1846 c.2517 ACAGTCG (80.06) Site broken-100 





Figure 5.4. Expression analysis of isoforms using RNA-seq data from carriers of BRCA1 2521C>T 
(rs1800709).  
The position of the variant is indicated by the vertical blue line (Nominal p=0.05 significance indicated by the 
dotted red line; multiple comparison adjusted significance by the solid red line (Bonferroni corrected p-values)). 
The labelled splice junctions are those shown to be disrupted by minor allele with the adjacent arrow indicating 
the direction of disruption. Junctions are shown as black horizontal lines. 
 
The one sample T-test undertaken for each of the common variants in Section 5.3.2, above, 
was also used here to reveal that ASE patterns of BRCA1 c.2521 C>T (rs1800709) deviated 
from the expected 1:1 ratio (Figure 5.5). The minor (T) allele was found to have an increased 
expression over the wild type (C) allele. The RNA-seq analysis showed an increased expression 
of ∆9-10 in the variant carrier (located in exon 11) (Figure 5.4). It could be hypothesised that 
the increased expression of the minor (C) allele is due to the importance of the ∆9-10 event, 
which may act protectively to remove variants found in exons 9 and 10 that induce frame shift 
events, such as ∆10 [de la Hoya et al. 2016]. To maintain this variant’s protective function, 
deletion events that involve exon 11 (such as ∆11q) are therefore less likely to occur in the 




Figure 5.5. Box plot of the observed allele-specific expression for BRCA1 c.2521 C>T (rs1800709).  
P-values derived from 1-sample T-tests comparing the proportion of the major allele to the expected 0.5 for treated 
and untreated samples, respectively, and comparing the differences in proportion between treated and untreated 
to the expected 0 if treatment does not have an effect. **Denotes P-values that are significant according to the 






This study combined the capabilities of targeted RNA-seq with genotyping and allele-specific 
expression analysis to identify expression changes of normally expressed BRCA1 mRNA 
isoforms induced by a rare variant. While this analysis was extended to assess BRCA1 and 
BRCA2 common variants, no associations were identified. 
Rare BRCA1 variant c.2521 C>T, located in exon 11, is predicted by ESE Finder to disrupt an 
exonic splicing enhancer [Cartegni et al. 2003]. However, no splicing change was observed 
when analysed previously with mini-gene and rtPCR assays [Anczukow et al. 2008]. Here, 
nine samples containing this variant were analysed using targeted RNA-seq, identifying a 
significant increase in the expression of ∆9-10 and a decrease of the full length exon 10-11 
junction. This expression change would likely have been missed using traditional non-
quantitative PCR-based assays, such as those used by Anczukow et al. (2008) who focused 
solely on exons 10, 11 and 12. As BRCA1 c.2521 C>T may be associated with lower risk in 
breast cancer patients, the associated increased ∆9-10 expression may have a protective effect 
against detrimental genetic changes that would otherwise be expressed.  
It is hypothesised that other factors, such as further nucleotide variation across these genes, 
may have a significant impact on regulating the splicing process. Although common variants 
have been shown to influence isoform level expression [Zhang et al. 2015], no such 
associations were identified with common variants across the BRCA1 and BRCA2 genes. These 
results were in contrast to predictions by bioinformatics analysis tools suggesting the variant 
might disrupt splicing. However, the ASE patterns observed for the majority of these variants 
are shown to deviate from the expected 1:1 allelic ratio. A reason for this may be that the minor 
allele results in a transcript that is frequently degraded, leaving only the complement of 
normally expressed isoforms. Allelic imbalance can be influenced by genetic, epigenetic and 
environmental factors [Buil et al. 2015]. Causes other than splicing that explain this difference 
may derive from trans-acting genetic variants that control the expression of certain cis-acting 
regulatory variants, as has been shown previously [Hemani et al. 2014]. Linkage disequilibrium 
between such variants and the common variants studied here could explain the observed 
imbalances. Other elements, such as transcription factors, have been shown to display allele-




variants located in the binding sites [Kasowski et al. 2010]. The regulatory elements may 
therefore be able to bind better to the wild type allele, preventing detectable expression 
differences otherwise predicted for the alternative allele. Further work is required to explore 
the genotype patterns of the variants studied to determine if the observed allelic imbalances are 
consistent within the same haplotype. Additional research into determining linkage patterns 
between variants that are influenced by external sources, such as trans-acting elements, would 
also allow a greater understanding of the ASE patterns observed. 
NMD is found in previous chapters to improve mRNA isoform detection in splicing assays 
(Chapters 3 and 4). While the mechanism behind this is appreciated, an understanding of 
whether or not NMD inhibitors have additional effects on junctions detection remained 
unknown. Although no difference was detected in the majority of variants, the work presented 
here identified one (BRCA1 c.*1287 C>T, rs12516) that had a marginally significant difference 
in ASE between samples treated with NMD inhibitors and those not treated. BRCA1 c.*1287 
C>T is located in the 3’ UTR of BRCA1 and was not associated with any splicing changes 
detected. However, it may be located in the binding site of a regulatory element, which is able 
to bind better to the wild type allele and so leads to an observable ASE difference. While further 
exploration is required to determine if this is a true effect and why a difference was found only 
for this single variant, the results suggest that NMD inhibitors potentially have a small impact 
on the ASE effect associated with the transcribed mRNA isoforms. 
This study could be improved by utilising more extensive NGS platforms, such as whole 
transcriptome. While combining Targeted RNA-seq with genotyping and ASE analysis is a 
useful approach for assessing potentially spliceogenic variants, whole transcriptome RNA-seq 
would allow variant discovery across the entirety of each of the genes of interest. In addition 
to this, it would then also be possible to identify all of the mRNA isoforms expressed, rather 
than being limited by probe design. It would then be possible to consider all the variation 
present in the coding regions of each gene for its likely impact on the mRNA variability 
observed. While cost constraints currently limit the utilisation of such platforms, these costs 
continue to decline, making whole transcriptome RNA-seq more attainable for future research 
projects. 
mRNA variability was observed in Chapter 3 after standardising splicing protocols between 




chapters highlight how some of the observed variability is accounted for by rare variants 
driving mRNA isoform expression to levels outside the range expected in controls; however, 
significant unexplained variability remained. The work in this chapter highlights that common 
genetic variants overlapping BRCA1 and BRCA2 may have only a limited effect on mRNA 
isoform expression variability. Relative expression levels observed here for BRCA1 and 
BRCA2 common variants are not likely to be due to any of the observed splicing changes. 
External factors may instead be influencing the observed expression patterns. While NMD 
inhibitors were not found to significantly alter ASE for the majority of variants, one variant 
(rs12516) was found to return a very small, but significant change. The implication of this is 
unknown and additional studies would be advised to confirm this difference. However, ASE 
was otherwise found to be very comparable between NMD inhibitor treated and untreated 




: Assessing the effect of culturing practices and technical 
variability on mRNA detection 
6.1 Introduction 
As discussed in Chapter 3, a significant level of variability has been identified previously 
between the results obtained from the range of splicing assays currently used by research and 
clinical laboratories [Whiley et al. 2014]. This work suggested that standardising certain 
protocol conditions improved the uniformity in reported results. Work in Chapter 5 further 
highlighted the extent to which genetic variants can influence mRNA expression variability, 
while also showing that ASE can be used as an indicator of underlying splicing changes not 
accounted for by detected variants. However, this work focused on exploring the genetic 
sequence itself as the source of variability, and the role of methodological (cell culture, storage 
practices and assay design) factors that potentially contribute to the observed isoform 
expression patterns remained unclear. An understanding of whether methodological factors 
also require a level of standardisation is important as they each have the potential to play a role 
in what mRNA transcripts are detected at any given time point [Warren et al. 2006].  
Obtaining mRNA expression differences using RNA-seq has many advantages over PCR-
based approaches as advanced NGS platforms are able to simultaneously quantify isoforms 
with a high level of detail across whole genes. To determine whether the observed inter-
laboratory variation in mRNA isoform detection was influenced by intra-laboratory 
methodological factors, this study explored the impact of  liquid N2 storage, time in culture and 
the technical variability, when assessing BRCA1 and BRCA2 mRNA splicing across the BRCA1 
and BRCA2 using a targeted RNA-seq platform. 
6.2 Methods 
RNA isolated at six time points (weekly, with three biweekly freeze/thaw cycles, Figure 3.2)) 
from a single LCL (Sample #7, Table 2.1) (Chapter 3) were sequenced using the Illumina 
Truseq Targeted RNA Expression protocol described in Section 2.9 with three technical 
replicates. Culturing, NMD inhibitor treatment, RNA extraction and cDNA synthesis methods 





To explore the contribution of Targeted RNA-seq and culturing practices to variability in 
BRCA1 and BRCA2 mRNA expression patterns, isoform expression was observed in the three 
technical replicates (identical RNA pool) across the six LCL processing time points (Figure 
3.2).  
The expression of each alternative event is lower and more variable between sample replicates 
compared to that observed for full length junctions. Two alternative events (BRCA1 ∆13p (3 
nt) and BRCA2 ∆12) were represented by more than 500 reads in one replicate, while there 
were no reads in the other two (Figures 6.1 and 6.2). BRCA1 Δ9-10 and Δ1Aq were the only 
alternative splicing events detected across all three replicates at all six time points, while eight 
additional events (BRCA1 ▼1, Δ8p, Δ10, ∆14p, and BRCA2 ∆12, ▼21 (21 nt), ▼25a and 
▼25b) were detected in all replicates in at least one time point (Figures 6.1 and 6.2). Of all the 
previously described predominant events, four (∆9-10, ∆1Aq, ∆8p and ∆11q) were detected by 
at least one technical replicate across all time points, whereas ∆13p and ∆14p were detected in 
at least one technical replicate across 5 time points. The minor alternative events were detected 
sporadically across time points, often only by a single technical replicate (Figures 6.1 and 6.2).  
Detection consistency is greatest between samples represented by more than 100,000 reads 
across BRCA1 and BRCA2 using the RNA-seq platform utilised here (Appendix F, Table S11). 
This is shown in time point 6 with all replicates exceeding that target (Figures 6.1 and 6.2). 
Uniformity was greatest at this time point with 8/14 BRCA1 and 4/9 BRCA2 alternative events 
detected across all three technical replicates. The low read counts for the replicates of time 
point four displayed more variable expression patterns across each gene with only 3/12 BRCA1 





Figure 6.1. BRCA1 mRNA isoforms identified in one LCL (Sample #7, Table 2.1) at six time points. 
A freeze-thaw process was undertaken after the second and fourth time points. Sample is treated with NMD 
inhibitors. Technical replicates are listed under each time point. 
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Figure 6.2. BRCA2 mRNA isoforms identified in one LCL (Sample #7, Table 2.1) at six time points. 
A freeze-thaw process was undertaken after the second and fourth time points. Sample is treated with NMD 
inhibitors. Technical replicates are listed under each time point. 
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After normalising the reads of each sample to 40,000 per gene expression levels vary across 
the gene, possibly due to the presence of alternative junctions where exon skipping events are 
prominent (Figures 6.3 and 6.4). Selection bias of the probes within the targeted RNA-seq 
platform may have also influenced the variability observed, as the binding efficiency may be 
superior at some junctions, which would alter the relative expression levels observed. The 
inconsistencies observed between replicates at each time point highlight samples that are 
represented by a relatively low total number of reads (<70,000 reads) prior to normalisation. 
After normalisation the difference in expression levels between junctions was enhanced in 
some samples due to low read counts (i.e. replicate 1 in time point 3 and replicate 2 in time 
point 4 for both BRCA1 and BRCA2) (Figures 6.3 and 6.4). This effect was prominent in the 
NMD untreated samples (Appendix G, Figures S2-S3). 
Testing for significance using the linear model found no consistent effect by time point or 
freeze-thaw in either NMD inhibitor treated or untreated samples for BRCA1 and BRCA2. 
Visual inspection of the plots highlighted only one junction (BRCA2 exons 17-18) that showed 
evidence of a non-linear relationship, which is indicated by a pattern that is not straight, but 
may instead conform to an exponential or a parabolic curve (Appendix H, Figures S4-S7). 
While one junction would be expected by chance to display a non-linear relationship, the exons 
specified in this junction are involved in alternative event ∆17-18. This junction may have had 
altered expression levels across time points; however, limitations in the Targeted RNA-seq 
probe design prevented detection of this event to compare its expression across time points.  
While overall detection of alternative splicing events was similar between NMD treated and 
untreated samples, detection across time points was lower in the samples not treated with NMD 
inhibitors in both BRCA1 and BRCA2 (Figures 6.1 and 6.2, Appendix I, Figures S8 and S9). 
This is not unexpected as the total read counts for the untreated samples were generally lower 







Figure 6.3. Expression of BRCA1 full length junctions between technical triplicates at six time points. 
RNA from cycloheximide treated LCL (Sample #7). Zero read counts at any junction are excluded. The 10-11 





Figure 6.4. Expression of BRCA2 full length junctions between technical triplicates at six time points. 
RNA from cycloheximide treated LCL (Sample #7). Zero read counts at any junction are excluded. The 10-11 







Splicing assays are used to assess variants for their ability to disrupt normally expressed 
patterns of mRNA isoforms. Of the differences observed previously between such assays, only 
a small proportion is accounted for by the encompassed variants and little is understood about 
the factors that underpin the remaining variability. The novel targeted RNA-seq platform 
utilised in Chapters 4 and 5 was used here to compare BRCA1 and BRCA2 isoforms expressed 
in the same LCL over time, with the inclusion of technical replicates to assess the sensitivity 
of the sequencing technology. The results from this work indicate that there is no significant 
effect of normal cell culturing practices, such as liquid N2 storage and the time cells are in 
culture, on mRNA expression across BRCA1 and BRCA2. While culturing for longer periods 
may allow currently undetectable effects to reach identifiable levels, this finding highlights that 
the prominent mRNA variability observed is more likely to stem from other sources.  
mRNA variation was identified across the time points, regardless of the utilisation of a single 
standardised protocol for detection. Predominant isoforms were detected in at least five of the 
six time points, while the minor events displayed more sporadic expression patterns. One 
possible explanation is normal cellular fluctuation. Presuming that naturally predominant 
events are important for cellular function, then the expression of these isoforms is likely to 
occur more often than the less crucial isoforms.  The higher expression frequency would 
increase the likelihood of detection at any given time, while the expression level of these 
isoforms would also be greater than the minor events. Minor events may not be expressed as 
often, which would limit the likelihood of detection at every time point.  
One of the main contributing factors for the mRNA detection disparity across time points is 
the total read counts returned for each sample. As shown in Chapter 4, read counts have an 
effect on the number of alternative events detected (Figure 4.2). The detection consistency of 
these events between technical replicates here is found to be optimal when comparing samples 
sequenced at a higher depth (time point 6). This is not unexpected, as the relationship between 
adequate sequence coverage and read depth is well recognised [Wang et al. 2009, Mercer et al. 
2012]. However, this relationship does reiterate the importance of sequencing depth to allow 
detection of the rarer isoforms, especially when studying genes with a high transcriptional 
complexity, like BRCA1 [Colombo et al. 2014]. This is an issue that may be limiting the 




processed simultaneously, the PCR amplification step undertaken prior to sequencing will 
amplify the transcripts equally across samples. This means that the samples containing the 
highest concentrations of the target regions will be likely to return the most reads, while 
allowing the detection of more alternative isoforms than the other samples regardless of the 
overall sequencing depth obtained. 
Another factor that may influence isoform detection between technical replicates is low 
sampling fraction, which has been suggested previously to lead to technical inconsistencies 
[McIntyre et al. 2011]. Low levels of the target gene mRNA transcripts in the original RNA 
pool would be further stretched when extracting replicates, causing the respective levels of 
each isoform to deviate from the average when sequenced. This would be more prominent for 
minor events and may have led to some of the detection differences observed here across the 
replicates at each time point. While the samples extracted across the time points were quality 
assessed prior to library construction, the relative levels of the target genes within each was not 
examined. Natural fluctuations in gene expression may have resulted in levels of the targeted 
genes that were much lower in some of the samples, relative to the total RNA, and were 
stretched further when extracting the technical replicates. 
Previous chapters highlight how mRNA isoform detection rates vary between samples, with 
the more prominent differences observed often accounted for by rare variants within each 
sample. The work presented here found no relationship between mRNA isoform expression 
and the methodical differences (liquid N2 storage and time) used to culture LCLs. Much of the 
variation detected between time points and technical replicates is likely due to natural cellular 
fluctuations and assay-specific technicalities, with read depth shown to be a major factor 
having an effect on mRNA isoform detection. Further work is required to determine the level 
of expression that results from underlying cell-specific expression differences. This would help 
understand what level of mRNA variation between samples is likely accounted for by the 




: Using RNAscope to explore specific BRCA1 and 
BRCA2 mRNA isoform expression at single-cell resolution 
7.1 Introduction 
As shown previously (Chapters 3-6), mRNA isoform expression differences are observed at 
many levels. Qualitative and quantitative variation was shown to occur between samples and 
in the same sample over time, indicating that BRCA1 and BRCA2 mRNA isoforms are not 
expressed at a constant level. This finding is supported by several studies that show how gene 
expression is stochastic and occurs in bursts, irrespective of the transcription factors present at 
the time [Raj et al. 2006, Suter et al. 2011]. However, there is a lack of understanding of how 
variable BRCA1 and BRCA2 mRNA expression levels are in cellular populations. Sequencing 
and PCR-based techniques utilised in Chapters 3 and 4 analyse whole populations of cells per 
assay, generating the average mRNA expression across all cells within a sample. Thus, these 
gene expression analyses were unable to determine the variation among individual cells in these 
populations.  
This qualitative and quantitative study has exploited RNA-seq technology to advance our 
current understanding of BRCA1 and BRCA2 isoform expression based on mRNA derived from 
LCLs. However, it is unknown whether BRCA1 and BRCA2 expression in the cell population 
is significantly different to what might be assumed from extrapolating quantitative data to an 
‘average cell’. Moreover, exploring gene expression at the single cell level may provide further 
understanding about BRCA1 and BRCA2 expression variability between samples.  
Recent advances in in situ hybridisation (ISH) technologies have permitted accurate 
measurement of single-cell transcriptional levels and enabled a more thorough analysis of 
BRCA1 and BRCA2 expression variability. One of these novel technologies, RNAscope 
(Advanced Cell Diagnostics (AcdBio), Inc., Hayward, CA, USA), uses either fluorescent or 
chromogenic labelling to detect and quantify mRNA transcripts in single cells [Wang et al. 
2012]. Previous studies exploring the capabilities of this technique returned results that validate 
RNA-seq data [Hickman et al. 2013], and that were also comparable to qPCR and other in-situ 




overcomes ISH-associated gene detection sensitivity and specificity limitations by employing 
a specialised dual Z-probe design to selectively target and quantify specific mRNA in single 
cells (Figure 7.1).  
 
Figure 7.1. Schematic of RNAscope Z-probe design, binding and signal amplification.  
A. RNAscope specific Z-probe design. B. RNAscope overview – sequential hybridisation steps to obtain a signal. 
Contiguous probe binding to target mRNA sequence, preamplifiers bind to paired probe tail sequences, amplifiers 
bind to preamplifiers and signal labels bind to complementary sequences on the amplifiers for detectable 
signalling. Up to 20 probe pairs are designed across the region of interest. The assay design limits off-target 
amplification as two Z-probes are required to bind contiguously to create a platform, or tail sequence, (top of the 
two Z-probes (A)) where the preamplifier can hybridise. Amplifiers then bind to any of the 20 binding sites on 
the preamplifier, before the detectable fluorescent molecule contained within the label probes binds to any of the 
20 binding sites on each amplifier. Three Z-probe pairs are required to produce a detectable signal for any given 
mRNA transcript, increasing the specificity of the assay while limiting the likelihood of non-specific binding 
[Wang et al. 2012]. 
 
RNAscope has been used previously to study mRNA expression variability of HER2 in 




cannabinoid receptors in mouse neuronal tissues [Li and Kim 2015], and the expression of 
human papilloma virus RNA transcripts in head and neck squamous cell carcinoma tissue 
arrays [Ukpo et al. 2011, Bishop et al. 2012]. Additionally, studies have used RNAscope to 
assess BRCA1 mRNA levels in relation to methylation status [Naipal et al. 2014], the molecular 
parameters of triple negative breast cancer [Boukerroucha et al. 2015], and glioblastoma 
development [Boukerroucha et al. 2015]. However, to date no studies have used this 
technology to study RNA expression of BRCA2, nor have any studies focused on specific 
mRNA isoforms in either BRCA1 or BRCA2. This chapter investigates LCLs with and without 
spliceogenic variants and describes the first mRNA isoform-specific expression study of 
BRCA1 and BRCA2 using RNAscope. 
7.2 Methods 
7.2.1 Study samples 
Two LCLs (described in Chapter 2, Table 2.1) containing variants known to cause specific 
splicing disruptions were selected for analysis. LCL #4 contained BRCA1 c.671-2 A>G, which 
expresses higher levels of BRCA1 ∆11 than controls (see Chapter 4). LCL #7 contained the 
BRCA2 c.7988 A>T variant, which is known to cause increased levels of BRCA2 ∆17,18 
[Walker et al. 2010, Whiley et al. 2014]. Samples were cultured as previously described 
(Chapter 2, Section 2.2). mRNA was detected in LCLs cultured with and without NMD 
inhibitor cycloheximide (100 µg/mL).  
7.2.2 Probe design 
Z probe pairs were designed to target specific BRCA1 and BRCA2 alternative isoforms, so that 
RNAscope could be used to detect and compare the associated expression levels between 
variant carriers (BRCA1 c.671-2 A>G and BRCA2 c.7988 A>T) and controls (#19 and #24, 
Chapter 2, Table 2.1). These site-specific oligonucleotides are each detectable in separate 
colour channels, referred to as C1 (conjugated to Alexa 488 - Green) and C2 (conjugated to 




Selection of targeted isoforms was restricted by the requirements of the probes. Ten to 20 
probes are needed for optimal signalling, which in turn necessitates a stretch of mRNA between 
500 and 1,000 nt long within the targeted skipping event. This meant that events less than 500 
nt long are not adequate for optimal detection with this technology. BRCA1 C1 probes were 
designed to target exon 11 (3426 nt), and C2 probes to target exons 1-10 (670nt) (from here on 
these BRCA1-specific probes are referred to as C11 and C1-10, respectively). BRCA2 C1 
probes were designed to target exons 17/18 (526 nt), and C2 to target exon 11-16 (5,896nt) 
(from here on BRCA2-specific probes are referred to as C17-18 and C11-16, respectively) 
(Figure 7.2). Probes were designed so that BRCA1 C11 probe binding will not be observed for 
transcripts with exon 11 skipping, while BRCA2 C17-18 probe binding would not be observed 
for transcripts with exons 17-18 skipping. Transcripts with detectable binding for both probes 
do not carry the targeted deletion. While the probe locations were specified by the candidate to 
fit the requirements of this project, RNAscope probes are created within the founding 
organisation and the precise sequences are proprietary (AcdBio, Hayward, CA). 
 
Figure 7.2. Location of RNAscope fluorescent probes for mRNA specific detection. 
Location and number of RNAscope fluorescent probes used to detect BRCA1 ∆11 and BRCA2 ∆17-18, plus the 
total mRNA BRCA1 and BRCA2 expression patterns. Colour represents the detectable fluorescence of the probes. 





7.2.3 RNAscope assay 
RNA in situ hybridisation was performed once for each sample using the RNAscope® 
Fluorescent Multiplex kit (AcdBio) according to the manufacturer’s instructions specified in 
RNAscope® Fluorescent Assay for PBMC and Non-Adherent Cells (Part 1) (Cat. No. 320539), 
and the RNAscope® Fluorescent Multiplex Kit User Manual Part 2 (Rev. Data 20131104) 
[Wang et al. 2012].  
7.2.3.1 Cell adhesion and hybridisation preparation 
Briefly, cultured LCL samples were harvested by centrifugation (400 g), washed with PBS, 
resuspended in formalin (10%) and incubated at 37°C for one hour to fix the cells for analysis. 
Cells were then centrifuged (1000 rpm), washed in PBMC-Wash (AcdBio) and resuspended in 
70% ethanol ready for fixing to slides. Suspended cells were transferred into pre-assembled 
cyto-centrifuge cartridges (Thermo Fisher Scientific), spun in a Shandon CytoSpin II 
Cytocentrifuge (Shandon Scientific, Cheshire, UK) at 800 RCF for 20 minutes, and then air 
dried. 
Slides were prepared for pre-treatment with four consecutive 5 minute ethanol incubation steps 
at room temperature (50% ethanol twice, followed by 70% and 100%). Slides were 
subsequently dried at 37°C for 30 minutes in a HybEZTM oven (AcdBio). All following 
incubations were completed in the HybEZTM oven in a humidity control tray to prevent the 
samples drying out. Cell spots were circled with a hydrophobic barrier pen to contain 
treatments and hybridisation mix across the cell spread. Pretreat 3 solution was then added, 
covering each cell spot entirely, before incubation at 40°C for 30 minutes. Slides were washed 
in PBS prior to probe hybridisation. 
7.2.3.2 Probe hybridisation and slide mounting 
Gene-specific C1 and C2 probes were incubated at 40°C in the HybEZTM oven for 10 minutes, 
then left to cool to room temperature before mixing at a 1:50 ratio. The prepared probes, and 
those provided for the positive and negative controls, were pipetted onto their respective 
samples to completely cover the cells, prior to hybridisation in a two hour 40°C incubation. 
Four 40°C incubation steps followed to consecutively hybridise several amplifiers to these 




minutes, followed by AMP 2-FL for 15 minutes, AMP 3-FL for 30 minutes and AMP 4-FL for 
15 minutes. Each of these hybridisation steps alternated with a washing step involving two 
sequential 2 minute incubations at room temperature in fresh wash buffer. Cells were then 
counterstained with DAPI via a 30 second incubation at room temperature. Anti-fading solution 
(2 mg/mL p-phenylenediamine (Sigma-Aldrich, New Zealand) in 80% glycerol pH 7.8 (ice 
cold solution)) to prevent photo-bleaching was then applied as the mounting medium before a 
cover slip was immediately placed over the cells on each slide. 
7.2.4 Slide imaging 
Fluorescent signals were captured and manually quantified using an epifluorescent Zeiss 
AxioVision microscope and associated software (AxioVersion 4.5. Apotome software, Carl 
Zeiss Microscopy, LLC, Thornwood, New York, USA). The EC plan-Neofluar 40x/1.3 oil Dic 
M27 objective was used with DAPI, TRITC and FITC filters. Fluorescent labelling was 
quantified for the cells within randomly selected fields of view until 50 cells were recorded for 
each sample. 
7.2.5 Data acquisition and statistical analysis 
The number of transcripts containing the targeted deletion event in each cell was determined 
through differences in the number of detected fluorescently labelled probes. For example, 
where there is an equal number of BRCA1 C11 and C1-10 fluorescent signals in a cell, it is 
expected that all detected isoforms carry all targeted exons. Absence of the C11 (green) probes 
indicates an exon skipping event, in this case, ∆11 (Figure 7.3). The Yates corrected chi square 
test was used to test for independence in the presence of the delta events between cases and 
controls. This is a conservative test used to prevent an overestimation of significance when 
analysing small datasets, and especially when some values in the test are below the 







Figure 7.3. Example of mRNA expressed by the gene of interest in individual cells using RNAscope. 
Differences in the number of each probe detected indicate the number of mRNA isoforms in each cell that carry 
the deletion. A, cellular mRNA that does not carry the targeted deletion as indicated by equal expression of both 
green (C1) and orange (C2) probes. B, cellular mRNA that contains the deletion of interest, with the orange probe 
(C2; total number of mRNA expressed) detected more frequently that the green (C1; targeting the deletion). 
 
7.3 Results 
In this study, RNAscope was used to explore the expression patterns of specific mRNA 
isoforms in LCLs with and without spliceogenic variants.  
As expected from earlier chapters, a higher number of mRNA transcripts were identified here 
in the NMD inhibitor treated samples compared to the untreated samples (BRCA2 c.7988 A>T: 
160treated versus 97untreated, BRCA1 c.671-2 A>G: 104treated versus 20untreated), limiting statistical 
conclusions from the latter due to the low number of observed signals (Appendix J, Tables 
S12-S16, Figures S10 and S11). BRCA1 mRNA was detected in 44% (22/50) of cycloheximide 
treated cells assessed in the case (BRCA1 c.671-2 A>G) and 8% (4/50) of untreated cells 
(Appendix J, Table S12); by comparison only 4% (2/50) and 10% (5/50) were detected in the 
treated and untreated control, respectively (Appendix J, Table S13). BRCA2 mRNA was 
detected in 58% (29/50) of treated cells assessed in the case (BRCA2 c.7988 A>T) and 48% 
(24/50) in the untreated cells (Appendix J, Table S14), compared with 24% (12/50) in the 
treated control and 10% (5/50) in the untreated control (Appendix J, Table S15). Positive and 




The range of mRNA expression observed between the cells within each sample was greater 
and more variable in the cases (up to 17 and 29 mRNA molecules, respectively, detected per 
cell in BRCA1 and BRCA2 variant carriers, and up to 10 mRNA molecules per cell in the 
controls) (Appendix J, Tables S12-S15). Cells were identified in each sample studied that 
contained a higher number of exon skipping-specific mRNA than the total amount of expressed 
mRNA, as indicated by the second probe (27% (6/22) BRCA1 c.671-2 A>G and 28% (8/29) 
BRCA2 c.7988 A>T cells) (Appendix J, Tables S12 and S14). This is not to be expected if the 
latter is a true representation of all mRNA transcripts present for that particular gene and may 
be due to superior binding demonstrated by the exon-skipping-specific probe. 
Counting signals from C1 and C2 probes in 50 NMD inhibitor treated LCLs showed a 
significantly higher number of BRCA2 ∆17,18 mRNA molecules in BRCA2 c.7988 A>T 
variant carrier cells, compared to non-carrier cells (p-value = 0.039, Figure 7.4, Table 7.1). It 
was not possible to compare these results to the expression of BRCA2 exons 17 and 18 detected 







Figure 7.4. BRCA1 expression detected in LCLs using RNAscope. 
BRCA1 mRNA expression levels in a LCL containing BRCA1 c. 671-2 A>G (panel A), and in a control LCL 




Table 7.1. Fluorescently labelled BRCA2 mRNA counts in cells compared between samples containing 
BRCA2 c.7988 A>T, and controls. 
Samples are treated with the NMD inhibitor cycloheximide. 
 
Number of signals 
from C17-18 and 
C11-16, or C17-18 
only 
Number of signals 
from C11-16 
probes onlya    
Control 24 7 p-valueb 0.039 
BRCA2 c.7988 A>T  89 71 OR (C.I) 2.74 (1.114, 6.712) 
a Number of ∆ transcripts (no detectable exons 17-18 probe signal). 





All samples analysed contained a proportion of cells where RNAscope did not detect any 
targeted mRNA isoforms containing delta events. This observation was significantly more 
prominent in the controls compared to the variant samples (p-value 0.041, Table 7.2).  
 
Table 7.2. The number of cells expressing the targeted delta event (BRCA2 ∆17-18) compared between 
samples containing BRCA2 c.7988 A>T, and controls. 
Samples are treated with the NMD inhibitor cycloheximide. 
 Delta No delta   
BRCA2 c.7988 A>T  14 36 p-valueb 0.041 
Control 5 45 OR (CI) 3.5 (1.152, 10.63) 
bYates corrected chi-squared test. 
 
 
Counting signals from C1 and C2 probes in 50 NMD inhibitor treated LCLs found no 
significant difference in the number of BRCA1 ∆11 between BRCA1 c.671-2 A>G and the 





Figure 7.5. BRCA2 expression detected in LCLs using RNAscope. 
BRCA2 mRNA expression levels in a LCL containing BRCA2 c.7988 A>T (panel A), and in a control LCL (panel 





Table 7.3. Fluorescently labelled BRCA1 mRNA counts in cells compared between samples containing 
BRCA1 c.671-2 A>G, and controls. 
Samples are treated with the NMD inhibitor cycloheximide. 
 
Number of signals 
from C11 and C1-
10, or C11 only 
Number of signals 
from C1-10 
probes onlya    
Control 8 5 p-valueb 0.482 
BRCA1 c.671-2 A>G 78 26 OR (C.I) 0.53 (0.1603, 1.775) 
a Number of ∆ transcripts (no detectable exon 11 probe signal). 
bYates corrected chi-squared test. 
 
 
The BRCA1 variant sample (BRCA1 c.671-2 A>G) was found to contain a significantly higher 
number of cells containing the ∆11 isoform compared to the control (p-value 0.002 in BRCA1, 
Table 7.4).  
 
Table 7.4. The number of cells expressing the targeted delta event (BRCA1 ∆11) compared between samples 
containing BRCA1 c.671-2 A>G, and controls. 
Samples are treated with the NMD inhibitor cycloheximide. 
 Delta No delta   
BRCA1 c.671-2 A>G 13 37 p-valueb 0.002 
Control 1 49 OR (CI) 17.22 (2.155, 137.6) 
bYates corrected chi-squared test. 
 
 
A higher proportion of BRCA1 ∆11 to full length transcripts (33%) was detected using 
RNAscope than that observed using RNA-seq (19%) in Chapter 5 (Table 7.5).  
 
Table 7.5. Expression of the deletion events as detected by RNAscope and RNA-seq. 
 RNAscope* RNA-seq
a 
 Variant carrier Variant carrier 
BRCA1 Delta 11 33% (38/104) 19% 
BRCA2 Delta 17,18 44% (71/160) NA 
*Percentage of delta mRNA detected out of the total for all 50 cells sampled. 






Sequencing or PCR based methods are often used to detect and quantify mRNA splice isoforms 
and typically follow a population approach, where the abundance of each isoform is quantified 
from a large number of cells. The use of these platforms in Chapters 3-6 identified BRCA1 and 
BRCA2 mRNA isoform expression variability between samples, which was largely maintained 
between populations of the same sample analysed over time. An investigation into the level of 
variability in mRNA expression between individual cells may help determine the extent to 
which cellular heterogeneity contributes to this variation. 
Here, RNAscope is used as an innovative approach to quantify specific BRCA1 and BRCA2 
mRNA isoforms in individual LCLs. Using this method, BRCA2 ∆17,18 was found to be 
expressed at higher levels in LCL cells isolated from the BRCA2 c.7988 A>T carrier than those 
from a control LCL. This result supports previous work utilising qPCR that found this variant 
to be pathogenic after detecting increased expression levels of BRCA2 ∆17,18 and ∆18 in 
several LCLs [Walker et al. 2010]. RNAscope allowed the work presented here to go a step 
further and explore expression levels within single cells. Interestingly, analysis at this 
resolution identified that BRCA2 ∆17,18 was not uniformly expressed across all of the cells 
analysed for the BRCA2 carrier. While the majority did express the exon skipping event, and it 
was exclusively expressed in some cells, a small proportion of cells expressed the BRCA2 
without the BRCA2 ∆17,18 transcript. These results suggest that the BRCA2 c.7988 A>T 
variant does not lead exclusively to a ∆17,18 event, a finding that is supported by previous 
work [Walker et al. 2010]. 
BRCA1 and BRCA2 expression levels are shown to vary between cells in the samples analysed, 
with a high number of mRNA transcripts observed in some cells and no expression in others 
(Appendix J, Tables S12-S15). This is consistent with previous reports of gene expression 
between individual cells [Raj et al. 2006, Marinov et al. 2014], but has not been shown for 
BRCA1 and BRCA2. Disparity between mRNA and corresponding protein levels is a 
phenomenon frequently observed for many genes, likely due to the post-transcriptional 
regulatory factors controlling protein expression [de Sousa Abreu et al. 2009, Schwanhausser 
et al. 2011]. Slow protein degradation rates may explain how cells survive the mRNA 




maintaining sufficient protein levels over the periods of no mRNA expression [Raj et al. 2006]. 
However, shorter cycles may cause the overexpression of unwanted transcripts, while longer 
periods may extend past the lifetime of the protein, which could be damaging for cells without 
continuous protection from DNA repair proteins, such as BRCA1 and BRCA2. Determining if 
this fluctuation period is extended or shortened with the presence of certain variants, or mRNA 
isoforms, would help to further tease out how these changes influence cellular functioning, and 
the likely impact thereof. 
mRNA isoforms detected in samples at very low levels may actually be highly abundant in a 
small number of cells. Identifying such instances is important, as isoforms carrying changes 
that significantly increase the risk of disease when highly expressed are unlikely to be identified 
using population-based methods if they are only expressed in a limited number of cells. This 
may lead to certain isoforms being overlooked as likely contributors towards individual risk. 
Ideally, all BRCA1 and BRCA2 alternative mRNA isoforms would be studied at single 
molecule resolution to determine the expression level at which each is tolerated in normal cells. 
This would help identify changes observed in patient samples that are outside the expected 
range. Previous work found no significant difference between tissue types analysed (breast 
tissue versus blood-related sources) and the BRCA1 mRNA isoforms detected at the qualitative 
level [Romero et al. 2015], so isoform expression analyses could potentially be undertaken 
from routine blood sample collection. RNAscope may offer a means for future diagnostic work 
to assess known high risk isoforms across individual cells and identify cell-specific 
overexpression in blood and/or breast tissue that may be disruptive enough to cause 
tumourigenesis. 
Nonsense-mediated decay inhibitors are often used in splicing analysis as they prevent the 
degradation of mRNA, so improving the chances of detecting the present mRNA transcripts. 
Here, more cells containing BRCA1 or BRCA2 mRNA isoforms were detected in the treated 
samples compared to the untreated samples, while a higher number of mRNA was also present 
in each cell (Supplementary Tables S12-S15). Higher expression in the treated samples made 
quantification and comparison much easier, whereas the mRNA numbers detected in the 
untreated samples were not sufficient to determine any significant differences, suggesting that 




One limitation of this technology is the time required to manually count an adequate number 
of cells for each sample. There are a large number of freeware tools available to detect and 
quantify cellular fluorescence from 2-dimentional micrographs [Wiesmann et al. 2015], which 
would speed up the analysis process and potentially improve the reproducibility and 
comparability between assays. However, automation of this step with the software tools 
currently available also has its drawbacks, as even the most functional and user-friendly tools 
usually require a degree of manual assessment to obtain accurate results [Hanley et al. 2013, 
Wiesmann et al. 2015]. Additionally, the detection sensitivity would be limited to one level of 
view, so will not detect all the fluorescently labelled mRNA situated throughout the cell 
cytoplasm’s 3-dimensional environment. Studies that include a large number of samples would 
likely require imaging software tools with 3-D capabilities, in addition to automated analysis 
for faster processing. Determining the optimal parameters for accurate analysis using most of 
the available software packages is a time consuming process, which may mean it is more 
advantageous to undertake the detection process manually for smaller experiments until more 
suitable software becomes available.  
Several technical irregularities were observed that led to alterations to how data collection was 
undertaken. One interesting feature was the way the fluorescent signals moved when viewing 
under the microscope. Manual counting from the cell slides, rather than captured images, 
allowed a more accurate record of the number of each probe bound to mRNA in the cells, as 
the constantly moving labels prevented all signals from being captured in a 2D image. This 
phenomenon may be prevented through the use of an alternative anti-fade mount, which may 
more firmly fix each cell’s enclosed mRNA in place. Additionally, the detected signals from 
the C1 and C2 probes were not often situated proximally in pairs within each cell, but were 
more frequently located in separate regions of the cell. It was expected that the binding of both 
probes to the same mRNA transcript would lead to signals very close together, and an 
explanation for this unexpected finding is yet to be determined. 
While RNAscope has proved useful for identifying mRNA expression differences between 
samples, one limitation is that the current protocol is not sufficient for identifying less 
prominent changes. This is because no significant mRNA expression difference for BRCA1 
∆11 was identified using RNAscope, although it is found to be upregulated 1.3-fold in the case 




expressed ∆11 in the case compared to the control, even though the overall level of expression 
was not significantly different. While investigations into the respective probes’ binding 
abilities would need to be undertaken, it would not have been possible to detect such findings 
without focusing on single cell expression in a population. Increasing the total number of cells 
counted in each sample would improve the sensitivity of the assay and would make it more 
likely to detect smaller expression differences between samples, while also increasing the 
significance of the results gained. Additionally, more control samples would increase power 
for detecting these differences. As more samples are analysed at the single-cell resolution, it 
would be worth considering sharing mRNA expression ranges observed in cases and controls 
through the development of a publically available online database. Collating such data may 
allow a more in depth understanding of what changes are associated with variant carriers 
compared to expression patterns observed in controls.  
An improvement to this assay could be made through altering the placement of the assay 
probes, as more C1 probe signal (specific to the exon skipping event of interest) was 
unexpectedly detected at higher levels in some cells compared to the C2 probes (total mRNA 
expressed). C2 probes were situated over large regions, encompassing multiple exons, with the 
aim of detecting most of the mRNA molecules expressed from BRCA1 or BRCA2. Of all known 
BRCA1 mRNA isoforms, only two (∆1Aq-10 and ∆2-10) have the potential to exclude 
significant lengths of BRCA1 to prevent an adequate number of C2 probes from binding and 
creating a signal. These BRCA1 isoforms are two of 26 minor isoforms previously identified in 
control samples that exclude at least one exon in this region [Colombo et al. 2014]. Due to this, 
they were not perceived as likely to cause a significant impact on the number of mRNA 
detected. Of the BRCA2 isoforms currently known to be situated within the C2 probe binding 
region, only ∆11 deletes a significant proportion (83.6%) of the targeted C2 region. The 
RNAscope recommendations for probe design indicate that a region around 1 kb long is 
adequate for 20 Z probe pairs to bind [Wang et al. 2012]. While the BRCA2 C2 region, 
excluding exon 11, is just short of that target (964 bases), the 20 Z probe pairs were designed 
to spread over the 5.9 kb region that includes exon 11, so it is unlikely that the required three 
pair minimum is situated outside of exon 11 to guarantee a signal if exon 11 is deleted. BRCA2 
∆11 has been reported previously in controls, but only in a single publication and with no 
information regarding its observed expression level [Fackenthal et al. 2016]. While BRCA2 




delta event from previous literature suggests that it is not a predominant isoform, so unlikely 
to be highly expressed, if at all, in the samples studied here. Repeating the assays using probes 
that are located in different regions, for example BRCA2 exons 12-16, would make an 
interesting comparison to the current design to determine if such a change would improve 
detection of BRCA2 isoforms. 
Additional work is required to more comprehensively determine the accuracy of RNAscope 
through comparison of isoform expression levels obtained using RNAscope with those 
generated using sequencing and/or PCR based methods. This would help validate the results 
obtained, or highlight any likely limitations in the current probe design that make it inadequate 
to detect all targeted mRNA transcripts expressed in each cell. The results from the BRCA1 
RNAscope experiments obtained here identified a higher proportion of ∆11 to full length 
transcripts (33%) than that seen in the RNA-seq data (19%, Chapter 4) (Table 7.5). The reason 
for this difference may be explained by using RNA sequencing technology, such as direct 
sequencing (dsRNA-seq). This is a suitable and sensitive method to validate RNAscope as it 
has the capacity to focus on single cells without the requirement of mRNA amplification prior 
to detection [Ozsolak et al. 2009]. Additionally, a higher number of cells counted with 
RNAscope may also make it a more accurate comparison. 
The unique probe design RNAscope uses to obtain high specificity also limits the number of 
isoforms that are able to be detected with this technique. Three probe pairs are required to 
return a detectable signal, each pair taking up 36-50 nucleotides of the target sequence, while 
10-20 pairs are recommended to gain optimal detection [Wang et al. 2012]. While shorter 
probes can be used, deletion or insertion events less than 350 bases in length are unlikely to be 
suitable for probe design to obtain sensitive results, restricting the number of mRNA isoforms 
that can be studied to a select few of the known deletion events that involve more than one 
exon (apart from BRCA1 exon 11, BRCA2 exons 11 and 18). Probe design limitations are also 
observed for Targeted RNA-seq (Chapter 4) when detecting mRNA isoforms, where short 
exons restrict the possibility of having a probe at each end, preventing the detection of certain 
exon skipping events. Future work into improving the current RNAscope technology by 
reducing the minimum requirement for probe placement, while maintaining sensitivity, would 




RNAscope is a novel ISH technology that can be used to quantify mRNA isoforms and identify 
those expressed outside their normal range, both across a population of cells and in single cells. 
This information is invaluable for closer scrutiny of exactly how splice-disruptive variants are, 
as it is possible to detect the overexpression of mRNA isoforms at a level that would not be 
picked up using sample-based approaches. This work is the first to uncover BRCA1 and BRCA2 
expression patterns at the single cell level in LCLs and shows how the level of variation is 
significant between cells of each sample, potentially explaining some of the variation observed 
when studying expression at a cell population level. The variable expression levels of BRCA1 
and BRCA2 isoforms detected between cells here suggest that more work is required to 
understand the range of mRNA isoform expression that can be tolerated in single cells. Such 
thresholds may become the crucial indicators of early cancer development and would open the 





: Exome sequencing of BRCA1/BRCA2 mutation 
negative patients to identify candidate breast cancer risk 
variants 
8.1 Introduction 
Breast cancer risk is greatly elevated in individuals who carry disruptive variants in breast 
cancer susceptibility genes BRCA1 and BRCA2. These high-penetrance variants may account 
for more than 20% of familial, and 3-5% of sporadic, breast cancer cases [Antoniou et al. 2008, 
Sevcik et al. 2012]. Routine BRCA1 and BRCA2 (BRCA) gene screening for such mutations is 
offered to affected individuals from high-risk breast-ovarian cancer families. Currently, the 
pre-test probability of a genetic test identifying a known pathogenic BRCA1 or BRCA2 
mutation in these high risk individuals is very low (<20%), while we are also yet to gain a 
thorough understanding of how to interpret many of the variants that are identified. Although 
a negative BRCA test result (BRCAx) has been shown to decrease anxiety in the patient and 
their families [Gooding et al. 2006], these BRCA tests do not explore the possibility that 
patients harbour high-risk genetic variants in other gene regions. Identifying such variants 
would provide a genetic marker for cancer risk in family members of that patient, enabling 
improved stratification of high- and low- risk individuals, so that treatment and risk-reducing 
options can be better targeted by health professionals  
A number of breast cancer susceptibility genes, additional to BRCA1 and BRCA2, have been 
identified, including ATM, BRIP1, CHEK2, PALB2 and TP53 [Rahman et al. 2006, Seal et al. 
2006, Baynes et al. 2007]. Expanding current breast cancer genetic testing to include these 
additional genes would provide a more in-depth investigation to identify variation that 
increases disease risk. High-throughput sequencing technologies are quickly becoming the 
most cost-effective option for genetic studies and the method of choice for variant detection 
[Yang et al. 2013]. Unlike Sanger sequencing, which is restricted to specific genomic locations, 
massively parallel sequencing technologies have the ability to obtain significantly more 
information throughout the genome from a single assay. Although sequencing the whole 
genome (WGS) has recently been carried out for US$1,000 [Kruglyak et al. 2016], at the time 
of this study whole exome sequencing (WES) still provided a cost effective alternative. This 




known human genes, including the vast majority of known disease-associated variation [Choi 
et al. 2009]. This technology has been utilised by a number of groups to identify novel low, 
moderate and high risk variants in individuals from breast/ovarian cancer families [Thompson 
et al. 2012, Gracia-Aznarez et al. 2013, Noh et al. 2015]. It is likely that exome and/or whole 
genome sequencing will pave the way for the identification of more breast cancer susceptibility 
genes as a higher number of high-risk families are analysed. Although not conclusive, 
important evidence for or against disease association is acquired through the detection of 
candidate variants in the same genes in multiple families. While variants have been identified 
from these studies in a variety of candidate genes, such as FANCM [Kiiski et al. 2014], XRCC2 
[Park et al. 2012], FANCC and BLM [Thompson et al. 2012], their role in breast cancer risk 
remains uncertain. 
Candidate gene analysis is a simple yet effective method to extract a manageable number of 
variants from the total pool of calls that are located in known disease susceptibility genes and 
so may have a higher potential of contributing to the studied disease. Using this analysis 
approach for WES data has proven effective previously [Thompson et al. 2012], even from low 
sample numbers [Ng et al. 2010], and so is a promising tool for variant prioritisation when 
dealing with the huge datasets returned from massively parallel sequencing-based studies. 
In this study, WES analysis was carried out to identify candidate moderate/high risk variants 
in four women who underwent genetic testing for BRCA mutations by Genetic Health Service 
New Zealand but received uninformative results.  
 
8.2 Methods 
8.2.1 Sample preparation and sequencing 
Peripheral blood DNA was obtained from four unrelated women (Table 8.1) recruited into the 
New Zealand Familial Breast Cancer Study, an expanding cohort of women at high risk for 
breast cancer who meet Genetic Health Service New Zealand criteria for genetic testing (Box 
1, Section 1.3). Informed consent was obtained at study entry, permitting blood collection for 
genomic research. The study was approved by the Southern Health and Disability Ethics 




BRCA1 and BRCA2 mutations, but the results showed no evidence of a pathogenic mutation in 
these genes. In this study, non-BRCA1/2 mutation carriers are defined as BRCAx. 
Genomic DNA was extracted from whole blood using the salting-out method (Section 2.2.1) 
prior to agarose gel electrophoresis to check integrity (Section 2.5), and quantification using a 
nanodrop spectrophotometer. Five micrograms of each sample was treated with DNAstable® 
to dry and stabilise the DNA when at ambient temperatures. 
 
Table 8.1. Reported genetic variants in BRCA1 and BRCA2 from the BRCAx samples. 
No pathogenic variants were detected. 
Sample ID: 735 736 737 738 
Age diagnosed (years): 64 48 26 26 
Low risk variants 
BRCA2:        NA  NA 
c.9976A>T  rs11571833         
  c.9257-16T>C  rs11571818         
Unclassified variants 
/polymorphisms: 
BRCA1:   BRCA1:   NA   NA 
IVS8-58delT  rs273902772 c.2612C>A  rs799917     
c.4308T>C  rs1060915 c.3113A>G  rs16941     
c.4837A>G  rs1799966 c.3548A>G  rs16942     
c.5074+65 G>A  rs8176235 c.4837A>G  rs1799966     
BRCA2:   BRCA2:       
c.-26G>A  rs1799943 c.1114A>C  rs144848     
c.7242A>G  rs1799955         
Abbreviation: IVS, Intervening sequence; NA, None applicable (no variants reported); UTR, Untranslated region. 
8.2.2 Whole Exome Sequencing 
Whole exome capture and sequencing was performed by Otogenetics (Norcross, GA USA). 
Their quality control, library preparation and sequencing methods are described in Appendix 
L. Briefly, the purity and concentration of the DNA was checked with agarose gel and OD ratio 
tests prior to fragmentation using the Bioruptor. The concentration and size distribution of the 
resulting fragments was tested using nanodrop and an Agilent Tapestation 2200. Illumina 
libraries were created using SPRIworks HT Reagent Kit (Beckman Coulter, Inc. Indianapolis, 
IN USA, catalog# B06938) followed by exome enrichment using Agilent SureSelect AV5 + 
UTR Exon Coverage (Agilent Technologies, Wilmington, DE USA, catalog# 5190-6213). 
Sequencing was carried out using Illumina HiSeq 2000 (HighOutput v3 chemistry) to generate 
101 nt paired-end reads with a minimum average coverage of 50x (Appendix M, Tables S17-




highlight any initial mapping issues in the data [Andrews 2010]. Due to the library size (350-
400 nt) being greater than the sequencing size (100 bp) there was little read through into 
adapters. For this reason trimming was not performed before raw reads were aligned to the 
reference genome in Section 8.2.3.1. Exomes were sequenced at an average depth of 65x, with 
a range between 61.21 and 67.68. More than 97% of the targeted regions had at least a 10-fold 
coverage across all samples (ranging between 97.19% and 97.40%, with an average of 97.3%). 
8.2.3 Data processing 
Read mapping, variant calling and variant quality score recalibration (VQSR) steps were 
performed by a collaborator, Dr Klaus Lenhert (University of Auckland, New Zealand). 
8.2.3.1 Read mapping and variant calling 
The Otogenetics generated FASTQ reads were aligned to the 1000 Genomes reference 
assembly GRCh37.p13 using the Burrows-Wheeler aligner v 0.7.10 [Li and Durbin 2009]. The 
resulting BAM file was sorted by chromosome coordinate prior to indexing with SAMTools 
(version 0.1.19) [Li et al. 2009] and removal of PCR duplicates with Picard (v1.111) 
[picard.sourceforge.net]. Genome Analysis Toolkit algorithms (v 3.3-0) were used for the local 
realignment of the reads around the insertions and deletions [McKenna et al. 2010], base 
quality score recalibration, variant calling, genotyping and quality score recalibration [DePristo 
et al. 2011]. Local reassembly of haplotypes was completed with HaplotypeCaller v3.3-0 in 
GVCF mode to identify likely SNVs and indels [DePristo et al. 2011]. This process was 
completed individually for each sample and was restricted to the regions targeted by the 
enrichment kit, plus an additional 100bp at the 5’ and 3’ ends. Genotyping with 
GenotypeGVCF v 3.3-0 was completed jointly with 121 additional exomes, which are from a 
range of different projects undertaken by local researchers. This joint analysis is important to 
increase the sensitivity and precision of each call by providing additional information regarding 
each respective locus, which helps to determine whether the call is true or an artefact of the 
sequencing or alignment steps. The additional exomes included for joint analysis were 
processed using the same sequencing and alignment protocols as our four samples, but are of 
unknown phenotype and BRCA status. The resulting unfiltered VCF file for the four samples 





8.2.3.2 Variant Quality Score Recalibration (VQSR) 
The quality scores of the 222,006 variants in the 125-exome call set were recalibrated using 
the GATK tools VariantRecalibrator and ApplyRecalibration v 3.3-0 [DePristo et al. 2011]. 
Variant Quality Score Recalibration computes the log odds ratio of a variant call being true 
versus false by examining the properties (e.g. mapping quality, read position and strand bias) 
of the variant site in comparison to known true training sites from published large-scale genome 
studies and to dbSNP. Briefly, VariantRecalibrator takes a 1000 Genomes verified ‘true’ 
(training) set of variants, that overlap those called in Section 8.2.3.1, to create a Gaussian 
mixture model. This model examines the annotations at each variant site to produce a 
recalibration file, which is applied to every variant in the call set to assign a score that represents 
the probability of each call being a true variant. The variants in the training set are then ranked 
by this score. ApplyRecalibration applies these variant-specific model parameters to annotate 
each of the calls made for our samples in Section 8.2.3.1 with its VQSRLOD value. 
ApplyRecalibration also uses a specified sensitivity threshold to bin variants into tranches, 
which establish thresholds that indicate different levels of sensitivity relative to the training 
sets. The higher tranches incorporate a more accurate call set than the lower tranches, which 
are more sensitive and so contain more true variants but at the cost of also including more false 
positives. The values assigned to each variant by VQSR indicate an estimate of the accuracy 
of that call by assigning a relative ranking to help distinguish true variants from false positives, 
such as sequencing and data processing artefacts. 
8.2.4 Candidate gene analysis and variant annotation 
A candidate gene list of implicated and known low, moderate and high risk breast cancer 
susceptibility genes was assembled, including those in current multigene breast cancer risk 
panels [Easton et al. 2015], those that carry driver mutations in breast cancer tumours [Stephens 
et al. 2012], and/or those implicated to be associated with breast cancer in the COSMIC 
database [Forbes et al. 2011] or in large genome-wide association studies (GWAS) [Ghoussaini 









Table 8.2. Candidate genes implicated to be involved in breast cancer development. 
Gene Gene protein categorya Reference 
AKT1 Enzyme, protooncogene 
[Forbes et al. 2011, Stephens et al. 2012, Easton et al. 
2015] 
AKT2 Enzyme, protooncogene [Stephens et al. 2012] 
APC Adhesion, transcription factor, signalling [Stephens et al. 2012, Easton et al. 2015] 
ARID1A Tumour suppressor [Forbes et al. 2011, Stephens et al. 2012] 
ARID1B DNA associated [Forbes et al. 2011, Stephens et al. 2012] 
ARID2 Transcription factor [Stephens et al. 2012] 
ASXL1 Regulatory [Stephens et al. 2012] 
ATM 
Enzyme, signalling, receptor membrane 
serine/threonine [Easton et al. 2015] 
ATR Enzyme [Easton et al. 2015] 
AXIN2 Chaperone/stress, regulatory [Easton et al. 2015] 
BAP1 Enzyme 
[Forbes et al. 2011, Stephens et al. 2012, Easton et al. 
2015] 
BARD1 Transcription factor, tumour suppressor [Easton et al. 2015] 
BLM Enzyme, DNA associated [Easton et al. 2015] 
BMPR1A 
Tumour suppressor, receptor membrane G 
serine/threonine [Easton et al. 2015] 
BRCA1 
Regulatory, transcription factor, tumour 
suppressor 
[Forbes et al. 2011, Stephens et al. 2012, Easton et al. 
2015] 
BRCA2 Tumour suppressor 
[Forbes et al. 2011, Stephens et al. 2012, Easton et al. 
2015] 
BRIP1 Enzyme [Forbes et al. 2011, Easton et al. 2015] 
CASP8 Enzyme [Forbes et al. 2011, Stephens et al. 2012] 
CDH1 Adhesion 
[Forbes et al. 2011, Stephens et al. 2012, Easton et al. 
2015] 
CDK4 Enzyme, tumour suppressor [Easton et al. 2015] 
CDKN1B Enzyme, regulatory [Forbes et al. 2011, Stephens et al. 2012] 
CDKN2A Enzyme, regulatory, tumour suppressor [Stephens et al. 2012, Easton et al. 2015] 
CHEK2 
Enzyme, receptor membrane 
serine/threonine [Forbes et al. 2011, Easton et al. 2015] 
CTNNB1 Regulatory, signalling [Easton et al. 2015] 
EPCAM Adhesion, antigen [Easton et al. 2015] 
ERBB2 
Enzyme, protooncogene, signalling, receptor 
membrane [Forbes et al. 2011, Stephens et al. 2012] 
FAM175A DNA associated [Easton et al. 2015] 
FANCC DNA associated [Easton et al. 2015] 
GATA3 Transcription factor [Forbes et al. 2011, Stephens et al. 2012] 
GEN1 Enzyme [Easton et al. 2015] 
HOXB13 Transcription factor [Easton et al. 2015] 
KRAS Protooncogene [Stephens et al. 2012] 
MAP2K4 Enzyme [Forbes et al. 2011, Stephens et al. 2012] 
MAP3K1 Enzyme [Forbes et al. 2011, Stephens et al. 2012] 
MAP3K13 Enzyme [Forbes et al. 2011, Stephens et al. 2012] 










Table 8.2 (continued) Candidate genes implicated to be involved in breast cancer development. 
Gene Gene protein categorya Reference 
MEN1 
Regulatory, transcription 
factor, protooncogene [Easton et al. 2015] 
MLH1 DNA associated [Easton et al. 2015] 
MRE11A Enzyme, DNA associated [Easton et al. 2015] 
MSH2 DNA associated [Easton et al. 2015] 
MSH6 DNA associated [Easton et al. 2015] 
MUTYH Enzyme, DNA associated [Easton et al. 2015] 
NBN DNA associated [Easton et al. 2015] 
NCOR1 Regulatory, transcription factor [Forbes et al. 2011, Stephens et al. 2012] 
NF1 Regulatory [Stephens et al. 2012, Easton et al. 2015] 
NRIP1 Regulatory, transcription factor, receptor [Ghoussaini et al. 2012] 
PALB2 Chaperone/stress [Forbes et al. 2011, Easton et al. 2015] 
PALLD Adhesion [Easton et al. 2015] 
PIK3CA Enzyme, receptor membrane 
[Forbes et al. 2011, Stephens et al. 2012, 
Easton et al. 2015] 
PMS1 DNA associated [Easton et al. 2015] 
PMS2 DNA associated [Easton et al. 2015] 
PTEN Enzyme, tumour suppressor [Stephens et al. 2012, Easton et al. 2015] 
PTHLH Signalling growth factor, receptor [Ghoussaini et al. 2012] 
RAD50 DNA associated [Easton et al. 2015] 
RAD51 Regulatory, DNA associated [Easton et al. 2015] 
RAD51C DNA associated [Easton et al. 2015] 
RAD51D DNA associated [Easton et al. 2015] 
RB1 Protooncogene [Forbes et al. 2011, Stephens et al. 2012] 
SETD2 Enzyme, regulatory, tumour suppressor [Stephens et al. 2012] 
SF3B1 RNA associated, tumour suppressor [Stephens et al. 2012] 
SMAD4 DNA associated, transcription factor [Stephens et al. 2012, Easton et al. 2015] 
SMARCD1 Transcription factor [Forbes et al. 2011, Stephens et al. 2012] 
STK11 
Enzyme, tumour 
suppressor, signalling, receptor membrane G 
serine/threonine kinase [Stephens et al. 2012, Easton et al. 2015] 
TBX3 Transcription factor [Forbes et al. 2011, Stephens et al. 2012] 
TP53 DNA associated, transcription factor 
[Forbes et al. 2011, Stephens et al. 2012, 
Easton et al. 2015] 
VHL Regulatory [Easton et al. 2015] 
XRCC2 DNA associated [Easton et al. 2015] 
XRCC3 DNA associated [Easton et al. 2015] 






Variants located within these genes were extracted from the VCF file resulting from Section 
8.2.3.2 using the Galaxy bioinformatics server. Briefly, the table browser within the UCSC 
genome browser was used to extract the hg19 coordinates for the exons, plus 100 bp into the 
introns at each end, of each gene using the “REFseq Genes” track. Trim (Galaxy Tool Version 
0.0.1) was used to remove the “chr” from the beginning of every row to make the file 
compatible with Galaxy tool “Select variants from VCF file” (Version 0.0.2) [DePristo et al. 
2011], which extracted the variants from the VCF file (Section 8.2.3.2) that were located in the 
candidate gene regions specified. SNVs and small indels were extracted and annotated with 
SeattleSeq (http://snp.gs.washington.edu/SeattleSeqAnnotation138/), version 9.06, reference 
NCBI 37/hg19) prior to filtering. This annotation provides additional information on each 
variant, such as the dbSNP rs ID, gene name, function, conservation score and HapMap minor 
allele frequency (MAF), all of which can then be used to filter variants. Common variants 
(MAF >5%) were filtered out as these variants are unlikely to be associated with a moderate 
or high risk [Bodmer and Bonilla 2008]. Population MAFs were obtained from the Exome 
Variant Server (EVS) (http://evs.gs.washington.edu/EVS/), HapMap, Exome Aggregation 
Consortium browser (ExAC) (http://exac.broadinstitute.org/) and 1000 Genomes [Genomes 
Project et al. 2012]. Calls were also filtered based on their frequency in the pool of 125 exomes 
(the four samples in this work and the 121 additional exomes, mentioned above) used for 
genotyping. Those reported in more than 10 exomes were filtered. 
Variant calls that were found more than 20 bp into the intron were also discarded, as these are 
more likely to be false calls or less likely to be functionally deleterious [Rivas et al. 2015]. 
Synonymous variants were also excluded as these changes do not alter amino acid coding and 
are rarely found to be pathogenic, so only exonic variants located within 2 bp of splice sites 
were included. Reference sequences are known to contain the minor allele at many loci, which 
can result in variant calls that are actually the more frequently expressed allele [Fuentes Fajardo 
et al. 2012]. This has come about because the original human genome was constructed from an 
amalgamation of DNA transcripts from five individuals, so contains variants that are actually 
rare in the general population and have yet to be corrected [Venter et al. 2001]. Such “variant” 
calls, identified in all four of our samples, were confirmed as the major allele through dbSNP 






Figure 8.1. Summary of filtering and prioritisation strategies implemented on exome data to identify 
variants that impact breast cancer risk.  
Abbreviations: EVS, Exome Variant Server; EXAC, The Exome Aggregation Consortium; GERP, Genetic 
Evolutionary Rate Profiling Score; MAF, Minor allele frequency; Ref, reference; HSF, Human Splicing Finder; 
VQSR, Variant Quality Score Recalibration; 1000G, 1000 Genome Project. 
 
The quality metrics of the shortlisted variant list were analysed to remove those that were likely 
artefacts of the sequencing or data processing and leave the true variants. Although it risks the 
exclusion of true positives, all “Low quality” VQSR calls were discarded to eliminate many of 
the calls that are found to have low quality values. Variants called with a total read depth lower 
than 10 were also removed and the genotype calls were evaluated. An example of a good 





0/1 : 28,26 : 54 : 99 : 853,0,882 
(a)  (b) (c) (d) (e) 
. 
(a) Variant genotype. 0 represents the reference allele and 1 represents the alternative allele. 
(b) Allelic depths for reference and alternative variants. 
(c) Approximate read depth (low mapping quality reads are excluded). 
(d) Genotype quality (Phred scale, capped at 99). 
(e) Normalized, Phred-scaled likelihoods for genotypes defined in (a). Larger values indicate a lower 
likelihood of that genotype. This example indicates that a heterozygote is the highest probability, 
indicating this with a 0. A homozygous reference or homozygous alternative call is much less likely, as 
indicated by the higher values. 
 
Figure 8.2. An example of a good quality genotype call from Sample 736, as seen in variant call format files. 
 
8.2.5 Functional prioritisation of variants 
Variants were further prioritised by a combination of scores provided by several bioinformatics 
tools based on predicted disruption to gene function (Figure 8.1). Unless specified, these scores 
were not used as strict cut-off filters, but as an indication of the variation that is most likely to 
be associated with disease.  
To identify the most likely candidates to impact normal gene function, variants were prioritised 
by their functional effect using FunctionGVS (variant function determined by variant location) 
and FunctiondbSNP (variant function as defined in dbSNP). Splice site and nonsense 
mutations, followed by missense, were prioritised over untranslated region (UTR) and 
synonymous variants, as the latter are generally not found to be as damaging as codon changing 
variants [Bao et al. 2014]. Synonymous calls were prioritised if they were predicted by Human 
Splicing Finder (HSF) to alter splicing [Desmet et al. 2009]. The impact of missense variants 
on protein function was further assessed through PolyPhen2 [Adzhubei et al. 2010] and SIFT 
[Ng and Henikoff 2003]. These conservation based tools are useful for variant prioritisation as 
they use different algorithms to analyse sequence homology to predict if specified changes are 
likely to have an impact on protein function [Flanagan et al. 2010]. Variants were prioritised if 
they were predicted to be deleterious or damaging by either or both tools.  
 
The clinical significance of each variant was evaluated using available data from ClinVar 




clinical significance using the Breast Cancer Information Core (BIC) database 
(https://research.nhgri.nih.gov/projects/bic) and BRCAexchange ((http://brcaexchange.org/). 
Intronic variants were only prioritised if they were predicted to have an effect on splicing by 
HSF. SNVs were further prioritised by using SPANR (Splicing-based Analysis of Variants) 
[Xiong et al. 2015] and Combined Annotation Dependent Depletion (CADD) C scores [Kircher 
et al. 2014]. SPANR is a splicing predictor tool that uses machine learning to assess variants 
located in the coding regions or up to 300 nt into introns, and estimate their expected impact 
on local cis elements to predict associated changes to the level of exon inclusion through 
splicing [Xiong et al. 2015]. CADD is a single score that has been precomputed for all possible 
SNVs of the human genome [Kircher et al. 2014]. It incorporates several functional and 
conservation annotations into a single measure (C score), which predicts how deleterious each 
possible nucleotide change is likely to be. As CADD and SPANR are generated only for SNVs, 
INDELs were ranked separately by their Genetic Evolutionary Rate Profiling (GERP) scores 
[Cooper et al. 2005]. Frameshift events, and those predicted to disrupt splicing by HSF, were 
prioritised. 
8.3 Results 
A total of 222,006 variants were called using Agilent SureSelect AV5 + UTR Exon Coverage 
kit across all four samples sequenced. Prior to filtering, 1,528 SNVs and 309 INDELs were 




Table 8.2). The filtering steps, outlined in Section 8.2.4, significantly reduced this list, while 
prioritisation further condensed it until the top ten calls were chosen for further analysis (Figure 
8.3 and Table 8.4). Four SNVs are located in Sample 735, two in each of Samples 736 and 737, 
and three in Sample 738. Only one prioritised variant was identified in multiple samples 
(rs11571707, in Samples 736 and 738). All prioritised calls were SNVs. The quality metrics of 
all ten shortlisted variants show high genotype quality and reasonable read depth (Appendix 
N, Table S21). 
Of the variants reported by Genetic Health Service New Zealand genetic testing (Table 8.1), 
all were confirmed here with WES except the unclassified variants/polymorphisms for patient 
735. While all six of these variants were not identified in this patient, three (BRCA1: 
c.4308T>C (rs1060915), c.4837A>G (rs1799966) and c.5074+65 G>A (rs8176235)) were 
found in at least one of the other patients (Table 8.3), whereas the remaining three where not 
detected at all (BRCA1: IVS8-58delT (rs273902772), BRCA2: c.-26G>A (rs1799943) and 
c.7242A>G (rs1799955)). All BRCA1 and BRCA2 variant calls are listed in Table 8.3.  
Of the variants reported by Genetic Health Service New Zealand genetic testing (Table 7.1), 
all were validated here using WES except the six unclassified variants/polymorphisms for 
patient 735. Interestingly, three of these variants (BRCA1: c.4308T>C (rs1060915), 
c.4837A>G (rs1799966) and c.5074+65 G>A (rs8176235)) were identified in at least one of 
the other patients (Table 8.3), whereas the remaining three where not detected in any of the 
patients studied (BRCA1: IVS8-58delT (rs273902772), BRCA2: c.-26G>A (rs1799943) and 






Figure 8.3. Workflow for filtering and prioritising variants using a candidate gene analysis approach.  
Abbreviations: CADD, Combined Annotation Dependent Depletion; EVS, Exome Variant Server; EXAC, The 
Exome Aggregation Consortium; GERP, Genetic Evolutionary Rate Profiling Score; INDELs, insertion or 
deletion; MAF, Minor allele frequency; Ref, reference; HSF, Human Splicing Finder; SNV, single nucleotide 
variant; SPANR, Splicing-based Analysis of Variants; UTR, untranslated region; VQSR, Variant Quality Score 








Table 8.3. BRCA1 and BRCA2 variant calls detected with exome sequencing. 
Those returned in the genetic test results of any study sample are indicated in bold. 
aSample-specific variant details when the variant is identified in multiple individuals. Genome build: Human GRCh37/Feb2009 (hg19). Abbreviations: Alt, alternative; MAF, 









Ref/Alt Reads Genotype 
Quality 
VQSLOD MAF 
 Sample 1a  Sample 2a 
chr17:41277187 rs799905 c.-20+101C>G 736, 738 BRCA1 G/C 24,28 26,24 99 4.85 37.01% 
chr17:41251931 rs799923 c.442-34C>T 738 BRCA1 A/G 34,0   99 3.93 23.19% 
chr17:41246481 rs1799950 c.1067A>G 737 BRCA1 T/C 78,69   99 4.2 6.16% 
chr17:41245466 rs1799949 c.2082C>T 736 BRCA1 G/A 53,41   99 4.05 31.26% 
chr17:41245237 rs16940 c.2311T>C 736 BRCA1 A/G 69,84   99 3.85 33.11% 
chr17:41244936 rs799917 c.2612C>A 736 BRCA1 G/A 81,88   99 5.68 34.19% 
chr17:41244435 rs16941 c.3113A>G 736, 738 BRCA1 T/C 43,42 48,40 99 5.67 33.34% 
chr17:41244429 rs4986852 c.3119G>A 735 BRCA1 C/T 38,43   99 3.51 2.22% 
chr17:41244000 rs16942 c.3548A>G 736 BRCA1 T/C 62,58   99 4.58 33.25% 
chr17:41234470 rs1060915 c.4308T>C 736, 738 BRCA1 A/G 46,26 40,25 99 4.74 33.40% 
chr17:41223094 rs1799966 c.4837A>T 736, 738 BRCA1 T/C 55,44 26,36 99 3.79 33.50% 
chr17:41219560 rs8176235 c.5074+65G>A 736, 738 BRCA1 C/T 26,21 25,22 99 3.89 27.44% 
chr17:41197274 rs8176318 c.*421G>T 736, 738 BRCA1 C/A 32,20 28,36 99 4.99 35.94% 
chr17:41196408 rs12516 c.*1287C>T 736, 738 BRCA1 G/A 10,14 13,8 99 5.02 36.63% 
chr13:32903685 rs2126042 c.681+56C>G 738 BRCA2 C/T 8,10   99 2.95 19.38% 
chr13:32905219 rs760080447 c.793+52_793+53insT 736 BRCA2 AT/ATT 7,11   98 1.89 11.66% 
chr13:32906480 rs766173 c.865A>C 737, 738 BRCA2 A/C 18,11 20,11 99 5.55 3.53% 
chr13:32906729 rs144848 c.1114A>C 736 BRCA2 A/C 1,128  99 4.04 28.64% 
chr13:32906980 rs1801439 c.1365A>G 737, 738 BRCA2 A/G 57,47 55,42 99 3.49 3.53% 
chr13:32910721 rs1801499 c.2229T>C 737, 738 BRCA2 T/C 48,40 49,46 99 5.64 3.53% 
chr13:32911463 rs1799944 c.2971A>G 737, 738 BRCA2 A/G 14,18 19,21 99 4.17 3.53% 
chr13:32929478 rs11147489 c.7435+53C>T 737, 738 BRCA2 C/T 9,13 9,11 99 5.05 3.48% 
chr13:32930598 rs11571707 c.7469T>C 736, 738 BRCA2 T/C 102,39 99,13 99 0.96 0.02% 
chr13:32936646 rs9534262 c.7806-14T>C 737, 738 BRCA2 T/C 16,16 0,32 99 5.88 49.66% 
chr13:32973012 rs15869 c.*105A>C 735, 737 BRCA2 A/C 14,11 7,17 99 3.57 23.56% 
chr13:32973276 rs7334543 c.*369A>G 738 BRCA2 A/G 16,5   99 2.48 27.44% 
chr13:32912299 rs543304 c.3807T>C 735 BRCA2 C/T 15,8   99 4.02 19.56% 
chr13:32968810 rs11571818 c.9257-16T>C 735 BRCA2 C/T 5,5   99 4.89 0.92% 
chr13:32972626 rs11571833 c.9976A>T 735 BRCA2 A/T 43,48   99 4.02 0.92% 
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8.3.1 Bioinformatic analysis of prioritised variants  
Four of the ten prioritised variants were identified in Sample 735 (rs28904919, rs11571833, 
rs182733777 and rs755751413) (Table 8.4). rs28904919, a missense variant located in exon 
10 of ATM, is predicted to alter gene function by bioinformatic tools SIFT, PolyPhen and 
CADD (Table 8.4). A nonsense BRCA2 variant rs11571833 (located in exon 27) and intronic 
MLH variant rs182733777 are both predicted by CADD to alter gene function. However, 
rs11571833 (BRCA2 p.Lys3326Ter) has been classified as benign, or of little clinical 
significance, by an international expert panel, the ENIGMA consortium, 
(http://brcaexchange.org/). A further variant in Sample 735 was identified in the 5’ UTR of 
PTHLH (rs755751413) and is predicted by SPANR to alter splicing.  
 
rs2229995 and rs11571707 variants were detected in Sample 736. rs2229995 is located in the 
last exon (exon 16) of APC, while rs11571707 is situated in exon 15 of BRCA2. Both variants 
are predicted by CADD to impact gene function. rs11571707 is listed as low clinical 
significance in the BIC database and is yet to be classified in BRCAexchange. 
 
Missense variants, rs28363284 (RAD51D, exon 8) and rs1800366 (FANCC, exon 10), were 
both detected in Sample 737 (Table 8.4). Both are predicted to alter splicing by SPANR, while 
rs28363284 is also predicted to be damaging by PolyPhen. 
 
Of the three missense variants detected in Sample 738 (rs139569694, rs77424145 and 
rs11571707), rs139569694 (SMAD4, exon 9) is predicted by SIFT, PolyPhen and CADD to 
alter gene function, while rs77424145, located in the last exon of GEN1 (exon 14), and 
rs11571707 (BRCA2) are predicted by CADD to alter gene function. 
 
BRCA2 rs11571707 is the only prioritised variant identified in multiple samples (Samples 736 





























rs28904919 c.998C>T chr11:108117787 C/T,C,C,C 735 ATM Missense 0.23% Deleterious 
Possibly 
Damaging 
  15.9 36 
rs755751413 c.-69G>C chr12:28123004 C/G,C,C,C 735 PTHLH 5’ UTR 0.00%       13.45 98.5 
rs11571833 c.9976A>T chr13:32972626 A/T,A,A,A 735 BRCA2 Stop-
gained 
0.90%       51   
rs2229995 c.7504G>A chr5:112178795 G,A/G,G,G 736 APC Missense 2.09% Tolerated Benign 
+donor 
+acceptor 
15.62   
rs11571707 c.7469T>C chr13:32930598 T,C/T,T,C/T 736, 738 BRCA2 Missense 0.02% Tolerated Benign   15.18 26 
rs1800366 c.934A>G chr9:97887430 T,T,C/T,T 737 FANCC Missense 0.05% Tolerated Benign   9.207 96.8 
rs28363284 c.698A>G chr17:33430313 T,T,C/T,T 737 RAD51D Missense 1.45% Tolerated 
Possibly 
Damaging 
  12.96 3.8 
rs77424145 c.2644A>G chr2:17963123 A,A,A,A/G 738 GEN1 Missense 1.98% Tolerated Benign   19.03   
rs139569694 c.1106A>G chr18:48591943 A,A,A,A/G 738 SMAD4 Missense 0.00% Deleterious 
Probably 
Damaging 
  28.2 12 
HSF: NCP=No predicted change. + = New site. 
SPANR: NPA = No prediction available. 
a Population MAFs were averaged from the frequencies reported by EVS, HapMap, ExAC and 1000 Genomes.  
b Significance = >15 
c Significance = PSI percentile >90 (exon skipping predicted to less frequent in presence of the variant compared to WT), or <10 (exon skipping predicted to more frequent in 
presence of the variant compared to WT). 
Abbreviations: CADD, Combined Annotation Dependent Depletion; EVS, Exome Variant Server; ExAC, The Exome Aggregation Consortium; HSF, Human Splicing Finder; 




Breast cancer is a complex genetic disease with many genes known to contribute to individual 
risk. Current tests for detecting pathogenic variants are often focused on the high risk genes, 
BRCA1 and BRCA2, which are well known to play a considerable role in familial breast cancer 
risk but are not detected in 85-90% of patients who undergo genetic testing [Walsh et al. 2006]. 
Patients from high-risk families may instead carry rare disease-associated moderate/high risk 
variants that are associated with other cancer susceptibility genes. In this study, candidate gene 
analysis is used to identify putative breast cancer variants in four BRCAx breast cancer patients. 
Of the ten variants prioritised, four were detected in a single patient (Sample 735), one of which 
(rs11571833) is a known BRCA2 nonsense mutation (BRCA2 p.Lys3326Ter) and has been 
previously classified as a low risk variant. rs11571833 (BRCA2 c.9976A>T) terminates the 
BRCA2 gene 93 amino acids prematurely and it has previously been identified more frequently 
in breast cancer cases than in controls (2.5% and 1.65%, respectively) [Thompson et al. 2015]. 
A large genotyping study found this variant to have a small but significant association with 
breast cancer risk (OR 1.26, P-value 4.9 x 10-8) [Michailidou et al. 2013]. More recently, a 
comprehensive analysis confirmed this increased risk in both breast and ovarian cancers was 
independent of a pathogenic variant (BRCA2 c.6275_6276delTT) often found in linkage 
disequilibrium (LD) [Meeks et al. 2016]. rs11571833 is the only variant that is currently known 
to increase breast cancer risk out the ten prioritised in this study. Disease risk is not always 
accounted for by a single variant. Instead multiple low risk variants may together elevate 
disease likelihood; however, no evidence was found to indicate that other variants found in 
Sample 735 are associated with breast cancer risk. rs28904919 is a missense mutation (ATM 
p.Ser333Phe) located in exon 10 of ATM and shown here to be predicted to alter gene function 
(Table 8.4). While rare, previous research has found similar allele frequencies between cases 
and controls (0.92% (6/652) and 0.83% (5/604) in cases and controls, respectively), indicating 
that the variant is not likely to be associated with breast cancer risk [Tommiska et al. 2006]. 
Intronic MLH1 variant rs182733777 has been shown to cause weak exon 9 skipping via 
minigene splicing assays, but the same study was not able to confirm this finding with qPCR 
[Tournier et al. 2008]. The remaining variant from Sample 735 (PTHLH rs755751413), has 
been recorded only once in the EXAC database of more than 55,000 entries (accessed 
07/01/2016). Bioinformatic analysis of rs755751413 suggests the 5’UTR variant has the 
potential to disrupt splicing and lead to the use of a known alternative start site. Further work 
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is required to establish if this variant causes any aberrant splicing changes, and determine 
whether it has a role in breast cancer development. 
 
Of the two variants shortlisted in Sample 736, only BRCA2 rs11571707 (c.7469T>C; 
p.Ile2490Thr) has been included in a study focusing on breast cancer risk, but was not found to 
cause splicing changes using rtPCR and capillary electrophoresis [de Garibay et al. 2014]. 
rs2229995 is a missense variant (APC p.Gly2502Ser) located in tumour suppressor gene APC, 
which is associated with familial adenomatous polyposis and colorectal cancer risk. Non-
significant frequencies of rs2229995 have been observed between colon cancer cases and 
controls (p-value = 0.54), suggesting that the missense change is not disruptive [Wong et al. 
2010, Koskenvuo et al. 2016].  
 
rs28363284 (RAD51D) and rs1800366 (FANCC) were detected in Sample 737 (Table 8.4). 
While earlier work suggested rs28363284 (RAD51D p.Glu233Gly) had some association with 
disease due to overrepresentation in a very specific subgroup of breast cancer cases [Rodriguez-
Lopez et al. 2004], more recent case-control studies do not support that finding, with no 
significant association with disease risk identified [Dowty et al. 2008, Jara et al. 2010]. 
rs1800366 has not previously been studied for its association with breast cancer, and a 
conservative amino acid change (a valine for an isoleucine, I312V), is not thought likely to alter 
gene function [Gibson et al. 1996]. As both variants are predicted by SPANR to alter splicing, 
analysis with splicing assays would help to establish if either is likely to be functionally 
disruptive. RNA from Sample 737 was not available for this study to confirm bioinformatics 
predictions. 
 
Of the two variants identified in Sample 738, rs77424145 (GEN1 p.Lys882Glu) is not thought 
to be associated with breast cancer risk as it has been detected in similar frequencies in cases 
and controls (6/372 (1.6%) and 7/360 (1.9%), respectively) [Turnbull et al. 2010]. The second 
variant, rs139569694 (SMAD4 p.Asn369Ser), has not previously been studied for its 
association with breast cancer risk, but is predicted to disrupt gene function by three separate 
tools (Table 8.4). Further, functional studies, including splicing assays, are needed to confirm 
bioinformatics predictions to establish whether these variants disrupt normal gene processing 




The use of bioinformatic tools to assess for disruption of gene function is a method commonly 
used for prioritising potential pathogenic variants identified by WES- or WGS-based studies. 
However, such tools are limited and often over estimate pathogenicity. For example, a recent 
study showed that around 80% of the PolyPhen2, and 85% of the CADD, calls predicted to be 
deleterious were false positives [Miosge et al. 2015]. In an effort to exclude as many false 
positives as possible, variants in this study were prioritised if there was a consensus seen 
between the SIFT and PolyPhen2 predictions. Finding consistency between the different 
predictive algorithms may help establish confidence in determining whether variants are likely 
to impact on disease risk [Frousios et al. 2013]. Prioritising instead of filtering these observed 
inconsistencies may be important to limit the likelihood of excluding likely true positive calls 
for further investigation. 
Many rare variant calls obtained from previous WES studies have little or no information 
available regarding their likely impact on gene function and disease [Noh et al. 2015]. Studies 
often account for this uncertainty by targeting truncating variants, splice site variation and 
frameshift events as these events are presumed to be pathogenic [Snape et al. 2012, Thompson 
et al. 2012]. However, until formal classification is completed it is difficult to determine the 
degree of risk associated with each identified variant, even in well studied genes such as BRCA1 
and BRCA2, and case/control frequency studies are recommended to infer likely associations 
[Snape et al. 2012]. 
This study could be improved by including multiple affected individuals from each family. 
While proband-only exome sequencing has been previously used to identify variants that 
predispose individuals to their disease, this method can be augmented by genotyping other 
family members to establish if the variant of interest segregates with the disease [Johnson et al. 
2010, Sobreira et al. 2010, Hunter et al. 2016]. Without this additional information, it is difficult 
to make any robust conclusions regarding likelihood that the identified variants are the causal 
factors behind the disease in the patients studied. Additionally, the candidate gene approach 
employed here reduces the number of variants called to cancer associated loci and is therefore 
limited by our current knowledge of the disease. The candidate gene list used here was obtained 
from the most up-to-date list of known breast cancer susceptibility genes on the Sanger Institute 
website, supplemented with additional genes from published literature, including those listed 
in COMPLEXO. COMPLEXO is a collaborative international effort for researchers to combine 
massively-parallel sequencing information and assess NGS data analysis pipelines to better 
understand the genetics of breast and ovarian cancers [Southey et al. 2013]. Such collaborations 
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are essential to allow variant data from smaller studies, such as this one, to compare results with 
much larger sequencing projects. As a more detailed understanding of breast cancer is obtained, 
more susceptibility genes may be uncovered, which have the potential of harbouring disease 
predisposing variants. 
WES successfully identified 7/13 variants reported in the Genetic Health Service New 
Zealand BRCA1 and BRCA2 genetic tests for the patients included in this work, while also 
detecting an additional 22 variants that were not reported. While fifteen of these variants were 
detected in multiple patients, only two of these variants were reported in genetic testing, and 
only in one of the two known carrier’s genetic tests in each case, indicating that common 
polymorphisms were not reported by the testing laboratory. Only returning the known 
pathogenic and unclassified variants would provide the results that are the most likely to 
influence patient management decisions. Reasons for why six of the eight variants returned in 
the genetic test from patient 735 were not detected by WES is not clear. While it would be 
expected that the two intronic variants might not be detected, a reason for the other four variants 
remains unclear. As three of the reported variants were identified by WES in other patients, it 
is unlikely that WES failed to detect these variants in 735 based on technical issues. 
Unfortunately, it has not been possible to reassess these results with the original genetic testing 
laboratory. 
The main limitation of using WES over whole genome sequencing (WGS) in this study is the 
limited capture of information outside the coding regions. Intronic and intergenic regions are 
known to encompass a huge proportion of SNVs associated with disease [Hindorff et al. 2009], 
while also containing many gene expression regulators that control a multitude of biological 
functions and play important roles in the development and progression of diseases [Gutschner 
and Diederichs 2012, Spizzo et al. 2012, Belkadi et al. 2015]. The use of WES may have 
prevented the detection of such intronic and intergenic disease-associated variants; however, it 
was the preferred option due to the reduced computational requirements, both with regard to 
data processing and storage [Lelieveld et al. 2015]. In addition, it was the more cost-effective 
approach for a pilot study compared to WGS, although the latter is becoming more financially 
accessible as sequencing costs fall, and is likely to become the method of choice in the future 
[Belkadi et al. 2015]. 
Regardless of its limitations, WES is still an exceptional technique for the efficient capture of 
variants in the coding regions of genomes, with technological advances now generating 
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coverage of the target regions comparable to that returned by WGS [Lelieveld et al. 2015]. 
However, several issues remain more persistent in WES than WGS, such as strand bias, the 
level and variability of coverage across regions, and the number of false positive calls [Belkadi 
et al. 2015, Lelieveld et al. 2015]. These issues may stem from the sequencing, and subsequent 
processing steps, undertaken for data generation and analysis. With this in mind, only the most 
recent and trusted software analysis tools were used here to generate and process the data, all 
while following the recommended GATK guidelines. 
This study was unable to unequivocally identify any rare variants outside of BRCA1 and BRCA2 
that significantly increase breast cancer risk in four unrelated patients. Functional assays would 
be useful for establishing whether any of the shortlisted variants disrupt gene function, 
especially for those variants with limited information available in current literature that are 
predicted by multiple bioinformatic tools to be functionally disruptive (i.e. rs139569694, 
SMAD4). Expression and activity levels of the associated proteins, especially those with 
important DNA repair functions within the cell, utilisation of large variant databases generated 
using WES/WGS data from cases and controls, and segregation analysis, would provide further 




: General discussion 
Breast cancer is known to have a significant genetic basis, and understanding variant associated 
risk in known disease susceptibility genes would provide invaluable information for clinicians 
when making patient management decisions. The principal goal of this thesis was to establish 
novel technologies for the sensitive assessment of potential spliceogenic changes to help 
classify BRCA1 and BRCA2 variants of unknown clinical significance. Splicing protocol 
limitations, including inadequate PCR primer design, limited quantitative assessment to 
determine isoform expression patterns and incomplete sequence confirmation of the isoforms 
detected, were highlighted in a collaborative study with the ENIGMA consortium (Chapter 3). 
To address these limitations, a targeted RNA-seq platform was utilised to quantify mRNA 
isoforms and establish an expression range for isoforms that naturally occur in control samples 
(Chapter 4). Samples containing rare variants were then assessed to identify mRNA expression 
changes that deviated from these expected ranges (Chapter 4). Source(s) of mRNA expression 
variation between samples was explored in more detail by studying the contribution of common 
variants (Chapter 5), and the splicing patterns of a single LCL at several time points after storage 
in liquid nitrogen (Chapter 6). Further investigation into mRNA variability was explored at the 
single cell level using RNAscope (Chapter 7). Finally, whole exome sequencing was 
undertaken to identify candidate risk variants in breast cancer patients who had tested negative 
for variants in BRCA1 and BRCA2 (Chapter 8). 
9.1 PCR-based splicing assays 
The wide range of PCR-based tools currently available for profiling variant-induced splicing 
changes explain some of the disparity reported previously between studies targeting the same 
variants. Collaborative work with the ENIGMA Splicing Working Group identified that 
standardising splicing protocols significantly improved the detection consistency of targeted 
isoforms across participating laboratories (Chapter 3) [Whiley et al. 2014]. The main factors 
behind the observed differences were primer design and PCR cycling conditions. After 
standardising for these factors, the PCR product detection method was identified as the main 
driver determining detection sensitivity, although unexplained variability remained. Analysis 
of BRCA1 and BRCA2 mRNA isoforms from a single LCL using repeated PCR assays revealed 
that the most highly expressed isoforms were detected consistently across all time points. 
However, identification of the remaining isoforms was more inconsistent as their expression 
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level declined. As it could be expected that mRNA isoform detection would remain reasonably 
consistent when using identical assays, it may be possible that the expression changes observed 
result from cell-specific fluctuations or that the current assays are not sensitive enough for 
consistent detection.  
9.2 Exploration of BRCA1 and BRCA2 mRNA variability using a novel 
targeted RNA-seq platform 
As highlighted above, traditional PCR-based assays are often used to generate variable 
qualitative, but not quantitative, mRNA expression data. Advances in next-generation 
sequencing technologies have provided multiple platforms that can detect and quantify mRNA 
transcripts at a sensitivity superior to the other methods currently available [Marioni et al. 2008, 
Mortazavi et al. 2008]. Previous work has shown how we have only begun to understand the 
true complexity of the transcriptome after a direct relationship was found between the number 
of mRNA isoforms detected and the depth at which a sample is sequenced [Mercer et al. 2012]. 
To overcome many of the limitations identified previously for PCR-based approaches [Walker 
et al. 2013], a new targeted RNA-seq platform was employed here to provide the first qualitative 
and quantitative assessment of BRCA1 and BRCA2 isoforms in LCLs.  
 
9.2.1 Targeted RNA-seq for detecting mRNA splice isoforms 
While normally expressed mRNA isoforms have recently been comprehensively profiled in 
both BRCA1 and BRCA2 [Colombo et al. 2014, Fackenthal et al. 2016], the RNA-seq platform 
used here identified novel isoforms to add to the known complexity of these genes. Many of 
these isoforms were detected in a single sample or were intronic retention events, suggesting 
that there are likely to be additional undiscovered naturally occurring isoforms that may require 
more sensitive technologies for detection.  
Several of the limitations previously highlighted for splicing assays are overcome with the 
targeted RNA-seq platform utilised. Walker et al. (2013) suggest that primers are designed to 
encompass an area of the transcript that is larger than the exons immediately adjacent to the 
variant in question [Walker et al. 2013]. Such design flaws may have restricted previous PCR-
based assays from detecting intronic events and those outside the targeted range that 
incorporated the study variant, whereas it was possible in this project with multiple probes 
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distributed along the length of each gene. As small changes are difficult to distinguish using 
PCR-based assays (eg. BRCA1 ∆6q (del 9 nt)), sequencing confirmation is recommended, in 
addition to the inclusion of at least 10 controls to distinguish natural splicing events from 
variant-induced aberrations [Walker et al. 2013]. The work presented here followed these 
recommendations by detecting isoforms with a sequencing-based method using at least 10 
control samples. While current technology has the capacity to detect very rare BRCA1 and 
BRCA2 mRNA isoforms, questions remain over the clinical significance of these minor events. 
An isoform that is present at very low levels may actually be expressed at reasonable levels 
compared to the full length, but its transcripts are continually being destroyed by NMD. For 
example, BRCA1 ∆10 and ∆15 were detected only in NMD inhibited samples (Table 4.3). Such 
events can potentially encumber normal cellular function through a corresponding reduction in 
the production of the full length transcript. It could be assumed that many of these minor events 
are not predicted to alter the function of the cells if they are detected in normal controls. 
However, functional studies have yet to be carried out to confirm this. 
Targeted NGS approaches are cost-effective and return high quality data across the gene/s of 
interest. Alternatives such as whole transcriptome analysis are not restricted by probe placement 
and subsequently can provide information on all transcribed genes while allowing variant 
discovery. However, the information returned from lowly expressed genes can be very limited, 
while the added cost in terms of sequencing, computational power and the subsequent storage 
requirements is significant, especially when studying large numbers of samples. Deep 
sequencing to obtain sufficient detection of BRCA1 and BRCA2 (a read depth of 200-500 across 
the FL junctions) with a whole transcriptome platform was $3,540 per sample. In comparison, 
the targeted platform focused solely on BRCA1 and BRCA2 and returned read depths averaging 
over 2,000 across the FL junctions for only ~$86 per sample, showing how the more cost 
effective targeted approach can also better guarantee sufficient detection of multiple isoforms 
from lowly expressed genes. Like many of the high throughput platforms currently available, 
these technologies use fragmented library reads less than 300 nt long (Table 1.3), significantly 
restricting the ability to determine whether multiple events occur on the same transcript. Long 
read sequencers such as PacBio or the MinIONTM (Oxford Nanopore Technologies, Oxford, 
UK) could be utilised to obtain whole transcript information as this would allow co-occurring 
splicing events to be linked together. The MinION has been successfully used to do this when 
studying the splicing pattern of Dscam1. Containing 150 exons, this gene was found to produce 
more than 7,000 isoforms, each consisting of a combination of alternative events [Bolisetty et 
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al. 2015]. While the nucleotide accuracy of long read sequencing platforms requires 
improvement (PacBio RS has a raw error rate of 12.86%) [Bahassi and Stambrook 2014], the 
sequences returned could still potentially be used to distinguish transcript exon structure 
regarding all deletion and retention events across the same transcript. Such research may help 
determine if the reason why some BRCA1 and BRCA2 frameshift events (e.g. BRCA1 ∆10 and 
∆15) are destroyed by NMD, while others (e.g. BRCA1 ∆9 and ∆21) appear to avoid NMD, is 
due to co-occurring events that keep the transcript in frame. 
9.2.2 Expression ranges of naturally expressed BRCA1 and BRCA2 transcripts 
Recommendations have been proposed by ENIGMA to accurately quantify mRNA isoforms in 
splicing assays [Walker et al. 2013]. The targeted RNA-seq platform utilised in this work was 
able to overcome the limitations of PCR-based assays by quantifying mRNA transcripts 
simultaneously across BRCA1 and BRCA2. Adequate information was obtained to establish a 
natural expression range for each of the more prominent isoforms detected in controls.  
Further exploration quantifying isoform expression patterns identified altered levels of 
normally expressed BRCA1 ∆9-10 and FL 10-11 in samples containing rare variant BRCA1 
c.2640C>T; however, no such relationships were found for any of the common variants studied 
(Chapter 5). While the sample size may have been insufficient to see such a splicing effect, 
allele-specific imbalances were observed for common variants. These results suggest that the 
variants are associated with isoform expression levels but not through splicing changes. Factors 
such as cis-acting elements may be impacting the observed ASE patterns through the regulation 
of gene expression, as shown previously [Bray et al. 2003]. In addition, genetic duplications 
(i.e. copy number variation or segmental duplications) could also increase the perceived 
expression of a variant when located within the replicated region, or increase expression when 
a proximal duplication contains enhancer motifs that regulate the expression of regions close 
by [Palacios et al. 2009]. While genomic imprinting is known to alter ASE by preferentially 
expressing one allele, it is thought to only occur in a few hundred genes in the human genome 
[Ideraabdullah et al. 2008], and it is not known whether it has any role in expression of BRCA1 
or BRCA2. Further work is required to determine the impact each of these factors might be 
having on BRCA1/2 expression to determine where the observed mRNA variability originates.  
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9.2.3 Impact of storage and culturing conditions on mRNA detection 
To further tease out the unexplained mRNA expression differences observed between samples, 
repeated splicing analyses were undertaken on the same sample, which revealed a high 
variability in the isoforms expressed at any one time, regardless of the technical storage factors, 
procedures and practices used (Chapter 6). Previous work looking at LCLs over time has shown 
a loss of heterozygosity occurs in late passage LCLs [Oh et al. 2013]. While such changes could 
influence mRNA splicing, the long culturing period required for splicing to take place limits 
the likelihood of this being a factor behind the patterns observed here. Caliskan et al. (2014) 
identified that newly transformed LCLs have a vastly different mRNA profile to “mature” 
cultures, which are achieved after only two freeze-thaw cycles and display a more consistent 
expression pattern to newly established LCLs. This research supports the results found here, as 
the LCLs used in this work had all undergone several freeze-thaws prior to the study, so the 
mRNA expression profiles would therefore not be expected to be affected by additional freeze-
thaw cycles. The reason behind the detected variability is more likely to be due to other factors. 
Molecular mechanisms, such as those involving miRNAs, have been shown to regulate mRNA 
expression through the repression of translation [Olsen and Ambros 1999]. While miRNA 
interaction with BRCA1 and BRCA2 is not well understood, they may be having an impact on 
the variable mRNA expression observed. Further work studying BRCA1 and BRCA2 mRNA 
expression over time, and sequencing the samples to a comparably high read depth, would allow 
an appreciation of how much variability is due to technical limitations, and how much is likely 
to be from cellular regulatory factors. 
9.2.4 Quantification of intra-cellular expression variability 
Previous work has highlighted how gene expression often occurs in bursts, which are controlled 
by underlying regulatory components, such as transcriptional activators and random chemical 
reactions [Van Kampen 1992, Elowitz et al. 2002, Raj et al. 2006, Suter et al. 2011]. Therefore, 
gene expression might be expected to have some degree of fluctuation, even between 
genetically identical cells within a population. Cell-specific differences in mRNA isoform 
abundance were measured here using RNAscope, which successfully validated an increased 
BRCA2 ∆17-18 expression in an LCL containing the rare variant BRCA2 c.7988 A>T. While 
an average expression difference was not observed for BRCA1 ∆11, a significantly higher 
number of cells were found to express the deletion in the variant-containing sample compared 
to the control (Chapter 7).  
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Splicing analysis has typically focused on populations of cells to obtain the average isoform 
expression across all the cells studied. As shown in Chapters 3 and 4 this approach is sufficient 
for determining qualitative and quantitative mRNA changes. However, it removes the 
possibility of identifying spatial expression differences, which would allow an understanding 
of whether the targeted mRNA changes are aiding in cancer development and/or progression 
as indicated by the expression levels in and around tumours. RNAscope is limited by probe 
design, while it is also an expensive platform in terms of the time required to manually obtain 
the cell-specific expression information to identify expression differences. Due to this, 
RNAscope is not at a point where it can replace current splicing analysis platforms. However, 
the possibilities presented by this technology make it an attractive option to complement 
splicing assays by helping to understand the potential tumourigenic role of individual mRNA 
isoforms. 
9.2.5 The use of nonsense-mediated decay inhibitors in mRNA splicing assays 
The results presented here encourage the use of NMD inhibitors in mRNA splicing assays, as 
they facilitate the detection of isoforms that would otherwise be degraded by the natural control 
mechanisms within cells to prevent the potential production of dysfunctional proteins. 
Detection was enhanced in the treated samples across all assays included in this work, which 
made it possible to quantify and compare mRNA expression ranges for a higher number of 
isoforms than in untreated samples. This was not surprising as NMD inhibitors work by 
simultaneously preventing NMD degradation and mRNA translation. This leads to an 
accumulation of all transcribed mRNA isoforms, explaining why overall detection is superior 
in the NMD inhibitor treated cells. Treatment of NMD inhibitors was not found to affect ASE 
in the majority of variants in the samples studied; however, a small but significant difference 
was found for a common variant in BRCA1 (rs12516). Further work is required to determine 
why this change was observed for only one variant, and if it is directly related to the NMD 
treatment. The small difference in expression is insufficient to outweigh the benefits provided 
by NMD inhibitors, suggesting that recommendations are made to encourage their 
incorporation into routine splicing assays. 
9.2.6 Moving beyond PCR based assays for splicing assays 
Using RNA-seq for identifying variant-induced splicing changes would potentially introduce 
improvements over the accuracy and capabilities of PCR based assays, and therefore aid in 
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evaluating the clinical significance of BRCA1 and BRCA2 variants. RNA-seq is shown here to 
detect isoforms additional to those previously reported for variants using PCR-based assays 
(Chapter 4 and 5). Reassessment of variants that have been analysed previously using a 
restrictive primer design would allow the full spectrum of potentially variant-induced changes 
to be detected. BRCA2 c.9116 C>T, for example, is located within two bases of the splice site 
in exon 23, and was analysed with primers that limited mRNA events to those involving exon 
23, resulting with no alternative splicing events being identified [Menendez et al. 2012]. The 
gene-wide approach of Targeted RNA-seq would provide a more comprehensive analysis to 
determine if there are changes involving adjacent exons that are not able to be detected. Such 
changes may be crucial for classifying variants, as the system suggested by ENIGMA would 
currently classify BRCA2 c.9116 C>T as Class 2, as no splice changes were observed. However, 
detection of any splicing event outside those expected in controls would immediately put the 
variant into Class 3, 4 or 5, depending on the aberrant nature of the change [Walker et al. 2013]. 
This example highlights how accurate and comprehensive assessment is essential for variant 
classification. Further investigation to understand the impact splicing changes have at the 
protein level as this would also provide a better understanding of the functional impact the 
studied variants are having in cells. A discrepancy between mRNA and corresponding protein 
expression levels has been previously been frequently observed [de Sousa Abreu et al. 2009, 
Schwanhausser et al. 2011], so an appreciation as to the factors that underpin this difference 
would allow us to identify what mRNA changes are likely to be disruptive, and those that are 
unlikely to have any impact at the protein level.  
Current bioinformatic splicing predictor tools have not reached a stage where they can replace 
functional assays to accurately recognise spliceogenic variants. No splicing changes were 
identified for the common variants analysed here, even though predictions suggested otherwise. 
These variants may be influencing splicing at a very low level, but an investigation involving a 
much higher number of samples would be required to assess such changes. In contrast, a rare 
variant (BRCA1 c.2521 C>T) was found to lead to splicing changes consistent with 
bioinformatic analysis, but not with the results previously returned by a PCR-based assay. Even 
with advancements in available bioinformatic tools, such as the numerous improvements added 
to each update of HSF (http://www.umd.be/HSF/), their utility within the diagnostic setting is 
limited. Bioinformatic predictions remain indicators of variants that might influence splicing, 
as opposed to highlighting those that definitely have an impact. Due to this, splicing assays 
remain an essential aspect of the assessment of potentially spliceogenic variants. 
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9.3 Identifying novel high-risk pathogenic variants in BRCAx women  
The final aim of this work was to identify novel high-risk pathogenic variants in women who 
have tested negative for BRCA1/2 mutations. While candidate gene analysis is a valuable tool 
for identifying known and novel disease-associated variants, the work presented here did not 
conclusively identify any causative variants in the women studied (Chapter 8). Reasons for this 
may be that the high risk variants are located in the intronic/intergenic regions of the genome, 
or were not included in the list of candidate genes thought most likely to harbour pathogenic 
variants. Although bioinformatic splicing analysis was used to help prioritise candidate 
variants, no RNA was available from these samples to assess splicing changes. 
It is possible that there may not be a single high risk variant present in these individuals; instead 
the risk may be accounted for by several low and/or moderate risk variants that have been 
overlooked by the filtering criteria used in this study. Furthermore, it may be possible that the 
women included in this work do not carry a high risk of breast cancer despite reaching the 
criteria for genetic screening. As the proportion of breast cancer cases accounted for by genetic 
variants declines with age [Claus et al. 1996], it may not be expected that any risk variants 
would be detected in one of the women studied, who was 64 years old at diagnosis. Further 
work to include additional affected family members may help to identify the less penetrant risk 
variants that are likely to be behind the disease risk in these individuals. 
9.4 Future work 
This work has all been undertaken from LCLs derived from blood, which are a well 
characterised and justified model system for splicing analysis [Colombo et al. 2014, Romero et 
al. 2015]. However, comparing isoform expression in tumours and asymptomatic breast/ovarian 
tissue may help better understand whether BRCA1 and/or BRCA2 expression changes occur 
before or after tumour development. RNAscope creates opportunities for future work into the 
spatial distribution of BRCA1 and BRCA2 mRNA isoforms in tumour and normal tissue, 
particularly from formalin-fixed paraffin embedded (FFPE) samples. Such work would help to 
establish the spatial distribution of expression corresponding to each isoform, within and 
relative to the tumour, and potentially help define the role each isoform has in tumorigenesis. 
Tumours are known to be very heterogeneous, containing in excess of 100 million mutations, 
many of which are often restricted to specific regions of the tumour [Ling et al. 2015]. This 
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may also be the case with BRCA1 and BRCA2 mRNA isoforms. Advancing the capabilities of 
RNAscope to detect allele-specific information would allow quantification of the transcripts 
expressed by each allele. This would indicate how disruptive the variant is likely to be, as genes 
that encompass disruptive variants may be expressed at lower levels than those containing the 
wild type. RNAscope may therefore be a useful tool for evaluating candidate risk variants 
identified by whole exome- or whole genome sequencing studies. 
Furthermore, the results from this work highlight the importance of standardising splicing 
methodology using RNA-seq technologies between ENIGMA and non-ENIGMA research and 
diagnostic laboratories. Assays undertaken with such platforms would facilitate the 
establishment of thresholds that define the normal expression ranges of natural isoforms, 
allowing aberrant changes to be easily identified for other important disease susceptibility 
genes. 
9.5 Summary conclusions 
The work presented here highlights the important role of targeted RNA-seq and RNAscope in 
the detection and quantification of BRCA1 and BRCA2 mRNA isoforms, while also 
summarising the limitations of each technology. While qualitative analysis alone is sufficient 
for identifying many aberrant events, quantification of mRNA isoforms demonstrates how an 
understanding of the natural expression range of each isoform is also useful for determining 
abnormal changes. Incorporation of quantitative splicing analysis into routine variant 
classification would provide a more comprehensive assessment for determining the clinical 
significance of potential disease-associated variants. Using this information to classify variants 
of unknown clinical significance identified in BRCA1/BRCA2 genetic tests would remove much 
of the uncertainty regarding the underlying genetic risk of many high risk patients. Patient 
management would then be better informed, providing clinicians and genetic counsellors with 
the capacity to council patients more effectively as fewer variants of unknown clinical 
significance remain as such. More informative genetic test results will also mean that patients 
are less likely to be subjected to the stress and uncertainty otherwise often present when the 
reported variants remain unclassified. Such comprehensive analyses should be completed for 
other high risk genes so the same level of detail can be utilised to identify abnormal mRNA 
expression changes that are also potentially contributing toward disease risk. The results from 
this work support the inclusion of quantitative mRNA expression analysis into the current scope 
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Appendix A Targeted RNA-seq probes 
Supplementary Table 1. Oligonucleotide probes used for sequencing BRCA1 using the TruSeq Targeted mRNA Expression kit. 
BRCA1 chr17 Probe Strand - Minus 
  
  





















NM_007299 6730620 1 0 41277321 41276106 CTCAGGAGGCCTTCACCCTCTGCTCT 2 TTCATTGGAACAGAAAGAAATGGATTT 2 
NM_007300 6730382 2 1 41276068 41267768 AATGCTATGCAGAAAATCTTAGAGTGTCC 2 GGAGTTGATCAAGGAACCTGTCTCCA 1 
NM_007300 6730371 5 3 41258509 41256939 CACAGTGTCCTTTATGTAAGAATGATATAA 1 TACAAGAAAGTACGAGATTTAGTCAACTTG 1 
NM_007300 6730387 6 5 41256910 41256252 TTTTCAGCTTGACACAGGTTTGGAG 1 ATGCAAACAGCTATAATTTTGCAAAAA 1 
NM_007300 6730642 7 6 41256171 41251866 CTTCTACAGAGTGAACCCGAAAATCCT 1 CCAGTCTCAGTGTCCAACTCTCTAA 3 
NM_007300 6730366 8 7 41251826 41249273 ACAACCTCAAAAGACGTCTGTCTACA 1 TTCTTCTGAAGATACCGTTAATAAGGC 1 
NM_007300 6730648 9 8 41249295 41247897 TCTGAAGATACCGTTAATAAGGCAACT 1 ATTGTTACAAATCACCCCTCAAGGAACC 1 
NM_007300 6730119 10 9 41247895 41246839 GGGATGAAATCAGTTTGGATTCTGCAA 1 TTTTCTGAGACGGATGTAACAAATACTG 1 
NM_007300 6730639 11 10 41243488 41243013 AATAATCAAGAAGAGCAAAGCATGGATTC 1 TGGGTGTGAGAGTGAAACAAGCGT 1 
NM_007300 6730628 12 11 41242995 41234565 GGCTATCCTCTCAGAGTGACATTTTAACC 1 AGGGATACCATGCAACATAACCTGA 1 
NM_007300 6729855 13 12 41234455 41231382 CCTGCGAAATCCAGAACAAAGCACAT 1 TATACATGGCCAAAGGAACAACTCCATG 82 
NM_007300 6730131 14 13 41231391 41228598 CAACTCCATGTTTTCTAAAAGGCCTAGAG 107 TAACTTCACAGAAAAGTAGTGAATACCC 1 
NM_007300 6730125 15 14 41228539 41226510 TCTACCAGTAAAAATAAAGAACCAGGAGTG 1 TCATCCCCTTCTAAATGCCCATCATTAG 1 
NM_007300 6730113 16 15 41226384 41223219 TTGACGGAAACATCTTACTTGCCAAGG 1 TACCTGGAATCTGGAATCAGCCTCTT 1 
NM_007300 6730101 18 17 41219659 41215938 TACTGAAGAGACTACTCATGTTGTTATG 1 GAGTTTGTGTGTGAACGGACACTGAA 1 
NM_007300 6730893 19 18 41215923 41215357 TTGCGGGAGGAAAATGGGTAGTTAG 2 ACCCAGTCTATTAAAGAAAGAAAAATGCTG 1 
NM_007300 6730902 20 19 41215383 41209110 CCAGTCTATTAAAGAAAGAAAAATGCTGA 1 AGATGTGGTCAATGGAAGAAACCA 4 
NM_007300 6730622 21 20 41209103 41203091 GTCCAAAGCGAGCAAGAGAATCCCA 1 TCTGTTGCTATGGGCCCTTCACCAA 1 
NM_007300 6730634 22 21 41203110 41201180 TGCTATGGGCCCTTCACCAACAT 4 GGAATGGATGGTACAGCTGTGTGGT 1 
NM_007300 6730377 23 22 41201170 41199677 GTGAAGGAGCTTTCATCATTCACCCT 2 GGTTGTGCAGCCAGATGCCTGGACAGA 2 
NM_007300 6730107 24 23 41199688 41197797 TGCCTGGACAGAGGACAATGGCTT 2 AATTGGGCAGATGTGTGAGGCA 17 






































NR_027676 6963692 10 NA 41244028 41243971 TCTGCTGTTTTTAGCAAAAGCGTCCAG 1 GAGAGCTTAGCAGGAGTCCTAGCCCTT 1 
NR_027676 6963681 10 NA 41245267 41245211 GAAAGATCTGTAGAGAGTAGCAGTATTTC 1 TGGTACCTGGTACTGATTATGGCACT 1 
NR_027676 6963683 10 NA 41244160 41244104 TCAGATAACTTAGAACAGCCTATGGGA 1 GTCATGCATCTCAGGTTTGTTCTGAG 4 
NR_027676 6963684 10 NA 41245118 41245063 CCCCAAGGGACTAATTCATGGTTGTT 1 AAGATAATAGAAATGACACAGAAGGCT 1 
NR_027676 6963946 10 NA 41243978 41243920 TAGCCCTTTCACCCATACACATTTGG 1 TTACCGAAGAGGGGCCAAGAAATTAG 1 
NR_027676 6963937 10 NA 41244962 41244907 GGTTTCAAAGCGCCAGTCATTTGCT 1 TCAAATCCAGGAAATGCAGAAGAGG 10 
NR_027676 6963458 12 NA 41234500 41234446 TAACAGCTACCCTTCCATCATAAGTGAC 1 TCTGCCCTTGAGGACCTGCGAAAT 1 
NR_027676 6963460 13 NA 41228609 41228556 TAGTGAATACCCTATAAGCCAGAATCCAG 1 GGCCTTTCTGCTGACAAGTTTGA 7 
NR_027676 6963935 15 NA 41223003 41222946 CAGAAAGGGTCAACAAAAGAATGTCCA 1 TCTGGCCTGACCCCAGAAGAATT 8 
NR_027676 6963940 23 NA 41196434 41196380 AAGGACTAGGTCTTCCCTAGCCC 2 TGTGCAAGGGCAGTGAAGACTTGATT 1 
NR_027676 6963456 23 NA 41197304 41197245 TTTACTTCTCTAAAACCCTGTGTTCAC 1 AGAGAGTCAGACCCTTCAATGGAAGGA 1 








Supplementary Table 2. Oligonucleotide probes used for sequencing BRCA2 using the TruSeq Targeted mRNA Expression kit.  

























NM_000059 6803177 1 2 32890636 32893257 AATTTTTAAGACACGCTGCAACAAAGC 1 GTCTTAATTGGTTTGAAGAACTTTCTTCA 1 
NM_000059 6803189 3 4 32899287 32900272 TCCTGTCCACTTCTAAATTCTTGTCTT 1 GTTCTACAATGTACACATGTAACACCAC 1 
NM_000059 6803462 5 6 32900388 32900677 GGAGTTTGTTTCATACACCAAAGTTTGTG 1 AAAACATATTTCTGAAAGTCTAGGAGCTG 1 
NM_000059 6803181 7 8 32903597 32905095 TCTGAAACTGTATTTCCTCATGATACTAC 1 CTATTTTTCCAATCATGATGAAAGTCTGA 1 
NM_000059 6803463 8 9 32905135 32906449 AAAACACAAATCAAAGAGAAGCTGCAAG 2 ACATCAGGGAATTCATTTAAAGTAAATAGC 1 
NM_000059 6803183 9 10 32907494 32910432 GCACCACTTACATTTGCAAATGCTG 1 TTTATTGCATTCTTCTGTGAAAAGAAGCTG 1 
NM_000059 6803187 10 11 32915301 32918727 GAAAAAGAAGAGGAGAGCCCCTTATCT 1 AACCCTCAATCAAAAGAAACTTATTAAATG 1 
NM_000059 6803182 11 12 32918760 32921003 TCCTTAAAGGCTTCAAAAAGCACTCC 1 TCGAAGATTGTTTATGCATCATGTTTC 1 
NM_000059 6803185 13 14 32929393 32930594 TAACTTTCACAAAGTGTGAAGAAGAACC 1 TTTAATTACAAGTCTTCAGAATGCCAGAG 1 
NM_000059 6803184 14 15 32930716 32931920 CCAAGTTCCCTCTGCGTGTTCTCATAA 1 GCGTTTCTAAACATTGCATAAAAATTAAC 1 
NM_000059 6803180 15 16 32932032 32936698 AATGATGGAAAGGCTGGAAAAGAAGAA 1 ACTCCAGGTGTGGATCCAAAGCTTAT 1 
NM_000059 6803461 16 17 32936796 32937350 AGCCCAGAAAGGGTGCTTCTTCAACTA 1 ACGGAAATTGATAGAAGCAGAAGATCGG 1 
NM_000059 6803178 19 20 32945203 32950849 CACTAAAATTCAGGAGGAATTTGAAGAAC 1 CATATTTACCATCACGTGCACTAACAAG 1 
NM_000059 6803186 20 21 32950894 32953483 CAGTGAAGAATGCAGCAGACCCAGCTTA 1 GTTATTTCAGTGAAGAGCAGTTAAGAGCC 1 
NM_000059 6803460 21 22 32953610 32953916 AAGTTGCGTATTGTAAGCTATTCAAAA 1 TACTGAGTATTTGGCGTCCATCATCAG 1 
NM_000059 6803188 23 24 32954248 32968857 AATAGGATTTGTCGTTTCTGTTGTGAA 1 GCCCCTTTCGTCTATTTGTCAGACGAA 1 
NM_000059 6803179 24 25 32969036 32971078 AAGAGACATTCAACAAAATGAAAAATACTG 1 ATGAAGCAGAAAACAAGCTTATGCA 2 
NM_000059 6962406 9 NA 32906699 32906755 GATACTGATCCATTAGATTCAAATGTAGC 1 ATCAGAAGCCCTTTGAGAGTGGAAGT 2 
NM_000059 6962409 9 NA 32906452 32906509 CAAAGACCACATTGGAAAGTCAATGCC 1 ATGTCCTAGAAGATGAAGTATATGAAACA 1 
NM_000059 6962410 9 NA 32906952 32907009 TGCCACGTATTTCTAGCCTACCAAA 1 GAAGCCATTAAATGAGGAAACAGTGGT 1 
NM_000059 6962688 9 NA 32906869 32906927 ATGTGACCAAAATATTTCAGAAAAAGACC 1 TTAGACACAGAGAACAAAAGAAAGAAAG 1 
NM_000059 6962405 10 NA 32913025 32913081 ACGTGATGAAAAGATCAAAGAACCTACTC 1 TTGGGTTTTCATACAGCTAGCGGGAA 1 








Supplementary Table 2 (continued) Oligonucleotide probes used for sequencing BRCA2 using the TruSeq Targeted mRNA Expression kit. 



























NM_000059 6962403 10 NA 32914975 32915034 CAAACAACAGTTGGTATTAGGAACCAAAG 1 TCACTTGTTGAGAACATTCATGTTTTGGG 1 
NM_000059 6962407 12 NA 32921009 32929026 AGCCGATTACCTGTGTACCCTTT 5 ACTAAGGAACGTCAAGAGATACAGA 1 
NM_000059 6962404 17 NA 32937622 32944545 TCCTGATGCCTGTACACCTCTTGAA 1 CCCAGAATCTCTTATGTTAAAGATTTCTG 0 
NM_000059 6962408 18 NA 32944639 32945094 ATGGAGGAAATGTTGGTTGTGTTGATG 1 TATTCAAAGAGCATACCCTATACAGTG 1 




Appendix B RNA-seq code to map reads 








perl -e 'use File::Temp qw/tempdir/; use IO::File; $d=tempdir; $fh; 
map{if(m/^\>(\S+)\s/){$fh=IO::File->new(">$d/$1.fa");} print $fh 
$_;}`cat Homo_sapiens.GRCh37.72.dna.primary_assembly.fa`; foreach 
$c(1..22,X,Y,MT){print `cat $d/$c.fa`}; print `cat $d/GL*`' > 
Homo_sapiens.GRCh37.72.dna.primary_assembly.reordered.fa 
 





1. Loop complete the first pass with Star for all 96 samples: 
open FIN, "filelist"  or die "Can't open filelist."; 
 
while(<FIN>){ 
  chomp; 
  my $fin = $_; 
  my $sn = $fin; 
  $sn =~ s/^Data\/\w*-\d+-//;  
  $sn =~ s/-.+//g; 
  print "mkdir STAR_R1_$sn\n"; 
  print "cd STAR_R1_$sn\n";   
  print "pwd\n"; 
  print "STAR --genomeDir 
/home/john/src/STAR_2.3.0e.Linux_x86_64/ENSEMBL.homo_sapiens.release
-75 --readFilesIn ../$fin --runThreadN 4 --readFilesCommand zcat --
alignIntronMax 100000\n"; 
  print "cd .. \n"; 













1_adapt_trimed_q20_trimmed_SE_l50.fastq.gz --runThreadN 4 --
readFilesCommand zcat --alignIntronMax 100000 








1_adapt_trimed_q20_trimmed_SE_l50.fastq.gz --runThreadN 4 --
readFilesCommand zcat --alignIntronMax 100000 








1_adapt_trimed_q20_trimmed_SE_l50.fastq.gz --runThreadN 4 --
readFilesCommand zcat --alignIntronMax 100000 
cd .. 
 
1. A new genome was generated to incorporate the novel splice junctions.  




sjdbFileChrStartEnd R1-SJ.out.tab --sjdbOverhang 100 --runThreadN 6 
 
2. A second pass with STAR to map the reads for each sample to the updated genome. 
open FIN, "filelist"  or die "Can't open filelist."; 
 
while(<FIN>){ 
  chomp; 
  my $fin = $_; 
  my $sn = $fin; 
  $sn =~ s/^Data\/\w*-\d+-//;  
  $sn =~ s/-.+//g; 
  print "mkdir R2/STAR_R2_$sn\n"; 
  print "cd R2/STAR_R2_$sn\n";   
  print "pwd\n"; 
  print "STAR "; 
  print "--genomeDir 
/media/sdat/Vannessa/Targetted/ENSEMBL.homo_sapiens.release-75-pass2 
"; 
  print "--readFilesIn /media/sdat/Vannessa/Targetted/$fin "; 
  print "--runThreadN 4 "; 
  print "--readFilesCommand zcat "; 
  print "--alignIntronMax 100000\n"; 
  print "cd ../..\n"; 














1_adapt_trimed_q20_trimmed_SE_l50.fastq.gz --runThreadN 4 --









1_adapt_trimed_q20_trimmed_SE_l50.fastq.gz --runThreadN 4 --









1_adapt_trimed_q20_trimmed_SE_l50.fastq.gz --runThreadN 4 --





2. First pass with STAR using the same genome downloaded for the targeted reads. 
cd S1L003_IM100K 


































1.fastq.gz --readFilesCommand zcat --alignIntronMax 100000 
cd .. 
 
3. A new genome was generated to incorporate the novel splice junctions.  
cat PASS1/S*/SJ* | cut -f 1,2,3,4 | sort -u > Pass1-SJ.out.tab 





nice STAR --runMode genomeGenerate --genomeDir ./GRCH37.72-pass2 --
genomeFastaFiles 
/home/john/Genomes/GRCH37.72/Homo_sapiens.GRCh37.72.dna.primary_asse
mbly.reordered.fa --sjdbFileChrStartEnd Pass1-SJ.out.tab --
sjdbOverhang 100 --runThreadN 4 
 















































5. Collate data 
cat PASS2/S*/SJ* | cut -f 1,2,3 --output-delimiter=":" | sort -u > 
allSJs 
/media/.../P1/WholeTtome$ wc -l allSJs  
639807 allSJs 
 
ls -1d PASS2/S* | ./mkSJscript.pl > Pass2SJscript 
chmod 755 Pass2SJscript  
./Pass2SJscript 
 




Appendix C Read counts for samples analysed with RNA-seq 
Supplementary Table 3. Sample specific reads for treated and untreated samples sequenced in this study. 









1 BRCA2 c.426-12_8delGTTTT Yes 143304 95.60% 
1 BRCA2 c.426-12_8delGTTTT No 146422 95.85% 
2 BRCA1 c.5467+5G>C Yes 646022 95.91% 
2 BRCA1 c.5467+5G>C No 431597 96.08% 
3 BRCA2 c.9501+3A>T Yes 81053 96.07% 
3 BRCA2 c.9501+3A>T No 98073 95.15% 
4 BRCA1 c.671-2 A>G Yes 413149 95.95% 
4 BRCA1 c.671-2 A>G No 21047 95.91% 
5 BRCA1 c.594-2 A>C Yes 89323 92.23% 
5 BRCA1 c.594-2 A>C No 83005 95.34% 
6 BRCA1 c.135-1 G>T Yes 24561 95.41% 
6 BRCA1 c.135-1 G>T No 30768 95.56% 
7 BRCA2 c.7988 A>T Yes 22117 94.92% 
7 BRCA2 c.7988 A>T No 215297 95.98% 
8 BRCA2 c.8632+1G>A Yes 156715 95.12% 
8 BRCA2 c.8632+1G>A No 75038 96.18% 
9 BRCA1 2640 C>T (R841W) Yes 119655 95.99% 
9 BRCA1 2640 C>T (R841W) No 77185 95.51% 
10 BRCA1 2640 C>T (R841W) Yes 84107 95.44% 
10 BRCA1 2640 C>T (R841W) No 27279 95.62% 
11 BRCA1 2640 C>T (R841W) Yes 83196 94.16% 
11 BRCA1 2640 C>T (R841W) No 99386 94.89% 
12 BRCA1 2640 C>T (R841W) Yes 317435 95.65% 
12 BRCA1 2640 C>T (R841W) No 16799 95.81% 
13 BRCA1 2640 C>T (R841W) Yes 16395 94.27% 
13 BRCA1 2640 C>T (R841W) No 14929 95.72% 
14 BRCA1 2640 C>T (R841W) Yes 83642 95.23% 
14 BRCA1 2640 C>T (R841W) No 187811 95.45% 
15 BRCA1 2640 C>T (R841W) Yes 28771 96.44% 
15 BRCA1 2640 C>T (R841W) No 151226 95.74% 
16 BRCA1 2640 C>T (R841W) Yes 9066 95.96% 
16 BRCA1 2640 C>T (R841W) No 11399 94.64% 
17 BRCA1 2640 C>T (R841W) Yes 127966 90.75% 
17 BRCA1 2640 C>T (R841W) No 49685 95.30% 
18 Control Yes 110952 94.13% 
18 Control No 67260 97.26% 
19 Control Yes 171318 95.54% 
19 Control No 114396 95.94% 













20 Control Yes 176013 95.98% 
20 Control No 187840 96.04% 
21 Control Yes 140376 96.49% 
21 Control No 103652 95.30% 
22 Control Yes 366409 95.90% 
22 Control No 472421 96.12% 
23 Control Yes 298874 90.08% 
23 Control No 122817 94.60% 
24 Control Yes 542809 95.30% 
24 Control No 37988 95.12% 
25 Control Yes 199225 92.50% 
25 Control No 131922 94.78% 
26 Control Yes 120054 97.75% 
26 Control No 139471 94.46% 
27 Control Yes 271946 95.40% 








Supplementary Table 4. Raw read counts for BRCA1 mRNA splice junction in samples sequenced with the Targeted RNA expression platform, treated with NMD inhibitors.
  
  
Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction T T T T T T T T T T T T T T T T T T T T T T T T T T T
FL 1B-2 209 3320 940 2020 621 446 562 2380 521 568 38 1913 7 404 1 346 411 1080 1390 1286 906 2250 1716 4547 1403 716 1552
FL 2-3 2699 10013 544 6749 1103 95 189 2706 1344 1488 1479 3903 244 741 212 5 1146 1100 2415 2306 955 4379 5933 5708 2209 1703 1993
FL 5-6 1469 5151 897 2464 722 83 425 2149 1630 437 762 1824 203 1031 0 1 242 1395 328 1192 214 2692 2699 3494 1746 753 1168
FL 6-7 623 4511 316 2275 261 265 252 1542 919 580 642 1776 0 719 0 1 315 276 1101 840 302 1819 1921 1715 1006 539 1116
FL 7-8 742 4423 665 3273 340 139 47 775 725 569 545 1918 112 435 193 3 328 936 680 1256 744 3230 1457 3786 1397 476 1309
FL 8-9 1083 6854 346 5718 514 329 290 1118 924 564 667 1308 306 893 3 1 1 1022 3572 833 1156 1966 3803 4274 1556 650 1090
FL 9-10 874 3482 164 2787 563 146 75 265 1128 658 369 1685 5 876 34 0 1227 844 540 700 1255 2017 2097 2609 1450 812 1428
FL 10-11 13217 11317 5480 11412 2451 1764 1534 13463 6573 4204 2143 5478 1046 2439 3882 707 21158 7018 18500 8337 10061 25434 14368 24742 11958 3455 16970
FL 11-12 1585 8943 991 5934 1319 225 413 2207 1731 1049 726 5996 57 1991 390 2 627 1811 2253 2241 963 4347 4025 7224 2362 1767 2378
FL 12-13 3086 19029 1756 12850 2914 864 318 2749 2798 3322 2104 6687 213 2571 2 5 1987 2731 2805 1924 3369 5713 12690 14104 4016 3128 6737
FL 13-14 62 28 0 0 1 0 0 0 0 0 67 0 0 54 0 0 0 0 0 0 115 105 75 101 220 0 103
FL 14-15 1555 8383 931 7091 883 316 459 1795 1472 718 1516 2898 112 1634 216 107 770 1608 1281 2180 1506 3492 4252 6259 2623 1333 3102
FL 15-16 943 5505 466 3520 745 213 342 992 1238 360 1110 2055 7 997 182 153 1617 1280 1028 1148 286 2175 1960 2520 1148 338 1902
FL 17-18 556 6507 587 3967 1395 246 184 1188 1446 539 799 2306 159 704 307 2 294 489 1516 1286 843 992 2244 3552 823 251 1628
FL 18-19 771 3149 306 2968 354 99 5 1307 686 778 238 1395 70 304 118 1 785 916 612 1040 372 1431 2222 2708 569 409 575
FL 19-20 887 4688 285 3994 31 51 65 2090 810 695 228 1794 1 749 1 2 1120 1043 1611 1615 648 1358 3368 4215 1067 561 1773
FL 20-21 1527 7531 622 6226 256 209 2 1055 975 638 101 2001 4 1412 2 545 750 518 1685 1900 411 2110 1474 4010 1684 306 1964
FL 21-22 1452 4165 723 4941 516 142 2 1982 1315 845 4 2166 1 695 155 1 3538 964 2149 2197 462 3418 3580 5842 1751 1467 917
FL 22-23 5935 7383 2249 15188 2596 511 720 5983 3667 2458 1538 10569 157 4280 230 6 5662 3016 3507 5332 3173 6393 9318 15152 5415 1449 6292
FL 23-24 307 69 95 163 0 148 1 174 92 72 103 211 0 127 0 0 318 149 43 1 1 2 1 216 143 217 290
Cassette
Δ 2 0 141 0 210 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 632 1 318 0 0 0
Δ 5 1 131 0 186 0 0 0 0 0 0 0 124 0 0 0 0 0 0 0 0 0 0 413 15 0 0 176
Δ 9 34 141 0 197 0 0 0 0 288 0 0 575 0 0 0 0 0 0 127 451 0 88 1 775 0 1 0
Δ 10 54 0 38 36 638 1 0 0 0 0 0 0 0 0 0 0 379 0 186 1 0 0 0 167 227 0 0
Δ 11 1 213 0 1197 0 1 0 328 0 0 0 0 0 0 0 0 0 0 0 0 0 355 0 0 0 0 0
▼13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 135 0 0 0 0
Δ 14 0 0 0 0 0 0 0 207 0 0 0 0 0 0 0 0 0 0 0 0 0 100 267 51 0 0 0
Δ 15 0 156 1 170 123 0 0 130 45 115 0 0 0 0 0 0 0 0 0 0 0 0 104 0 70 0 22
Δ 17 94 23 0 228 1 0 32 0 0 0 26 73 0 0 0 0 0 0 164 0 0 0 0 0 5 125 0
Δ 18 141 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
Δ 21 193 382 0 0 0 0 0 0 214 0 0 310 0 0 0 0 0 0 0 0 0 1 0 0 0 0 296
Δ 22 118 0 0 0 0 1 0 117 0 0 0 158 0 0 0 0 0 0 58 0 0 68 0 1 0 0 0












Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction T T T T T T T T T T T T T T T T T T T T T T T T T T T
Multi-cassette
Δ 7,8,9,10 0 0 0 0 0 0 0 74 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 8,9,10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 75
Δ 9,10 1847 1078 1533 1370 1369 283 179 1466 525 445 467 1033 198 98 36 358 1702 561 2058 2432 2455 5561 2469 13586 2730 1452 3634
Δ 9,10,11 0 0 0 787 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 9,10,11,12 0 0 1 562 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 10,11 0 176 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 14,15 0 57 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 18,19 0 86 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Splice Acceptor shift
Δ 6p 1 1 0 102 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0
Δ 8p 413 886 163 277 0 51 0 340 179 140 133 509 1 200 0 0 198 386 137 206 165 387 341 1649 415 307 545
Δ 13p 454 2140 159 328 158 0 0 2 2 241 327 1222 0 1 0 1 383 348 426 418 0 0 1520 955 162 1 128
Δ 14p 0 482 0 131 0 0 81 0 99 139 0 67 0 0 0 0 311 0 103 218 0 58 255 274 176 0 85
Splice Donor shift
Δ1Aq 1232 2361 223 2928 1076 330 132 1155 1013 416 588 2383 2 372 1 7 964 776 614 248 830 2738 1664 5958 1120 641 864
▼1aA 17 152 0 142 191 1 0 161 28 0 131 98 1 227 0 0 280 169 179 27 0 226 193 564 183 119 363
Δ 5q 0 338 103 308 0 0 0 1 0 0 0 0 0 0 0 0 0 0 28 1 1 0 85 1 126 0 1
Δ 11q 0 0 0 131 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 11q 68 157 121 0 0 0 0 267 52 114 0 299 0 181 1 0 0 168 180 49 207 0 195 166 217 0 189
Δ 6q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 83 0
Splice Acceptor shift +cassette
▼1aA (89nt) Δ2 0 0 0 140 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 68 0 0 0 0
Δ2, Δ3p (7nt) 1 8 0 10 0 0 0 3 0 0 1 3 0 2 0 0 0 1 2 4 0 0 2 82 3 1 0
▼10p 0 0 0 109 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 82 0 0 0
Splice Donor shift +cassette
Δ1Aq-10 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 92 0 0 0
Δ1Aq, 2 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 102 0 241
Δ13q-24p 0 0 0 0 0 0 0 0 0 0 0 84 0 32 1 0 0 0 0 0 72 0 0 0 114 0 121
Splice Donor + splice acceptor + cassette
Δ13q, Δ14-23, Δ24p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 88








Supplementary Table 4 (continued) Raw read counts for BRCA1 mRNA splice junction in samples sequenced with the Targeted RNA expression platform, treated with 
NMD inhibitors. 
 
a according to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl reference 
transcript ENST00000357654. 
b NMD - nonsense-mediated decay, FS - frame shift, PTC - premature termination codon 
c Detected from q end of insertion and actual length is unconfirmed 
  
Exonisation
▼1 11 7 9 27 0 0 5 48 14 0 0 22 0 0 0 0 19 2 74 1 6 46 10 111 38 5 22
▼2* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 93 23 0 0
▼19* 74 0 0 0 0 0 0 0 0 0 88 0 0 0 0 0 0 0 0 0 0 0 0 0 25 0 9
▼13* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 67 0 0 0 0 0 0 0
▼8
c
0 106 146 0 0 0 0 0 0 0 165 1 0 0 0 0 0 0 0 0 77 168 0 164 0 0 0
▼12
c
0 0 47 0 0 0 0 0 0 0 0 122 0 1 0 0 0 0 3 0 0 0 0 203 99 0 0
▼21
c
0 25 0 142 92 0 0 1 0 0 50 0 0 0 0 0 1 0 0 10 18 127 0 0 16 0 0
▼21
c








Supplementary Table 5. BRCA1 mRNA splice junction raw read counts for samples sequenced with the Targeted RNA expression platform, not treated with NMD 
inhibitors.                
 
Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction U U U U U U U U U U U U U U U U U U U U U U U U U U U
FL 1B-2 740 4024 444 261 306 770 1674 644 866 152 1237 1 1 2261 799 2 0 918 1690 1386 883 2043 795 411 1620 538 1065
FL 2-3 2818 10129 1523 429 751 1 4356 1001 825 450 1437 2 98 2001 4290 3 2 912 1325 2795 751 6419 1051 995 2356 2422 3318
FL 5-6 2455 5306 593 144 631 194 2455 417 829 347 777 1 2 2094 552 2 645 127 548 2043 830 2948 1719 448 1454 663 1450
FL 6-7 942 2988 327 206 160 228 1875 199 601 350 499 2 1 1661 508 0 241 151 846 710 334 2567 191 284 609 718 1041
FL 7-8 1618 3739 1070 111 849 288 1987 627 362 337 669 171 281 1457 311 0 2 620 648 1203 684 3783 940 239 964 946 704
FL 8-9 1943 5726 106 147 293 300 1117 530 131 0 1184 0 121 1507 1969 1 540 808 1214 1696 393 3005 2019 32 1649 943 543
FL 9-10 820 3463 686 33 562 123 974 906 514 124 534 132 0 1074 838 1 278 1134 774 942 448 2308 74 120 782 1159 373
FL 10-11 5436 14927 11073 661 3420 2285 13743 8307 4128 933 2816 810 620 8094 19183 368 3786 3514 10942 21913 7159 20016 9289 2664 6372 5794 9734
FL 11-12 2780 8664 1113 544 764 587 5155 1330 1338 452 1982 231 149 4978 806 0 1371 681 2096 3536 1327 7128 882 717 2404 900 1788
FL 12-13 4235 18913 1448 1069 973 1398 5411 1195 2893 1181 1205 3 3 2580 1245 649 1346 1825 2663 4041 1563 15329 2265 816 3469 2256 3630
FL 13-14 1 417 0 54 0 0 211 0 0 82 80 0 0 0 0 0 1 0 0 64 0 344 0 0 0 0 68
FL 14-15 2295 7852 1158 425 825 320 2165 1171 1150 283 880 318 228 3141 1640 132 906 786 1686 2439 1259 4991 1477 555 2169 1914 856
FL 15-16 668 2482 122 149 933 73 939 531 237 373 868 223 57 2368 664 3 455 764 392 1931 583 3517 1105 142 737 1440 719
FL 17-18 501 3227 483 110 1174 119 2617 603 1031 203 1379 393 1 1680 1293 341 245 635 576 1440 1047 4035 1426 676 1165 536 975
FL 18-19 626 2353 289 89 96 102 1419 332 501 231 399 0 2 2158 274 0 210 76 348 582 549 1293 214 260 376 1187 386
FL 19-20 1100 3129 854 197 365 218 2249 825 940 272 380 196 142 2494 772 3 119 485 935 1157 840 3242 1308 428 456 1010 1660
FL 20-21 1127 2794 568 622 1663 190 3682 78 2311 266 117 0 3 3252 1689 0 1033 946 603 1439 1093 5571 965 4 807 1160 1903
FL 21-22 1569 3696 2095 43 984 57 3354 897 1345 89 432 75 65 3032 1243 1 633 412 646 1890 796 5425 2641 207 2589 212 2036
FL 22-23 4645 7406 2270 486 2975 280 8891 2753 3506 603 3233 261 806 9112 3281 355 459 3086 3609 6791 2666 16409 5421 2020 4644 2754 5664
FL 23-24 96 13 0 0 132 135 0 25 181 0 279 0 0 304 0 0 0 216 76 674 1 1 156 1 0 209 116
Cassette
Δ 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 282 0 0 0 0 0 116 1 1 0 0 0 0
Δ 5 140 0 0 0 1 0 119 0 92 21 0 0 0 0 0 0 0 186 0 0 0 62 123 0 0 0 0
Δ 9 155 1 0 0 0 0 0 0 0 2 123 0 0 2 0 0 0 417 1 0 0 77 0 0 0 0 0
Δ 10 0 0 34 0 196 20 1 0 0 0 0 0 0 0 204 1 0 0 0 0 0 0 0 0 0 0 0
Δ 11 0 337 10 0 192 0 1 0 0 0 0 0 0 0 0 0 0 0 310 0 212 0 0 0 0 0 0
▼13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 192 0 0 0 0 0 0 0 0
Δ 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 104 0 0 0 0 0 113 0 0 0 0 0
Δ 15 0 0 0 0 0 0 0 0 0 0 4 0 0 73 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 17 0 1 0 0 0 0 8 0 0 0 0 0 0 0 0 0 0 26 0 0 0 0 0 0 0 0 0
Δ 18 594 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 21 149 0 0 0 0 0 0 0 0 1 0 0 1 471 0 0 0 0 0 0 342 235 1 0 0 0 0
Δ 22 0 0 96 0 194 0 0 0 0 45 98 0 0 0 0 0 0 0 0 0 177 346 0 0 0 0 115








Supplementary Table 5 (continued) BRCA1 mRNA splice junction raw read counts for samples sequenced with the Targeted RNA expression platform, not treated with 
NMD inhibitors.                
 
Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction U U U U U U U U U U U U U U U U U U U U U U U U U U U
Multi-cassette
Δ 7,8,9,10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 8,9,10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 9,10 706 4087 988 411 3183 181 1950 2713 1089 370 162 0 194 2191 2117 327 1781 1899 3555 6756 2873 11288 5020 1673 2813 3510 2557
Δ 9,10,11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 9,10,11,12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 10,11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
Δ 14,15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 18,19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Splice Acceptor shift
Δ 6p 0 1 0 0 0 0 1 0 0 1 2 0 0 0 0 0 0 0 0 2 0 0 1 0 0 0 0
Δ 8p 185 1465 160 0 18 1 529 0 158 101 1 0 91 507 103 0 362 77 239 1086 85 1158 523 1 257 211 433
Δ 13p 1 1911 363 0 0 0 1754 0 319 423 592 0 2 436 1 0 659 1 1 547 0 458 1 0 301 639 2
Δ 14p 1 265 26 0 0 0 77 0 129 0 145 0 0 135 0 0 0 1 0 25 108 320 1 0 121 1 42
Splice Donor shift
Δ1Aq 1338 2305 1834 441 418 345 2603 324 993 424 547 192 82 1938 840 4 392 403 564 1182 1047 3539 666 22 1596 615 1377
▼1aA 348 172 4 0 0 0 0 178 156 1 86 0 31 259 1 0 0 0 156 246 0 460 0 0 150 213 234
Δ 5q 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 120 0 0
Δ 11q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ 11q 0 0 174 0 0 0 0 0 111 0 0 1 0 458 126 0 0 0 157 0 91 342 105 65 88 65 270
Δ 6q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
Splice Acceptor shift +cassette
▼1aA (89nt) Δ2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ2, Δ3p (7nt) 1 7 1 1 2 1 0 0 0 0 0 0 0 4 0 0 0 0 1 1 1 5 0 0 1 1 2








Supplementary Table 5 (continued) BRCA1 mRNA splice junction raw read counts for samples sequenced with the Targeted RNA expression platform, not treated with 
NMD inhibitors.                
 
a according to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl reference 
transcript ENST00000357654. 
b NMD - nonsense-mediated decay, FS - frame shift, PTC - premature termination codon 
c Detected from q end of insertion and actual length is unconfirmed 
  
Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction U U U U U U U U U U U U U U U U U U U U U U U U U U U
Splice Donor shift +cassette
Δ1Aq-10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ1Aq, 2 117 377 0 0 0 0 0 0 0 0 0 0 0 264 0 0 0 198 0 0 0 274 1 0 7 0 0
Δ13q-24p 0 1 0 0 51 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 78 0 0 0 0 142 82
Splice Donor + splice acceptor + cassette
Δ13q, Δ14-23, Δ24p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ11q, Δ12-23, Δ24p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Exonisation
▼1 5 0 56 0 33 16 30 49 50 0 2 7 0 39 0 13 0 30 13 66 18 50 60 0 32 0 27
▼2* 68 0 0 6 0 0 0 3 0 0 2 0 0 0 165 0 0 0 0 0 2 112 0 0 0 0 3
▼19* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 234 0 0 0 1 100 0 0 0 0 0
▼13* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
▼8c 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
▼12c 0 0 0 0 0 0 0 0 124 0 0 0 0 0 0 0 0 0 0 0 0 64 0 0 0 0 0
▼21c 0 0 0 1 0 0 0 0 0 0 0 53 0 0 0 0 0 0 0 0 0 0 0 0 0 0 46


















Sample # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction T T T T T T T T T T T T T T T T T T T T T T T T T T T
FL 2-3 1536 17981 2092 8792 1624 872 67 2207 1724 555 2027 7517 67 2127 925 3 1563 1873 1875 3564 1927 4149 3848 7710 3103 2825 6087
FL 4-5 446 6380 593 3034 739 6 86 1916 1280 221 432 1141 1 525 175 1 585 747 1558 1230 879 4278 1933 4706 1973 1167 3761
FL 5-6 0 3 0 0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 25 0 0 0 6 0 0 0 4
FL 6-7 2601 17663 1001 9242 1057 724 469 3641 1696 2217 1241 6425 18 617 366 6 1165 1635 1373 4582 1571 5585 7562 8664 3936 3058 4721
FL 8-9 1391 9570 1540 5807 511 305 54 1628 1510 1224 666 4172 76 858 267 70 1150 1123 1841 2448 1957 3384 4351 7074 3179 1347 2628
FL 9-10 2635 25953 1620 14542 2844 365 582 3605 4158 4115 3886 15221 268 2681 653 7 2097 2720 3431 5854 2135 6436 10806 20580 6432 3593 6213
FL 10-11 3226 21615 1910 13080 2257 821 1415 3230 3444 1393 1419 11394 467 1268 326 7 4179 2318 4532 7501 2155 9214 7610 16341 5446 2318 6471
FL 11-12 2089 11185 752 6127 480 162 5 2279 1409 855 1888 3442 191 180 0 909 655 1487 687 2707 1866 3909 2775 7487 1692 1564 2467
FL 12-13 1058 6097 216 2386 952 95 4 766 294 204 463 2914 119 708 1 1 300 381 657 1982 1261 2259 1764 3335 1488 683 1572
FL 13-14 1421 10775 804 4552 410 95 80 2226 311 1630 1338 4792 29 1311 306 4 1 1254 1657 1347 1194 2618 4145 9605 1475 831 2047
FL 14-15 416 3573 375 1935 242 101 89 1203 542 373 424 1110 75 415 0 1 0 286 511 1056 97 1378 589 2163 493 534 635
FL 15-16 1583 9841 1839 6174 817 233 301 1393 1028 687 1265 2501 114 1215 311 1 637 884 2043 1635 1179 4386 3716 7453 2137 808 2187
FL 16-17 1976 10186 1036 6362 2223 260 412 2041 692 548 1730 2756 2 502 789 3 1877 1442 842 1158 1552 4053 2836 5587 1518 210 2044
FL 17-18 3 2600 394 708 1235 1 271 628 479 0 327 1233 2 2 590 0 0 173 1 550 499 2113 1195 1659 1230 586 763
FL 20-21 1491 6213 1472 4243 754 389 120 1002 1840 507 1974 5423 229 1314 562 1 1066 699 1311 1740 1577 4117 2569 7169 1944 1911 3003
FL 21-22 1532 14675 1501 6852 2280 476 5 872 1166 1512 1533 4575 63 1655 236 4 101 2224 1048 4451 1631 5779 5248 10204 2642 2071 2603
FL 22-23 1090 5822 763 3801 620 3 187 807 730 862 461 4172 198 405 1 1 2 911 2114 1667 773 2828 2282 4754 1760 621 1579
FL 24-25 2805 18137 306 9469 860 662 8 2072 2162 2143 1354 6059 148 1929 36 2 1125 1133 1804 2873 1805 6832 6006 7449 3200 2356 2982
FL 25-26 2528 20417 2572 10710 774 342 400 1474 1919 1418 3086 9496 4 2365 293 6 2918 1783 2230 2471 938 8075 3995 8990 4743 3187 3927
Cassette
Δ11 0 240 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 195 0 0
Δ12 193 612 0 683 0 0 2 235 0 0 0 251 0 0 2 0 15 0 321 675 1 1103 233 2052 113 713 212
Δ20 0 0 0 25 1 11 1 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 112 0








Supplementary Table 6 (continued) Raw read counts for BRCA2 mRNA splice junction in samples sequenced with the Targeted RNA expression platform, treated with 
NMD inhibitors.
 
a according to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl reference 
transcript ENST00000357654. 
b NMD - nonsense-mediated decay, FS - frame shift, PTC - premature termination codon 
c Detected from q end of insertion and actual length is unconfirmed 
 
 
Sample # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction T T T T T T T T T T T T T T T T T T T T T T T T T T T
Δ22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 112 0
Δ25 0 0 139 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Multi-cassette
Δ3-4 0 133 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 179
Δ8-9 1 107 0 0 0 0 0 0 0 0 0 158 0 0 0 0 0 0 126 0 0 0 0 1 0 0 0
Δ15-16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 90 0 0 0
Δ11-12 0 246 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
Δ19-20 0 1 0 0 0 0 0 47 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
Splice Acceptor shift
Δ12p 7 470 0 13 0 1 0 7 6 1 2 4 0 0 0 3 3 2 3 3 12 381 4 241 4 4 239
Δ27p 0 0 0 0 0 0 124 0 0 0 0 0 0 55 0 0 0 0 0 0 0 0 0 0 0 0 0
Splice Donor shift
ins 8q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 110 0 0 0
Δ15q, 16p 0 0 35 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ17q,18p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ19q,20,21p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 194 0 0 0 0 0 0
Exonisation
ins i15 0 0 0 14 0 0 0 0 0 55 0 0 0 0 0 0 0 0 0 118 0 0 0 0 0 0 0
▼20 674 1648 206 733 180 0 72 168 316 223 156 712 1 242 145 1 244 312 565 594 589 368 614 598 345 388 846
▼20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 48 0 0 0 0
ins i24 94 0 0 74 0 0 0 0 193 0 150 171 0 0 0 0 319 0 0 0 0 356 0 123 0 0 15
ins i24 66 209 0 68 97 48 52 0 54 132 0 77 1 0 0 0 0 2 372 68 0 319 269 206 96 0 183
ins i25 102 275 0 276 22 0 1 217 0 0 1 102 0 135 0 0 0 6 0 139 1 253 95 123 58 0 17
Intronisation








Supplementary Table 7. BRCA2 mRNA splice junction raw read counts for samples sequenced with the Targeted RNA expression platform, not treated with NMD 
inhibitors.                
 
  
Sample # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction U U U U U U U U U U U U U U U U U U U U U U U U U U U
FL 2-3 2968 9090 2012 144 1744 9 4940 964 338 615 1968 21 337 1461 1912 2 1094 372 1448 2686 1514 6016 2090 165 1964 4291 2148
FL 4-5 964 2837 603 180 159 232 1203 428 192 299 547 184 169 809 630 243 657 282 1034 837 435 2656 1185 434 323 660 1371
FL 5-6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
FL 6-7 3170 11131 919 492 843 730 5072 601 1020 964 1810 503 93 2319 1704 1 641 1532 2655 1498 1772 7835 937 872 1527 1782 1990
FL 8-9 2595 4461 914 227 582 126 2603 410 572 121 585 174 235 1659 1440 38 294 808 905 1046 1005 3946 669 340 1612 1845 1247
FL 9-10 4735 12734 3232 339 1146 711 7992 229 1847 651 2419 234 302 4955 4029 443 554 1410 2077 2223 3294 11816 1755 559 2754 2799 3659
FL 10-11 4745 14950 2417 959 2223 721 4291 704 976 858 3330 845 269 2834 3189 1 2434 2117 2595 2149 2575 10101 1861 1276 2371 1519 4755
FL 11-12 1579 3746 667 98 312 0 2339 790 796 482 1007 0 2 774 2098 302 2 411 1521 1775 589 5421 285 784 1426 1219 545
FL 12-13 729 2766 576 284 98 204 865 593 776 264 434 90 14 866 697 162 0 1148 266 554 354 3029 0 96 1481 269 872
FL 13-14 1447 4801 1729 425 978 135 1422 5 393 2 18 70 124 669 2037 1 262 301 903 1329 450 5090 976 232 2642 515 1266
FL 14-15 926 1709 236 100 371 186 914 365 75 171 114 0 52 380 1032 0 0 171 56 424 183 1488 212 264 131 1 361
FL 15-16 1387 4504 333 117 338 227 2214 624 459 379 803 165 121 1297 1307 4 570 394 843 1070 563 3928 1149 540 1140 1096 1321
FL 16-17 2651 4427 649 2 1083 438 2145 381 230 181 1372 840 90 960 1019 3 149 377 388 1578 1 4394 1509 265 791 1339 807
FL 17-18 1100 2982 91 1 266 0 0 3 0 54 304 1 0 770 176 764 413 303 0 364 476 1549 546 3 837 850 564
FL 20-21 1961 4983 1512 153 1323 320 1748 412 467 198 899 1 257 1931 1076 5 789 354 816 1477 1003 5197 494 400 1145 1533 1967
FL 21-22 1868 5192 1275 105 728 742 1761 1190 762 531 1579 124 308 1840 1766 248 1 1126 2277 1412 991 5659 802 505 2818 1094 498
FL 22-23 579 3617 224 303 559 145 3719 1 1081 2 287 0 2 339 818 0 72 456 1254 888 590 3668 844 389 576 1095 1115
FL 24-25 2829 8205 948 133 949 737 3467 1718 1612 1139 2067 0 233 2767 1897 0 1333 967 699 3389 1511 6231 1886 698 3192 1171 3910
FL 25-26 3312 8635 914 151 1933 625 2934 764 679 393 2453 236 276 3872 1027 257 821 1128 1281 3204 2086 8493 1918 382 2715 1693 3747
Cassette
Δ11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 147 0 0 0 0 0
Δ12 133 1100 0 0 1 1 0 0 1 0 584 0 0 403 524 0 1 1 0 0 0 1 2 1 376 523 1








Supplementary Table 7 (continued) BRCA2 mRNA splice junction raw read counts for samples sequenced with the Targeted RNA expression platform, not treated with 
NMD inhibitors.                 
 
a according to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl reference 
transcript ENST00000357654. 
b NMD - nonsense-mediated decay, FS - frame shift, PTC - premature termination codon 
c Detected from q end of insertion and actual length is unconfirmed 
  
Sample # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Splice Junction U U U U U U U U U U U U U U U U U U U U U U U U U U U
Δ22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Multi-cassette
Δ3-4 0 0 0 0 0 0 0 0 0 0 236 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
Δ8-9 0 171 0 0 0 0 0 0 0 0 0 0 0 203 0 0 0 0 0 0 0 132 0 0 0 0 0
Δ15-16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ11-12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
Δ19-20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Splice Acceptor shift
Δ12p 5 394 2 0 0 0 448 2 0 0 0 0 0 3 3 0 0 0 5 1 1 347 2 2 0 2 0
Δ27p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Splice Donor shift
ins 8q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ15q, 16p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Δ17q,18p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 181 0 0 0 0 0
Δ19q,20,21p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Exonisation
ins i15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
▼20 1 344 118 80 1 31 85 193 0 0 1 0 0 0 203 1 1 0 104 1 142 140 0 42 0 0 249
▼20 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
ins i24 358 150 0 0 0 0 0 0 0 0 0 0 1 18 3 0 0 0 0 0 0 260 0 0 0 0 0
ins i24 0 335 8 0 0 0 89 0 0 0 0 0 1 104 0 0 0 0 1 271 0 18 0 0 88 175 1
ins i25 0 172 0 0 0 0 0 1 0 0 118 0 1 0 0 0 0 0 1 230 0 215 0 7 127 0 0
Intronisation








Supplementary Table 8. BRCA1 mRNA splice junction specific raw read counts for a NMD inhibitor treated sample sequenced over six time points with three technical 
replicates.  
 
Replicate 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
Splice Junction    Time point 1a 1a 1a 1b 1b 1b 2a 2a 2a 2b 2b 2b 3a 3a 3a 3b 3b 3b 
FL 1B-2 1274 2 405 1205 2069 1854 5 1508 1542 631 474 569 1646 1715 2175 6032 6568 811 
FL 2-3 3724 624 228 2274 141 991 1051 1013 1818 1200 820 2241 2764 1343 2921 9535 4829 3822 
FL 5-6 1873 256 550 248 309 1049 4 290 1583 2116 337 956 2948 179 2049 6193 4041 3013 
FL 6-7 2012 1339 451 732 256 380 366 30 1152 44 6 404 806 200 2296 4271 4009 2220 
FL 7-8 1969 582 182 1203 570 792 1884 1 2550 386 248 0 338 1337 1001 3035 6122 493 
FL 8-9 2358 56 96 713 1119 1 1080 2 567 686 1025 2 2206 727 1265 3112 3540 2777 
FL 9-10 1655 663 243 696 408 710 433 169 3056 845 3 1126 472 135 2471 2761 744 2103 
FL 10-11 5251 6345 5333 26281 21313 21525 11690 33063 29561 5859 15143 14848 11547 21590 19760 32320 44957 14141 
FL 11-12 3797 1213 523 514 2505 490 235 69 2120 2355 8 3327 2976 1196 3909 18693 6858 3673 
FL 12-13 3939 2801 1053 2255 607 3370 887 2944 6105 3544 921 1385 4959 1594 5561 12888 12909 7586 
FL 13-14 0 0 0 287 0 0 1 0 92 0 0 0 0 0 0 0 423 0 
FL 14-15 2465 454 588 2289 1558 688 1420 573 1333 1495 384 1926 1756 493 2962 8882 5744 2146 
FL 15-16 2114 242 497 665 764 904 5 682 1760 1963 574 948 1435 426 1180 4892 4380 734 
FL 17-18 2200 1145 176 1715 635 513 4 529 2110 1057 654 1868 1765 158 838 7374 3485 1628 
FL 18-19 857 114 0 1335 297 298 273 0 983 1243 654 153 1420 599 580 3341 2331 598 
FL 19-20 1825 643 562 811 408 531 300 249 506 1807 272 1009 1571 439 1149 5273 5982 1340 
FL 20-21 1426 335 391 667 524 1732 3 1971 2579 1404 5 1278 1146 450 4749 9426 6272 3097 
FL 21-22 957 1447 375 1397 556 1200 591 36 1731 2384 9 1350 1587 1904 2820 8058 6236 2554 
FL 22-23 6714 2145 917 2940 1204 5418 2123 4683 6949 1700 14 2596 3568 1809 6726 28445 16648 10481 
FL 23-24 452 0 2 0 234 1 505 1 356 9 1 794 0 0 1 1 1136 548 
Cassette                                     
Δ 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 257 0 230 
Δ 5 0 0 0 0 0 0 0 0 0 0 0 606 0 0 0 0 0 203 
Δ 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 298 0 
Δ 10 150 223 139 1 0 258 0 348 0 0 1 0 88 1 240 0 508 0 
Δ 15 0 0 0 0 0 0 1 2 0 1 269 0 187 0 0 251 0 0 
Δ 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 187 0 0 0 
Δ 21 374 0 494 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 









Supplementary Table 8 (continued) BRCA1 mRNA splice junction specific raw read counts for a NMD inhibitor treated sample sequenced over six time points with three 
technical replicates. 
  
a according to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl reference 
transcript ENST00000357654. 
b NMD - nonsense-mediated decay, FS - frame shift, PTC - premature termination codon. 
c Detected from q end of insertion and actual length is unconfirmed. 
Replicate 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
Splice Junction         Time point 1a 1a 1a 1b 1b 1b 2a 2a 2a 2b 2b 2b 3a 3a 3a 3b 3b 3b 
Multi-cassette                                     
Δ 8,9,10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 9,10 747 302 678 5030 1918 4036 1709 2833 4260 1971 1078 2476 991 5138 2936 3667 6849 2463 
Δ 9,10,11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
Splice Acceptor shift                                     
Δ 6p 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
Δ 8p 1146 127 3 154 0 0 3 0 918 1175 1 321 2 0 1342 2204 180 673 
Δ 13p 522 0 0 0 1 0 0 0 0 846 1 0 0 681 548 280 2184 2 
Δ 14p 0 0 0 0 100 0 1 0 1 1 0 0 0 125 0 435 89 107 
Splice Donor shift                                     
Δ1Aq 1451 874 669 1086 2252 1180 3 531 3022 5 6 5 1711 986 2872 4278 4825 690 
▼1aA 39 0 1 151 40 0 0 0 0 0 0 0 133 0 35 291 578 0 
Δ 5q 0 0 0 0 0 0 0 0 0 0 0 0 0 55 0 6 0 0 
Δ 11q 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 11q 224 0 0 14 0 570 1 705 0 0 1 0 2 254 245 658 162 0 
Splice Acceptor shift +cassette                                   
Δ2, Δ3p (7nt)  2 1 0 0 1 3 2 0 0 2 0 0 0 1 2 3 5 0 
Splice Donor shift +cassette                                     
Δ1Aq-10 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
Δ1Aq, 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Splice Donor + splice acceptor + cassette                                 
Δ11q, Δ12-23, Δ24p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Exonisation                                     
▼1 23 0 0 0 19 0 30 57 36 118 0 0 14 0 0 99 90 120 
▼2* 0 0 0 0 0 0 354 0 0 0 0 0 0 0 0 0 0 0 
▼19* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 16 1 0 0 
▼8c 0 0 0 0 0 0 0 0 85 0 0 0 0 0 0 0 0 0 











Supplementary Table 9. BRCA1 mRNA splice junction specific raw read counts for a sample sequenced over six time points with three technical replicates, not treated 
with NMD inhibitors. 
Replicate 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
Time point  Splice Junction     1a 1a 1a 1b 1b 1b 2a 2a 2a 2b 2b 2b 3a 3a 3a 3b 3b 3b 
FL 1B-2 329 987 0 270 1172 1 3 344 771 1 0 407 474 1156 940 745 3207 5 
FL 2-3 1835 732 773 1582 1580 2 1 897 3941 0 1 375 1912 3558 285 1050 1045 1563 
FL 5-6 628 693 345 0 711 0 2 282 1393 856 2 1 697 366 493 2 2052 1305 
FL 6-7 367 858 418 1 227 1 481 1 0 198 168 118 280 764 631 127 121 1444 
FL 7-8 180 1533 369 1 457 524 3 364 255 1 1 307 380 753 1372 0 938 1994 
FL 8-9 1012 1546 1 375 474 0 5 1 683 186 1 0 661 1067 1 6 3 3 
FL 9-10 233 1408 678 154 861 0 54 406 0 176 11 0 731 735 303 875 2893 83 
FL 10-11 14062 27419 3176 6206 24022 3386 6642 3805 8609 7741 8664 2193 3252 12098 11772 14799 10274 4216 
FL 11-12 923 2940 1539 523 1011 371 7 3 3607 905 5 0 1772 560 462 1173 3 1585 
FL 12-13 1278 1013 1487 579 2065 7 4 1278 999 3891 1301 2 730 2856 1783 2440 5 7800 
FL 13-14 0 402 0 0 0 0 344 0 0 0 0 0 155 1 0 0 0 0 
FL 14-15 1644 1872 1131 164 701 123 199 272 626 958 320 237 1422 1256 897 845 456 1010 
FL 15-16 451 1970 247 171 1354 240 5 250 1274 338 418 130 1359 1120 41 788 2 412 
FL 17-18 443 705 126 261 190 1 1 14 638 2 0 1 738 1175 136 3 0 1048 
FL 18-19 362 0 671 0 325 0 237 1 305 2 381 163 1810 762 0 5 253 294 
FL 19-20 732 774 655 248 719 1 3 4 807 1564 29 363 696 844 20 27 2 0 
FL 20-21 647 2816 0 2 2 2 450 2 689 2 3 2 296 1910 940 2 1480 2 
FL 21-22 2834 1255 1 2 928 1006 218 1 989 55 1737 571 682 722 477 5 1315 1696 
FL 22-23 3092 2454 1064 1425 3105 7 301 453 1983 2291 564 2638 2081 6108 1106 159 3778 4065 
FL 23-24 0 378 306 0 54 0 0 0 0 126 0 162 0 0 0 1 0 1655 
Cassette                                     
Δ 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 10 157 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 131 0 
Δ 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 17 0 0 1 0 0 0 0 0 0 0 0 290 0 0 0 0 0 0 
Δ 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 








Supplementary Table 9 (continued). BRCA1 mRNA splice junction specific raw read counts for a sample sequenced over six time points with three technical replicates, not 
treated with NMD inhibitors. 
a according to the HGVS guidelines (http://www.hgversusorg/mutnomen). Numbers indicate the nucleotide in relation to the A of the AUG initiation codon of Ensembl reference transcript ENST00000357654. 
b NMD - nonsense-mediated decay, FS - frame shift, PTC - premature termination codon. 
c Detected from q end of insertion and actual length is unconfirmed.  
Replicate 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
Splice Junction    Time point 1a 1a 1a 1b 1b 1b 2a 2a 2a 2b 2b 2b 3a 3a 3a 3b 3b 3b 
Multi-cassette                                     
Δ 8,9,10 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 9,10 2737 7657 1109 735 1765 426 1609 864 822 1835 1503 521 1101 925 1398 3980 3530 654 
Δ 9,10,11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Splice Acceptor shift                                     
Δ 6p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 8p 579 910 285 0 1 0 79 1 0 736 0 0 485 0 903 0 359 0 
Δ 13p 0 1 0 0 10 0 0 0 0 950 2 0 1 0 0 0 0 0 
Δ 14p 0 332 99 0 0 1 0 0 45 0 0 0 0 1 106 0 1 344 
Splice Donor shift                                     
Δ1Aq 870 1412 496 4 1058 109 4 1 1072 908 0 1 728 3 324 595 2 1434 
▼1aA 0 0 0 0 0 0 0 0 32 0 0 0 76 1 95 0 0 0 
Δ 5q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 11q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Δ 11q 0 0 292 0 0 0 231 0 0 101 0 0 0 232 0 0 238 0 
Splice Acceptor shift +cassette 
Δ2, Δ3p (7nt)  0 2 1 1 0 0 0 0 0 3 0 1 0 2 0 0 0 0                   
Splice Donor shift +cassette                                                       
Δ1Aq-10 0 0 0 0 166 0 0 0 0 0 0 0 0 0 0 0 1 0                   
Δ1Aq, 2 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 
                  
Splice Donor + splice acceptor + cassette 
Δ11q, Δ12-23, Δ24p 264 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0                   
Exonisation                                                       
▼1 24 154 0 0 17 0 0 0 4 0 0 0 31 33 0 68 0 19                   
▼2* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
                  
▼19* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
                  
▼8c 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
                  








Appendix D Protocols used by laboratories to detect BRCA1/2 mRNA isoforms in Whiley et al. (2014) 
Supplementary Table 10. Kits and protocols used by diagnostic and research laboratories for BRCA1 and BRCA2 mRNA isoform detection, as listed in Whiley et al. (2014). 
 
Protocol component 








cDNA synthesis kit DNA Polymerase Detection method 












SuperscriptIII Amplitaq Gold Agarose gel 
Band excision, cloning, 
sequencing 
pGemT 







PrimeScript RT reagent kit Hot start taq Capillary Gel EP 









High Fidelity transcriptor 
kit 
Platinum Taq DNA 
Polymerase 
Agarose gel PAA-gel 
silver staining 






















Superscript Firststrand Amplitaq Gold Agarose gel 














Short transcripts: High 
Capacity RNA to cDNA. 
Long: High Fidelity 
transcriptor 
Short: Ecotaq DNA 
pol. Long: Expand 
Long Range 
Agarose gel 





100 μg/mL 4hrs 
Trizol No Oligo d(T) SuperscriptIII Amplitaq Gold Agarose gel 











SuperscriptIII GoTaq Flexi 
Phase 1: Agarose gel and 
Agilent Bioanalyser Phase 
2: Cap gel EP 













SuperscriptIII Sigma Taq Polymerase Qiaxel agarose gel 
Qiaxel size visualisation, 
agarose gel, sequencing 
No 
10 No cell culture Trizol No 
Random 
Heximers 
SuperscriptIII Amplitaq Gold Bioanalyser 









SuperscriptIII MegaMIX Double Agarose gel 











Supplementary Table 10 (continued) Kits and protocols used by diagnostic and research laboratories for BRCA1 and BRCA2 mRNA isoform detection, as listed in Whiley 
et al. (2014). 








cDNA synthesis kit DNA Polymerase Detection method 














SuperscriptIII Amplitaq Gold Agarose gel 











Thermoprime Agarose gel 
Band excision and 
sequencing 
No 








FastStart Taq DNA 
Polymerase 
Agarose gel 
Band excision and 
sequencing 
No 





Phusion hot start Agarose gel 












Oligo d(T) SuperscriptIII Qiagen Taq Agarose gel 














RevertAid Premium First 
Strand 
Amplitaq Gold Agarose gel 
Band excision, cloning 
or sequenced PCR 
clones directly 
No 





Gene Specific SuperscriptIII Platnum Taq Agarose gel 










Gene Specific SuperscriptIII Platnum Taq Agarose gel 





100 μg/mL 4hrs 
Rneasy 
mini kit 
No Oligo d(T) SuperscriptIII 
Amplitaq DNA 
Polymerase 
Agarose gel and MultiNA MultiNA No 
21 
Cycloheximide 
100 μg/mL 4hrs 
Rneasy 
mini kit 
rDNase Oligo d(T) SuperscriptIII No Agarose gel 
















Labchip GX (capillary 
system) and agarose gel 













Amplitaq Gold (25 
cycles) 
Agarose gel and Cap EP Direct sequencing No 
 
233 
Appendix E mRNA isoforms detected with PCR-based methods, as shown using 
MultiNA 
Supplementary Figure 1. Analytical results of PCR products, obtained from a single LCL extracted at 







Appendix F Sample-specific read depth observed across time points and technical 
replicates 
Supplementary Table 11. Number of sample-specific reads returned from sequencing a single LCL across 
six different time points with three technical replicates using Targeted RNA-seq. 























































1 1 120,775 10 2 
1 2 43,192 5 3 
1 3 23,364 4 1 
2 1 84,758 7 2 
2 2 59,229 6 2 
2 3 81,529 5 4 
3 1 40,564 4 0 
3 2 71,409 6 1 
3 3 121,723 6 2 
4 1 73,117 6 1 
4 2 40,702 3 0 
4 3 66,563 4 0 
5 1 77,598 8 2 
5 2 66,451 7 1 
5 3 131,536 10 2 
6 1 375,445 13 4 
6 2 279,706 11 4 
6 3 123,599 7 3 
Untreated 
1 1 53,047 6 2 
1 2 96,750 6 0 
1 3 29,941 6 0 
2 1 16,042 2 0 
2 2 57,363 4 1 
2 3 11,723 4 0 
3 1 15,174 5 0 
3 2 10,805 1 0 
3 3 61,917 5 0 
4 1 39,045 8 1 
4 2 19,361 2 0 
4 3 15,644 3 0 
5 1 38,228 6 0 
5 2 64,074 4 0 
5 3 37,282 7 0 
6 1 32,964 3 0 
6 2 46,470 4 0 
6 3 69,529 5 0 
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Appendix G Expression of full length BRCA1/BRCA2 junctions between technical 
replicates 
 
Supplementary Figure 2. Expression of BRCA1 full length junctions between technical triplicates of a single 
LCL sequenced at six time points. 
RNA from LCL (Sample #7) not treated with NMD inhibitor. Zero read counts at any junction are excluded. The 





Supplementary Figure 3. Expression of BRCA2 full length junctions between technical triplicates of a single 
LCL sequenced at six time points. 
RNA from LCL Sample #7 not treated with cycloheximide. Zero read counts at any junction are excluded.
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Appendix H Plots testing for significance between time and expression of full length 
BRCA1/BRCA2 junctions 
Supplementary Figure 4. Testing for significance using the linear model by time point for BRCA1 in NMD 
inhibitor treated samples.  




Supplementary Figure 5. Testing for significance using the linear model by time point for BRCA2 in NMD 
inhibitor treated samples.  




Supplementary Figure 6. Testing for significance using the linear model by freeze-thaw for BRCA1 in NMD 
inhibitor treated samples.  




Supplementary Figure 7. Testing for significance using the linear model by freeze-thaw for BRCA2 in NMD 
inhibitor treated samples.  
X axis represents the six time point. Y-axis is the log of the counts for the samples represented. 
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Appendix I Heat plots of BRCA1 and BRCA2 mRNA isoforms detected across multiple 
time points 
  
Supplementary Figure 8. BRCA1 mRNA isoforms identified in an NMD untreated LCL at six time points. 
A freeze-thaw process was undertaken after the second and fourth time points. Technical replicates are listed under 
each time point. LCL (Sample #7, Table 2.1) was not treated with NMD inhibitors. 
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
1-2 10,000  
2-3 5,000    
5-6 1,000    

































Δ11q (1693),  Δ12-23, Δ24p
1Aq Δ2-10
▼2
Δ2, Δ3p (7nt) 
Ins 8p (8nt), Δ7 (8nt)
▼1, Δ2-9, Δ10p








Supplementary Figure 9. BRCA2 mRNA isoforms identified in an NMD untreated LCL at six time points. 
A freeze-thaw process was undertaken after the second and fourth time points. Technical replicates are listed under 
each time point. LCL (Sample #7, Table 2.1) was not treated with NMD inhibitors. 
 
  
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
2-3 10,000  
4-5 5,000    
5-6 1,000    































1 2 3 4 5 6
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Appendix J RNAscope probe counts per cell 
Supplementary Table 12. BRCA1 mRNA isoforms detected in BRCA1 c.671-2 A>G.  
  
 BRCA1 c.671-2 A>G Treated  BRCA1 c.671-2 A>G Untreated 










Delta)  TRITC FITC    TRITC FITC   
1 6 6   6 0 6  7 7   7 0 7 
2 6 5   5 1 6  4 6   6 0 6 
3 5 5   5 0 5  0 2   2 0 2 
4 3 7   7 0 7  0 5   5 0 5 
5 3 8   8 0 8  0 0   0 0 0 
6 0 1   1 0 1  0 0   0 0 0 
7 1 1   1 0 1  0 0   0 0 0 
8 1 4   4 0 4  0 0   0 0 0 
9 6 1   1 5 6  0 0   0 0 0 
10 3 3   3 0 3  0 0   0 0 0 
11 1 5   5 0 5  0 0   0 0 0 
12 4 0   0 4 4  0 0   0 0 0 
13 3 0   0 3 3  0 0   0 0 0 
14 1 0   0 1 1  0 0   0 0 0 
15 1 0   0 1 1  0 0   0 0 0 
16 17 9   9 8 17  0 0   0 0 0 
17 12 9   9 3 12  0 0   0 0 0 
18 4 6   6 0 6  0 0   0 0 0 
19 1 1   1 0 1  0 0   0 0 0 
20 4 4   4 0 4  0 0   0 0 0 
21 2 2   2 0 2  0 0   0 0 0 
22 1 1   1 0 1  0 0   0 0 0 
23 0 0   0 0 0  0 0   0 0 0 
24 0 0   0 0 0  0 0   0 0 0 
25 0 0   0 0 0  0 0   0 0 0 
26 0 0   0 0 0  0 0   0 0 0 
27 0 0   0 0 0  0 0   0 0 0 
28 0 0   0 0 0  0 0   0 0 0 
29 0 0   0 0 0  0 0   0 0 0 
30 0 0   0 0 0  0 0   0 0 0 
31 0 0   0 0 0  0 0   0 0 0 
32 0 0   0 0 0  0 0   0 0 0 
33 0 0   0 0 0  0 0   0 0 0 
34 0 0   0 0 0  0 0   0 0 0 
35 0 0   0 0 0  0 0   0 0 0 
36 0 0   0 0 0  0 0   0 0 0 
37 0 0   0 0 0  0 0   0 0 0 
38 0 0   0 0 0  0 0   0 0 0 
39 0 0   0 0 0  0 0   0 0 0 
40 0 0   0 0 0  0 0   0 0 0 
41 0 0   0 0 0  0 0   0 0 0 
42 0 0   0 0 0  0 0   0 0 0 
43 0 0   0 0 0  0 0   0 0 0 
44 0 0   0 0 0  0 0   0 0 0 
45 0 0   0 0 0  0 0   0 0 0 
46 0 0   0 0 0  0 0   0 0 0 
47 0 0   0 0 0  0 0   0 0 0 
48 0 0   0 0 0  0 0   0 0 0 
49 0 0   0 0 0  0 0   0 0 0 
50 0 0   0 0 0  0 0   0 0 0 
Totals 85 78  78 26 104(25%)  11 20  20 0 20(0%) 
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Supplementary Table 13. BRCA1 mRNA isoforms detected in a control. 
 Control Treated  Control Untreated 









Delta)  TRITC FITC    TRITC FITC   
1 10 5   5 5 10  0 2   2 0 2 
2 0 3   3 0 3  0 4   4 0 4 
3 0 0   0 0 0  0 2   2 0 2 
4 0 0   0 0 0  1 1   1 0 1 
5 0 0   0 0 0  2 2   2 0 2 
6 0 0   0 0 0  0 0   0 0 0 
7 0 0   0 0 0  0 0   0 0 0 
8 0 0   0 0 0  0 0   0 0 0 
9 0 0   0 0 0  0 0   0 0 0 
10 0 0   0 0 0  0 0   0 0 0 
11 0 0   0 0 0  0 0   0 0 0 
12 0 0   0 0 0  0 0   0 0 0 
13 0 0   0 0 0  0 0   0 0 0 
14 0 0   0 0 0  0 0   0 0 0 
15 0 0   0 0 0  0 0   0 0 0 
16 0 0   0 0 0  0 0   0 0 0 
17 0 0   0 0 0  0 0   0 0 0 
18 0 0   0 0 0  0 0   0 0 0 
19 0 0   0 0 0  0 0   0 0 0 
20 0 0   0 0 0  0 0   0 0 0 
21 0 0   0 0 0  0 0   0 0 0 
22 0 0   0 0 0  0 0   0 0 0 
23 0 0   0 0 0  0 0   0 0 0 
24 0 0   0 0 0  0 0   0 0 0 
25 0 0   0 0 0  0 0   0 0 0 
26 0 0   0 0 0  0 0   0 0 0 
27 0 0   0 0 0  0 0   0 0 0 
28 0 0   0 0 0  0 0   0 0 0 
29 0 0   0 0 0  0 0   0 0 0 
30 0 0   0 0 0  0 0   0 0 0 
31 0 0   0 0 0  0 0   0 0 0 
32 0 0   0 0 0  0 0   0 0 0 
33 0 0   0 0 0  0 0   0 0 0 
34 0 0   0 0 0  0 0   0 0 0 
35 0 0   0 0 0  0 0   0 0 0 
36 0 0   0 0 0  0 0   0 0 0 
37 0 0   0 0 0  0 0   0 0 0 
38 0 0   0 0 0  0 0   0 0 0 
39 0 0   0 0 0  0 0   0 0 0 
40 0 0   0 0 0  0 0   0 0 0 
41 0 0   0 0 0  0 0   0 0 0 
42 0 0   0 0 0  0 0   0 0 0 
43 0 0   0 0 0  0 0   0 0 0 
44 0 0   0 0 0  0 0   0 0 0 
45 0 0   0 0 0  0 0   0 0 0 
46 0 0   0 0 0  0 0   0 0 0 
47 0 0   0 0 0  0 0   0 0 0 
48 0 0   0 0 0  0 0   0 0 0 
49 0 0   0 0 0  0 0   0 0 0 
50 0 0   0 0 0  0 0   0 0 0 
Totals 10 8  8 5 13(38%)  3 11  11 0 11(0%) 
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Supplementary Table 14. BRCA2 mRNA isoforms detected in the BRCA2 c.7988 A>T.  
 BRCA2 c.7988 A>T Treated  BRCA2 c.7988 A>T Untreated 










Delta)  TRITC FITC    TRITC FITC   
1 1 1   1 0 1  7 2   2 5 7 
2 3 1   1 2 3  3 1   1 2 3 
3 1 1   1 0 1  8 6   6 2 8 
4 3 0   0 3 3  1 1   1 0 1 
5 8 5   5 3 8  4 0   0 4 4 
6 9 4   4 5 9  5 5   5 0 5 
7 0 1   1 0 1  7 2   2 5 7 
8 1 1   1 0 1  3 0   0 3 3 
9 4 1   1 3 4  6 6   6 0 6 
10 4 4   4 0 4  2 0   0 2 2 
11 1 2   2 0 2  3 0   0 3 3 
12 1 2   2 0 2  8 1   1 7 8 
13 5 6   6 0 6  4 3   3 1 4 
14 0 1   1 0 1  1 1   1 0 1 
15 0 4   4 0 4  1 0   0 1 1 
16 0 1   1 0 1  2 0   0 2 2 
17 14 14   14 0 14  2 1   1 1 2 
18 0 12   12 0 12  6 1   1 5 6 
19 3 2   2 1 3  6 2   2 4 6 
20 1 1   1 0 1  4 2   2 2 4 
21 24 11   11 13 24  1 0   0 1 1 
22 7 3   3 4 7  3 1   1 2 3 
23 7 1   1 6 7  4 2   2 2 4 
24 7 1   1 6 7  5 6   6 0 6 
25 29 8   8 21 29  0 0   0 0 0 
26 1 1   1 0 1  0 0   0 0 0 
27 1 0   0 1 1  0 0   0 0 0 
28 2 0   0 2 2  0 0   0 0 0 
29 1 0   0 1 1  0 0   0 0 0 
30 0 0   0 0 0  0 0   0 0 0 
31 0 0   0 0 0  0 0   0 0 0 
32 0 0   0 0 0  0 0   0 0 0 
33 0 0   0 0 0  0 0   0 0 0 
34 0 0   0 0 0  0 0   0 0 0 
35 0 0   0 0 0  0 0   0 0 0 
36 0 0   0 0 0  0 0   0 0 0 
37 0 0   0 0 0  0 0   0 0 0 
38 0 0   0 0 0  0 0   0 0 0 
39 0 0   0 0 0  0 0   0 0 0 
40 0 0   0 0 0  0 0   0 0 0 
41 0 0   0 0 0  0 0   0 0 0 
42 0 0   0 0 0  0 0   0 0 0 
43 0 0   0 0 0  0 0   0 0 0 
44 0 0   0 0 0  0 0   0 0 0 
45 0 0   0 0 0  0 0   0 0 0 
46 0 0   0 0 0  0 0   0 0 0 
47 0 0   0 0 0  0 0   0 0 0 
48 0 0   0 0 0  0 0   0 0 0 
49 0 0   0 0 0  0 0   0 0 0 
50 0 0   0 0 0  0 0   0 0 0 




Supplementary Table 15. BRCA2 mRNA isoforms detected in a control using RNAscope. 
 Control Treated  Control Untreated 









Delta)  TRITC FITC    TRITC FITC   
1 2 0   0 2 2  1 1   1 0 1 
2 5 5   5 0 5  1 1   1 0 1 
3 1 1   1 0 1  1 1   1 0 1 
4 1 0   0 1 1  1 0   0 1 1 
5 2 0   0 2 2  3 2   2 1 3 
6 4 4   4 0 4  0 0   0 0 0 
7 2 1   1 1 2  0 0   0 0 0 
8 3 2   2 1 3  0 0   0 0 0 
9 5 5   5 0 5  0 0   0 0 0 
10 4 4   4 0 4  0 0   0 0 0 
11 0 1   1 0 1  0 0   0 0 0 
12 1 1   1 0 1  0 0   0 0 0 
13 0 0   0 0 0  0 0   0 0 0 
14 0 0   0 0 0  0 0   0 0 0 
15 0 0   0 0 0  0 0   0 0 0 
16 0 0   0 0 0  0 0   0 0 0 
17 0 0   0 0 0  0 0   0 0 0 
18 0 0   0 0 0  0 0   0 0 0 
19 0 0   0 0 0  0 0   0 0 0 
20 0 0   0 0 0  0 0   0 0 0 
21 0 0   0 0 0  0 0   0 0 0 
22 0 0   0 0 0  0 0   0 0 0 
23 0 0   0 0 0  0 0   0 0 0 
24 0 0   0 0 0  0 0   0 0 0 
25 0 0   0 0 0  0 0   0 0 0 
26 0 0   0 0 0  0 0   0 0 0 
27 0 0   0 0 0  0 0   0 0 0 
28 0 0   0 0 0  0 0   0 0 0 
29 0 0   0 0 0  0 0   0 0 0 
30 0 0   0 0 0  0 0   0 0 0 
31 0 0   0 0 0  0 0   0 0 0 
32 0 0   0 0 0  0 0   0 0 0 
33 0 0   0 0 0  0 0   0 0 0 
34 0 0   0 0 0  0 0   0 0 0 
35 0 0   0 0 0  0 0   0 0 0 
36 0 0   0 0 0  0 0   0 0 0 
37 0 0   0 0 0  0 0   0 0 0 
38 0 0   0 0 0  0 0   0 0 0 
39 0 0   0 0 0  0 0   0 0 0 
40 0 0   0 0 0  0 0   0 0 0 
41 0 0   0 0 0  0 0   0 0 0 
42 0 0   0 0 0  0 0   0 0 0 
43 0 0   0 0 0  0 0   0 0 0 
44 0 0   0 0 0  0 0   0 0 0 
45 0 0   0 0 0  0 0   0 0 0 
46 0 0   0 0 0  0 0   0 0 0 
47 0 0   0 0 0  0 0   0 0 0 
48 0 0   0 0 0  0 0   0 0 0 
49 0 0   0 0 0  0 0   0 0 0 
50 0 0   0 0 0  0 0   0 0 0 





Supplementary table 16. Fluorescently labelled mRNA counts in cells compared between samples 
containing splice disrupting variants, and controls. 
Samples are not treated with NMD inhibitor cycloheximide. The P-value for BRCA1 c.671-2 A>G was not able to 
be calculated due to zero values from low signal detection. 
 
a Number of ∆ transcripts. 
bYates corrected chi-squared test. 
  
NMD untreated Number of signals 
from C1 and C2, or 
C1 only 
Number of 
signals from C2 
probes onlya    
Control 11 0 p-value = undefined 
BRCA1 c.671-2 A>G 20 0 OR= 0.000 
Control 5 2 p-value = 0.319 
BRCA2 c.7988 A>T  43 54 OR= 3.140 
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Appendix K BRCA1 and BRCA2 mRNA expression in NMD inhibitor untreated samples 
using RNAscope. 
 
Supplementary Figure 10. BRCA1 expression in using RNAscope detected in LCLs not treated with NMD 
inhibitors. 








Supplementary Figure 11. BRCA2 expression in using RNAscope detected in LCLs not treated with NMD 
inhibitors. 

















Appendix L Library preparation for whole exome sequencing 
 
DNA preparation and next-generation sequencing  
Genomic DNA (gDNA) was submitted to Otogenetics Corporation (Norcross, GA USA) for 
exome capture and sequencing. Briefly, gDNA was subjected to agarose gel and OD ratio tests 
to confirm the purity and concentration prior to Bioruptor (Diagenode, Inc., Denville, NJ USA) 
fragmentation. Fragmented gDNAs were tested for size distribution and concentration using an 
Agilent Tapestation 2200 and Nanodrop. Illumina libraries were made from qualified 
fragmented gDNA using SPRIworks HT Reagent Kit (Beckman Coulter, Inc. Indianapolis, IN 
USA, catalog# B06938) and the resulting libraries were subjected to exome enrichment using 
Agilent SureSelect AV5 + UTR Exon Coverage (Agilent Technologies, Wilmington, DE USA, 
catalog# 5190-6213) following manufacturer’s instructions. Enriched libraries were tested for 
enrichment by qPCR and for size distribution and concentration by an Agilent Bioanalyzer 
2100. The samples were then sequenced Illumina HiSeq 2000, using HighOutput v3 chemistry 
which generated paired-end reads of 101 nucleotides (nt). Data was analyzed for data quality 
using FASTQC (Babraham Institute, Cambridge, UK). 




Appendix M Exome quality control from DNAnexus 
Supplementary Table 17. Exome quality control from DNAnexus for patient 735. 
 
Supplementary Table 18. Exome quality control from DNAnexus for patient 736. 
 
 
Supplementary Table 19. Exome quality control from DNAnexus for patient 737. 
Sample details: Sample 35
Name:OtA4735_200-882a_hEx_AV5-UTR_6Gb_Com..







Mapped reads 67,905,203  97.35% 34,252,956  98.21% 33,652,247  96.49%
mapped confidently 66,482,439  95.31% 33,537,186  96.16% 32,945,253  94.46%
mapped repetitively 1,422,764   2.04% 715,770   2.05% 706,994   2.03%
Reads not mapped 1,847,407   2.65% 623,349   1.79% 1,224,058   3.51%
no mapping 141,668   0.20% 66,538   0.19% 75,130   0.22%
low quality 1,668,276   2.39% 537,440   1.54% 1,130,836   3.24%
ribosomal RNA 9,557   0.01% 4,890   0.01% 4,667   0.01%
primer 3   0.00% 0   0.00% 3   0.00%
control (phiX-174) 27,888   0.04% 14,473   0.04% 13,415   0.04%
poly-A 11   0.00% 6   0.00% 5   0.00%
poly-C 1   0.00% 0   0.00% 1   0.00%
poly-G 0   0.00% 0   0.00% 0   0.00%
poly-T 3   0.00% 2   0.00% 1   0.00%
Total reads 69,752,610 100.00% 34,876,305 100.00% 34,876,305 100.00%
Total bases 6,975,261,000 100.00% 3,487,630,500 100.00% 3,487,630,500 100.00%
All Left Right
Sample details: Sample 36
Name:OtA4736_200-882a_hEx_AV5-UTR_6Gb_Com..







Mapped reads 65,033,054  97.52% 32,795,608  98.36% 32,237,446  96.69%
mapped confidently 63,651,293  95.45% 32,101,613  96.28% 31,549,680  94.62%
mapped repetitively 1,381,761   2.07% 693,995   2.08% 687,766   2.06%
Reads not mapped 1,650,680   2.48% 546,259   1.64% 1,104,421   3.31%
no mapping 138,850   0.21% 64,371   0.19% 74,479   0.22%
low quality 1,481,044   2.22% 465,864   1.40% 1,015,180   3.04%
ribosomal RNA 7,868   0.01% 3,994   0.01% 3,874   0.01%
primer 11   0.00% 2   0.00% 9   0.00%
control (phiX-174) 22,889   0.03% 12,021   0.04% 10,868   0.03%
poly-A 11   0.00% 6   0.00% 5   0.00%
poly-C 0   0.00% 0   0.00% 0   0.00%
poly-G 0   0.00% 0   0.00% 0   0.00%
poly-T 7   0.00% 1   0.00% 6   0.00%
Total reads 66,683,734 100.00% 33,341,867 100.00% 33,341,867 100.00%





Supplementary Table 20. Exome quality control from DNAnexus for patient 738. 
 
  
Sample details: Sample 37
Name:OtA4737_200-882a_hEx_AV5-UTR_6Gb_Com..
Genome: H. sapiens (hg19)
Paired: Yes
Read details




Mapped reads 68,191,894  97.42% 34,385,230  98.24% 33,806,664  96.59%
mapped confidently 66,754,445  95.36% 33,663,037  96.18% 33,091,408  94.55%
mapped repetitively 1,437,449   2.05% 722,193   2.06% 715,256   2.04%
Reads not mapped 1,808,778   2.58% 615,106   1.76% 1,193,672   3.41%
no mapping 143,705   0.21% 67,591   0.19% 76,114   0.22%
low quality 1,624,367   2.32% 526,509   1.50% 1,097,858   3.14%
ribosomal RNA 9,442   0.01% 4,775   0.01% 4,667   0.01%
primer 6   0.00% 2   0.00% 4   0.00%
control (phiX-174) 31,247   0.04% 16,226   0.05% 15,021   0.04%
poly-A 10   0.00% 3   0.00% 7   0.00%
poly-C 0   0.00% 0   0.00% 0   0.00%
poly-G 0   0.00% 0   0.00% 0   0.00%
poly-T 1   0.00% 0   0.00% 1   0.00%
Total reads 70,000,672 100.00% 35,000,336 100.00% 35,000,336 100.00%
Total bases 7,000,067,200 100.00% 3,500,033,600 100.00% 3,500,033,600 100.00%
Left RightAll
Sample details: Sample 38
Name: OtA4738_200-882a_hEx_AV5-UTR_6Gb_Com..







Mapped reads 70,650,730  97.49% 35,620,220  98.31% 35,030,510  96.68%
mapped confidently 69,164,610  95.44% 34,873,049  96.24% 34,291,561  94.64%
mapped repetitively 1,486,120   2.05% 747,171   2.06% 738,949   2.04%
Reads not mapped 1,817,720   2.51% 614,005   1.69% 1,203,715   3.32%
no mapping 150,513   0.21% 69,782   0.19% 80,731   0.22%
low quality 1,635,768   2.26% 527,876   1.46% 1,107,892   3.06%
ribosomal RNA 6,259   0.01% 3,135   0.01% 3,124   0.01%
primer 1   0.00% 0   0.00% 1   0.00%
control (phiX-174) 25,170   0.03% 13,211   0.04% 11,959   0.03%
poly-A 6   0.00% 1   0.00% 5   0.00%
poly-C 0   0.00% 0   0.00% 0   0.00%
poly-G 1   0.00% 0   0.00% 1   0.00%
poly-T 2   0.00% 0   0.00% 2   0.00%
Total reads 72,468,450 100.00% 36,234,225 100.00% 36,234,225 100.00%










Appendix N Quality metrics of the short listed WES variants 


















chr3:37056045 rs182733777 c.790+10A>G 735 MLH1 A/G 34 44 78 99 0.278 
chr11:108117787 rs28904919 c.998C>T 735 ATM C/T 7 11 18 99 3.92 
cht12:28123004 rs755751413 c.-69G>C 735 PTHLH C/G 41 43 84 99 1.27 
chr13:32972626 rs11571833 c.9976A>T 735 BRCA2 A/T 43 48 91 99 4.02 
chr5:112178795 rs2229995 c.7504G>A 736 APC A/G 46 61 107 99 3.81 
chr13:32930598 rs11571707 c.7469T>C 736, 738 BRCA2 C/T 102\99 39\13 141\112 99/99 0.962 
chr9:97887430 rs1800366 c.934A>G 737 FANCC C/T 61 44 105 99 0.893 
chr17:33430313 rs28363284 c.698A>G 737 RAD51D C/T 9 9 18 99 2.32 
chr2:17963123 rs77424145 c.2644A>G 738 GEN1 A/G 52 48 100 99 4.22 
chr18:48591943 rs139569694 c.1106A>G 738 SMAD4 A/G 18 26 44 99 1.44 
Abbreviations: VQSLOD, variant quality score log odds. 
